: The AMEDEO Literature Guide

Home The Word Brain

My Amedeo

FAQ

Privacy

About

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

Parkinson's Disease

Free Subscription

Articles published in Mov Disord
Retrieve available abstracts of 831 articles:
HTML format

Single Articles

July 2024

KARIV S, Choi JW, Mirpour K, Gordon AM, et al
Pilot Study of Acute Behavioral Effects of Pallidal Burst Stimulation in Parkinson's Disease.
Mov Disord. 2024 Jul 15. doi: 10.1002/mds.29928.
PubMed Abstract available

ILLNER V, Novotny M, Kouba T, Tykalova T, et al
Smartphone Voice Calls Provide Early Biomarkers of Parkinsonism in Rapid Eye Movement Sleep Behavior Disorder.
Mov Disord. 2024 Jul 12. doi: 10.1002/mds.29921.
PubMed Abstract available

BERNHARDT AM, Nemati M, Boros FA, Hopfner F, et al
alpha-Synuclein Seed Amplification Assays from Blood-Based Extracellular Vesicles in Parkinson's Disease: An Evaluation of the Evidence.
Mov Disord. 2024 Jul 11. doi: 10.1002/mds.29923.
PubMed

WOOD KH, Nenert R, Miften AM, Kent GW, et al
Diffusion Tensor Imaging-Along the Perivascular-Space Index Is Associated with Disease Progression in Parkinson's Disease.
Mov Disord. 2024 Jul 11. doi: 10.1002/mds.29908.
PubMed Abstract available

GOLDMAN SM, Weaver FM, Gonzalez B, Stroupe KT, et al
Parkinson's Disease Progression and Exposure to Contaminated Water at Camp Lejeune.
Mov Disord. 2024 Jul 11. doi: 10.1002/mds.29922.
PubMed Abstract available

MUSTILE M, Kourtis D, Ladouce S, Edwards MG, et al
Investigating the Brain Mechanisms of Externally Cued Sit-to-Stand Movement in Parkinson's Disease.
Mov Disord. 2024 Jul 10. doi: 10.1002/mds.29889.
PubMed Abstract available

DE JESUS S, Daya A, Blumberger L, Lewis MM, et al
Prevalence of Late-Stage Parkinson's Disease in the US Healthcare System: Insights from TriNetX.
Mov Disord. 2024 Jul 4. doi: 10.1002/mds.29900.
PubMed Abstract available

BALTA BEYLERGIL S, Skelly P, Quagraine I, Kilbane C, et al
Navigating Visual Challenges: How Parkinson's Disease Alters Cognitive Priorities in Visual Search.
Mov Disord. 2024 Jul 4. doi: 10.1002/mds.29907.
PubMed Abstract available

GUO S, Yang G
Integrating Social Work in Late-Stage Parkinson's Care: A Multifaceted Approach.
Mov Disord. 2024;39:1249-1250.
PubMed

KRUSE C, Dodel R, Schrag A
Reply to Letter to the Editor-MDS-23-0498.R2/MDS-24-0318.R1.
Mov Disord. 2024;39:1251-1252.
PubMed

ADLER CH, Halverson M, Zhang N, Shill HA, et al
Conjugal Synucleinopathies: A Clinicopathologic Study.
Mov Disord. 2024;39:1212-1217.
PubMed Abstract available

ZHENG Y, Li Y, Cai H, Kou W, et al
Alterations of Peripheral Lymphocyte Subsets in Isolated Rapid Eye Movement Sleep Behavior Disorder.
Mov Disord. 2024;39:1179-1189.
PubMed Abstract available

June 2024

BURRE J, Edwards RH, Halliday G, Lang AE, et al
Research Priorities on the Role of alpha-Synuclein in Parkinson's Disease Pathogenesis.
Mov Disord. 2024 Jun 30. doi: 10.1002/mds.29897.
PubMed Abstract available

AKCIMEN F, van Midden V, Akerman SC, Makarious MB, et al
Investigating the Protective Role of the Mitochondrial 2158 T > C Variant in Parkinson's Disease.
Mov Disord. 2024 Jun 28. doi: 10.1002/mds.29892.
PubMed

COGAN G, Daida K, Billingsley KJ, Tesson C, et al
Long-Read Sequencing Unravels the Complexity of Structural Variants in PRKN in Two Individuals with Early-Onset Parkinson's Disease.
Mov Disord. 2024 Jun 28. doi: 10.1002/mds.29914.
PubMed

FABBRI M, Rascol O, Foltynie T, Carroll C, et al
Advantages and Challenges of Platform Trials for Disease Modifying Therapies in Parkinson's Disease.
Mov Disord. 2024 Jun 26. doi: 10.1002/mds.29899.
PubMed Abstract available

LEODORI G, De Bartolo MI, Piervincenzi C, Mancuso M, et al
Mapping Motor Cortical Network Excitability and Connectivity Changes in De Novo Parkinson's Disease.
Mov Disord. 2024 Jun 24. doi: 10.1002/mds.29901.
PubMed Abstract available

WANG X, Fu S, Yoo K, Wang X, et al
Individualized Structural Perturbations on Normative Brain Connectome Restrict Deep Brain Stimulation Outcomes in Parkinson's Disease.
Mov Disord. 2024 Jun 18. doi: 10.1002/mds.29874.
PubMed Abstract available

KIMURA Y, Mochizuki H
Targeting Glucagon-Like Peptide 1 Signaling: A Potential Disease Modifying Therapy for Parkinson's Disease.
Mov Disord. 2024 Jun 14. doi: 10.1002/mds.29884.
PubMed

BREFEL-COURBON C, Harroch E, Marques A, Devos D, et al
Oxycodone or Higher Dose of Levodopa for the Treatment of Parkinsonian Central Pain: OXYDOPA Trial.
Mov Disord. 2024 Jun 8. doi: 10.1002/mds.29878.
PubMed Abstract available

JENSEN I, Heine J, Ruf VC, Compta Y, et al
Impact of Magnetic Resonance Imaging Markers on the Diagnostic Performance of the International Parkinson and Movement Disorder Society Multiple System Atrophy Criteria.
Mov Disord. 2024 Jun 7. doi: 10.1002/mds.29879.
PubMed Abstract available

KORCZYN AD
Rethinking Parkinson's Disease: A Syndromic Perspective.
Mov Disord. 2024;39:1079-1080.
PubMed

LEODORI G, Mancuso M, Marchet F, Belvisi D, et al
The Role of the Motor Cortex in the Parkinsonian Tremor Network: Is it Time for an Upgrade?
Mov Disord. 2024;39:1084.
PubMed

OUTEIRO TF, Antonini A, Ferreira JJ
Reply to: "Rethinking Parkinson's Disease: A Syndromic Perspective".
Mov Disord. 2024;39:1080-1081.
PubMed

SCHNEIDER RB, Mills KA, Nirenberg MJ, Dobkin RD, et al
Defining the Importance of Minor Hallucinations in Parkinson's Disease.
Mov Disord. 2024;39:1083.
PubMed

OLANOW CW, McIntyre D, Matarazzo M, Leinonen M, et al
Continuous Levodopa Delivery with an Intraoral Micropump System: An Open-Label Pharmacokinetics and Clinical Study.
Mov Disord. 2024;39:945-954.
PubMed Abstract available

BUUR L, Wiedemann J, Larsen F, Ben Alaya-Fourati F, et al
Randomized Phase I Trial of the alpha-Synuclein Antibody Lu AF82422.
Mov Disord. 2024;39:936-944.
PubMed Abstract available

SIMONET C, Perez-Carbonell L, Galmes-Ordinas MA, Huxford BFR, et al
The Motor Dysfunction Seen in Isolated REM Sleep Behavior Disorder.
Mov Disord. 2024;39:1054-1059.
PubMed Abstract available

AVENALI M, Cerri S, Palmieri I, Ongari G, et al
Functional Study of SNCA p.V15A Variant: Further Linking alpha-Synuclein and Glucocerebrosidase.
Mov Disord. 2024;39:1060-1065.
PubMed Abstract available

May 2024

GRIPPE T, Shamli-Oghli Y, Darmani G, Nankoo JF, et al
Plasticity-Induced Effects of Theta Burst Transcranial Ultrasound Stimulation in Parkinson's Disease.
Mov Disord. 2024 May 24. doi: 10.1002/mds.29836.
PubMed Abstract available

VAN MIDDEN V, Simoncic U, Pirtosek Z, Kojovic M, et al
The Effect of taVNS at 25 Hz and 100 Hz on Parkinson's Disease Gait-A Randomized Motion Sensor Study.
Mov Disord. 2024 May 17. doi: 10.1002/mds.29826.
PubMed Abstract available

ZHANG J, Liu Y, Zhao C
SNCA-Related Parkinson's Disease Caused by Complete Chromosome 4 Paternal Uniparental Disomy.
Mov Disord. 2024 May 13. doi: 10.1002/mds.29823.
PubMed

HEISS JD, Ray-Chaudhury A, Kleiner DE, Ehrlich DJ, et al
Persistent GDNF Expression 45 Months after Putaminal Infusion of AAV2-GDNF in a Patient with Parkinson's Disease.
Mov Disord. 2024 May 8. doi: 10.1002/mds.29820.
PubMed Abstract available

XIAO H, Lang L, Ye Z, Wu J, et al
Subthalamic Nucleus Stimulation Modulates Cognitive Theory of Mind in Parkinson's Disease.
Mov Disord. 2024 May 2. doi: 10.1002/mds.29830.
PubMed Abstract available

MA JH, Dong C, Qiao HW, Barret O, et al
Striatal and Extrastriatal Monoaminergic Disruption in Progressive Supranuclear Palsy.
Mov Disord. 2024;39:847-854.
PubMed Abstract available

April 2024

DODET P, Houot M, Leu-Semenescu S, Gaurav R, et al
Isolated REM Sleep without Atonia Is Not Equivalent to REM Sleep Behavior Disorder in Early-Stage Parkinson's Disease.
Mov Disord. 2024 Apr 26. doi: 10.1002/mds.29813.
PubMed Abstract available

MONCHI O, Pinilla-Monsalve GD, Almgren H, Ghahremani M, et al
White Matter Microstructural Underpinnings of Mild Behavioral Impairment in Parkinson's Disease.
Mov Disord. 2024 Apr 25. doi: 10.1002/mds.29804.
PubMed Abstract available

SENKEVICH K, Miliukhina I, Zhuravlev A, Shumilova M, et al
Autosomal Dominant Parkinson's Disease Caused by SNCA p.E46K Mutation in a Family with Russian Ancestry.
Mov Disord. 2024 Apr 25. doi: 10.1002/mds.29821.
PubMed

KLUGE A, Schaeffer E, Bunk J, Sommerauer M, et al
Detecting Misfolded alpha-Synuclein in Blood Years before the Diagnosis of Parkinson's Disease.
Mov Disord. 2024 Apr 23. doi: 10.1002/mds.29766.
PubMed Abstract available

FREQUIN HL, Verschuur CVM, Suwijn SR, Boel JA, et al
Long-Term Follow-Up of the LEAP Study: Early Versus Delayed Levodopa in Early Parkinson's Disease.
Mov Disord. 2024 Apr 21. doi: 10.1002/mds.29796.
PubMed Abstract available

WANG Y, Li H, Song N, Xie J, et al
Yeast Prion Protein Sup35 Initiates alpha-Synuclein Pathology in Parkinson's Disease.
Mov Disord. 2024 Apr 16. doi: 10.1002/mds.29810.
PubMed Abstract available

LASS J, Luth T, Schluter K, Schaake S, et al
Stability of Mosaic Divergent Repeat Interruptions in X-Linked Dystonia-Parkinsonism.
Mov Disord. 2024 Apr 14. doi: 10.1002/mds.29809.
PubMed Abstract available

SHARMA K, Kishore A, Lechado-Terradas A, Passannanti R, et al
A Novel PINK1 p.F385S Loss-of-Function Mutation in an Indian Family with Parkinson's Disease.
Mov Disord. 2024 Apr 8. doi: 10.1002/mds.29792.
PubMed Abstract available

NIEMI KJ, Huovinen A, Jaakkola E, Glerean E, et al
Bodily Maps of Symptoms and Emotions in Parkinson's Disease.
Mov Disord. 2024 Apr 8. doi: 10.1002/mds.29785.
PubMed Abstract available

DU J, Zhang P, Tan Y, Gao C, et al
Idiopathic Rapid Eye Movement Sleep Behavior Disorder (iRBD) Shares Similar Fecal Short-Chain Fatty Acid Alterations with Multiple System Atrophy (MSA) and Parkinson's Disease (PD).
Mov Disord. 2024 Apr 1. doi: 10.1002/mds.29803.
PubMed Abstract available

ONDER H
Recurrence of Parkinson's Disease Tremor after Focused Ultrasound Thalamotomy?
Mov Disord. 2024;39:758-759.
PubMed

PETERS J, Maamary J, Kyle K, Olsen N, et al
Reply to: Recurrence of Parkinson's Disease Tremor after Focused Ultrasound Thalamotomy?
Mov Disord. 2024;39:759-760.
PubMed

BOOGERS A, Fasano A
Reply to: Comment on: A Transatlantic Viewpoint on the Role of Pallidal Stimulation for Parkinson's Disease.
Mov Disord. 2024;39:761.
PubMed

XIE T, Warnke PC
Comment on: "A Transatlantic Viewpoint on the Role of Pallidal Stimulation for Parkinson's Disease".
Mov Disord. 2024;39:760-761.
PubMed

PATEL J, Dawson VL, Dawson TM
Blocking the Self-Destruct Program of Dopamine Neurons through Macrophage Migration Inhibitory Factor Nuclease Inhibition.
Mov Disord. 2024;39:644-650.
PubMed Abstract available

KORNILOV E, Baker Erdman H, Kahana E, Fireman S, et al
Interleaved Propofol-Ketamine Maintains DBS Physiology and Hemodynamic Stability: A Double-Blind Randomized Controlled Trial.
Mov Disord. 2024;39:694-705.
PubMed Abstract available

STEINA A, Sure S, Butz M, Vesper J, et al
Mapping Subcortico-Cortical Coupling-A Comparison of Thalamic and Subthalamic Oscillations.
Mov Disord. 2024;39:684-693.
PubMed Abstract available

March 2024

Correction to "Management of Impulse Control and Related Disorders in Parkinson's Disease: An Expert Consensus".
Mov Disord. 2024 Mar 29. doi: 10.1002/mds.29805.
PubMed

VERONESE N, Nova A, Fazia T, Riggi E, et al
Contribution of Nutritional, Lifestyle, and Metabolic Risk Factors to Parkinson's Disease.
Mov Disord. 2024 Mar 26. doi: 10.1002/mds.29778.
PubMed Abstract available

DING H, Nasseroleslami B, Mirzac D, Isaias IU, et al
Re-emergent Tremor in Parkinson's Disease: Evidence of Pathologic beta and Prokinetic gamma Activity.
Mov Disord. 2024 Mar 26. doi: 10.1002/mds.29771.
PubMed Abstract available

LIU Y, Bainbridge J, Sillau S, Rajkovic S, et al
Short-Term Cannabidiol with Delta-9-Tetrahydrocannabinol in Parkinson's Disease: A Randomized Trial.
Mov Disord. 2024 Mar 15. doi: 10.1002/mds.29768.
PubMed Abstract available

FRIEDMAN JH
A New Definition of Psychosis Is Needed in Parkinson's Disease.
Mov Disord. 2024 Mar 14. doi: 10.1002/mds.29786.
PubMed

ZOETEWEI D, Herman T, Ginis P, Palmerini L, et al
On-Demand Cueing for Freezing of Gait in Parkinson's Disease: A Randomized Controlled Trial.
Mov Disord. 2024 Mar 14. doi: 10.1002/mds.29762.
PubMed Abstract available

CHOUGAR L, Faucher A, Faouzi J, Lejeune FX, et al
Contribution of MRI for the Early Diagnosis of Parkinsonism in Patients with Diagnostic Uncertainty.
Mov Disord. 2024 Mar 14. doi: 10.1002/mds.29760.
PubMed Abstract available

MENEZES JR, Nunes GA, Carra RB, da Silva Simoes J, et al
Trans-Spinal Theta Burst Magnetic Stimulation in Parkinson's Disease and Gait Disorders.
Mov Disord. 2024 Mar 13. doi: 10.1002/mds.29776.
PubMed Abstract available

PARDO J, Montal V, Campabadal A, Oltra J, et al
Cortical Macro- and Microstructural Changes in Parkinson's Disease with Probable Rapid Eye Movement Sleep Behavior Disorder.
Mov Disord. 2024 Mar 8. doi: 10.1002/mds.29761.
PubMed Abstract available

SISODIA V, Malekzadeh A, Verwijk E, Schuurman PR, et al
Bidirectional Interplay between Deep Brain Stimulation and Cognition in Parkinson's Disease: A Systematic Review.
Mov Disord. 2024 Mar 1. doi: 10.1002/mds.29772.
PubMed Abstract available

BINGHAM CS, McIntyre CC
Coupled Activation of the Hyperdirect and Cerebellothalamic Pathways with Zona Incerta Deep Brain Stimulation.
Mov Disord. 2024;39:539-545.
PubMed Abstract available

LEWITT PA, Stebbins GT, Christensen KV, Tan R, et al
Buspirone and Zolmitriptan Combination for Dyskinesia: A Randomized, Controlled, Crossover Study.
Mov Disord. 2024;39:613-618.
PubMed Abstract available

THOMSEN M, Marth K, Loens S, Everding J, et al
Large-Scale Screening: Phenotypic and Mutational Spectrum in Isolated and Combined Dystonia Genes.
Mov Disord. 2024;39:526-538.
PubMed Abstract available

MUNCHAU A, Klein C, Beste C
Rethinking Movement Disorders.
Mov Disord. 2024;39:472-484.
PubMed Abstract available

KAMATH SD, Holla VV, Phulpagar P, Kamble N, et al
Clinicogenetic Characterization of Patients with PD and Heterozygous GBA1 Variants in an Indian Cohort.
Mov Disord. 2024;39:628-630.
PubMed

February 2024

KRUSE C, Lipinski A, Verheyen M, Balzer-Geldsetzer M, et al
Care of Late-Stage Parkinsonism: Resource Utilization of the Disease in Five European Countries.
Mov Disord. 2024 Feb 29. doi: 10.1002/mds.29718.
PubMed Abstract available

WILKEN M, Andres DS, Bianchi G, Hallett M, et al
Persistence of Basal Ganglia Oscillatory Activity During Tremor Attenuation by Movement in Parkinson's Disease Patients.
Mov Disord. 2024 Feb 28. doi: 10.1002/mds.29679.
PubMed Abstract available

OJO OO, Bandres-Ciga S, Makarious MB, Crea PW, et al
GBA1 rs3115534 Is Associated with REM Sleep Behavior Disorder in Parkinson's Disease in Nigerians.
Mov Disord. 2024 Feb 23. doi: 10.1002/mds.29753.
PubMed Abstract available

DORSEY ER, Kinel D, Pawlik ME, Zafar M, et al
Dry-Cleaning Chemicals and a Cluster of Parkinson's Disease and Cancer: A Retrospective Investigation.
Mov Disord. 2024 Feb 23. doi: 10.1002/mds.29723.
PubMed Abstract available

AMBROSINI E, Cancilla R, Paul JJ, Bauer P, et al
Pure Parkinsonism as Possible Phenotype Expansion of THAP1-Related Disorders.
Mov Disord. 2024 Feb 15. doi: 10.1002/mds.29745.
PubMed

SOLIS GP, Larasati YA, Thiel M, Koval A, et al
GNAO1 Mutations Affecting the N-Terminal alpha-Helix of Galphao Lead to Parkinsonism.
Mov Disord. 2024 Feb 15. doi: 10.1002/mds.29720.
PubMed Abstract available

PAPAGIANNAKIS N, Liu H, Koros C, Simitsi AM, et al
Parkin mRNA Expression Levels in Peripheral Blood Mononuclear Cells in Parkin-Related Parkinson's Disease.
Mov Disord. 2024 Feb 15. doi: 10.1002/mds.29739.
PubMed Abstract available

WEINTRAUB D, Marras C, Amara A, Anderson KE, et al
Association between Subjective Cognitive Complaints and Incident Functional Impairment in Parkinson's Disease.
Mov Disord. 2024 Feb 6. doi: 10.1002/mds.29725.
PubMed Abstract available

KULCSAROVA K, Skorvanek M
Challenges and Future of the International Parkinson and Movement Disorder Society Prodromal Parkinson's Disease Criteria: Are We On the Right Track?
Mov Disord. 2024 Feb 4. doi: 10.1002/mds.29724.
PubMed

YUAN X, Wan L, Chen Z, Long Z, et al
Peripheral Inflammatory and Immune Landscape in Multiple System Atrophy: A Cross-Sectional Study.
Mov Disord. 2024;39:391-399.
PubMed Abstract available

January 2024

FOLLETT J, Guenther D, Xoi L, Amouri R, et al
Genetic Modifiers of LRRK2 Parkinson's Disease: A Replication Study in Arab-Berbers.
Mov Disord. 2024 Jan 31. doi: 10.1002/mds.29735.
PubMed

MANGONE G, Tosin MHS, Goetz CG, Stebbins GT, et al
Unveiling Assessment Gaps in Parkinson's Disease Psychosis: A Scoping Review.
Mov Disord. 2024 Jan 30. doi: 10.1002/mds.29710.
PubMed Abstract available

DAMIER P, Degos B, Castelonovo G, Anheim M, et al
A Double-Blind, Randomized, Placebo-Controlled Trial of Bumetanide in Parkinson's Disease.
Mov Disord. 2024 Jan 30. doi: 10.1002/mds.29726.
PubMed Abstract available

MARRAS C, Fereshtehnejad SM, Berg D, Bohnen NI, et al
Transitioning from Subtyping to Precision Medicine in Parkinson's Disease: A Purpose-Driven Approach.
Mov Disord. 2024 Jan 20. doi: 10.1002/mds.29708.
PubMed Abstract available

EIDEM LE, Birkeland E, Austdal M, Bardsen K, et al
Fatigue in Parkinson's Disease: A Proteomic Study of Cerebrospinal Fluid.
Mov Disord. 2024 Jan 20. doi: 10.1002/mds.29715.
PubMed

DEBOVE I, Paschen S, Amstutz D, Cardoso F, et al
Management of Impulse Control and Related Disorders in Parkinson's Disease: An Expert Consensus.
Mov Disord. 2024 Jan 17. doi: 10.1002/mds.29700.
PubMed Abstract available

ROSE KN, Schwarzschild MA, Gomperts SN
Clearing the Smoke: What Protects Smokers from Parkinson's Disease?
Mov Disord. 2024 Jan 16. doi: 10.1002/mds.29707.
PubMed Abstract available

MULLER S, Kassubek J, Hold ST, Kasper DC, et al
Morbus Fabry and Parkinson's Disease-More Evidence for a Possible Genetic Link.
Mov Disord. 2024 Jan 16. doi: 10.1002/mds.29686.
PubMed

TUNNICLIFFE L, Weil RS, Breuer J, Rodriguez-Barradas MC, et al
Herpes Zoster and Risk of Incident Parkinson's Disease in US Veterans: A Matched Cohort Study.
Mov Disord. 2024 Jan 16. doi: 10.1002/mds.29701.
PubMed Abstract available

AMMANN C, Oliviero A, Obeso JA, Foffani G, et al
Motor Cortex Disinhibition Is Not Associated with Freezing of Gait in Parkinson's Disease.
Mov Disord. 2024 Jan 5. doi: 10.1002/mds.29709.
PubMed

THOMAS GEC, Hannaway N, Zarkali A, Shmueli K, et al
Longitudinal Associations of Magnetic Susceptibility with Clinical Severity in Parkinson's Disease.
Mov Disord. 2024 Jan 3. doi: 10.1002/mds.29702.
PubMed Abstract available

SICILIANO M, Tessitore A, Morgante F, Goldman JG, et al
Subjective Cognitive Complaints in Parkinson's Disease: A Systematic Review and Meta-Analysis.
Mov Disord. 2024 Jan 3. doi: 10.1002/mds.29649.
PubMed Abstract available

DOMEN CH, Sillau S, Liu Y, Leehey MA, et al
Reply to: Cognitive Safety of Cannabis Products in Parkinson's Disease: Need for Solid Scientific Evidence to Guide Clinicians and Patients Currently on Shaky Grounds.
Mov Disord. 2024;39:222-223.
PubMed

GAN-OR Z, Alcalay RN
Genetics of Parkinson's Disease in Underrepresented Populations: New Studies Pave the Way.
Mov Disord. 2024;39:1-2.
PubMed

BEUDEL M
Comment on: "A Transatlantic Viewpoint on the Role of Pallidal Stimulation for Parkinson's Disease".
Mov Disord. 2024;39:223-224.
PubMed

SAMPSON TR
Circulating Extracellular Vesicles as a Potential Mediator of Synuclein Pathology in the Gut.
Mov Disord. 2024;39:3-5.
PubMed

RAU A, Hosp JA, Rijntjes M, Weiller C, et al
Cerebellar, Not Nigrostriatal Degeneration Impairs Dexterity in Multiple System Atrophy.
Mov Disord. 2024;39:130-140.
PubMed Abstract available

KRISMER F, Peran P, Beliveau V, Seppi K, et al
Progressive Brain Atrophy in Multiple System Atrophy: A Longitudinal, Multicenter, Magnetic Resonance Imaging Study.
Mov Disord. 2024;39:119-129.
PubMed Abstract available

HILL ME, Johnson LA, Wang J, Escobar Sanabria D, et al
Paradoxical Modulation of STN beta-Band Activity with Medication Compared to Deep Brain Stimulation.
Mov Disord. 2024;39:192-197.
PubMed Abstract available

December 2023

MIRELMAN A, Volkov J, Salomon A, Gazit E, et al
Digital Mobility Measures: A Window into Real-World Severity and Progression of Parkinson's Disease.
Mov Disord. 2023 Dec 27. doi: 10.1002/mds.29689.
PubMed Abstract available

ONG S, Funayama M, Mangyoku Y, Kawai H, et al
Investigation of 22q11.2 Deletion in Japanese Early-Onset Parkinsonism.
Mov Disord. 2023 Dec 25. doi: 10.1002/mds.29692.
PubMed

JANSSEN DAALEN JM, Koopman WJH, Saris CGJ, Meinders MJ, et al
The Hypoxia Response Pathway: A Potential Intervention Target in Parkinson's Disease?
Mov Disord. 2023 Dec 23. doi: 10.1002/mds.29688.
PubMed Abstract available

BAIK K, Kim YJ, Park M, Chung SJ, et al
Functional Brain Networks of Minor and Well-Structured Major Hallucinations in Parkinson's Disease.
Mov Disord. 2023 Dec 22. doi: 10.1002/mds.29681.
PubMed Abstract available

GONZALEZ-ROBLES C, Bartlett M, Burnell M, Clarke CS, et al
Embedding Patient Input in Outcome Measures for Long-Term Disease-Modifying Parkinson Disease Trials.
Mov Disord. 2023 Dec 22. doi: 10.1002/mds.29691.
PubMed Abstract available

TUNOLD JA, Tan MMX, Toft M, Ross O, et al
Lysosomal Polygenic Burden Drives Cognitive Decline in Parkinson's Disease with Low Alzheimer Risk.
Mov Disord. 2023 Dec 20. doi: 10.1002/mds.29698.
PubMed Abstract available

ESPAY AJ, Hauser RA, Dhall R, Thakkar S, et al
Safety and Efficacy of IPX203 in Parkinson's Disease: The RISE-PD Open-Label Extension Study.
Mov Disord. 2023 Dec 18. doi: 10.1002/mds.29685.
PubMed Abstract available

MARANO M, Anzini G, Saltarocchi L, Ricciuti R, et al
Left Vagus Stimulation Modulates Contralateral Subthalamic beta Power Improving the Gait in Parkinson's Disease.
Mov Disord. 2023 Dec 18. doi: 10.1002/mds.29690.
PubMed Abstract available

CARDOSO F, Goetz CG, Mestre TA, Sampaio C, et al
A Statement of the MDS on Biological Definition, Staging, and Classification of Parkinson's Disease.
Mov Disord. 2023 Dec 13. doi: 10.1002/mds.29683.
PubMed

MYLIUS V, Baars JH, Witt K, Benninger D, et al
Deep Brain Stimulation Improves Parkinson's Disease-Associated Pain by Decreasing Spinal Nociception.
Mov Disord. 2023 Dec 9. doi: 10.1002/mds.29666.
PubMed Abstract available

KIM DJ, Isidro-Perez AL, Doering M, Llibre-Rodriguez JJ, et al
Prevalence and Incidence of Parkinson's Disease in Latin America: A Meta-Analysis.
Mov Disord. 2023 Dec 8. doi: 10.1002/mds.29682.
PubMed Abstract available

BRISSENDEN JA, Scerbak T, Albin RL, Lee TG, et al
Motivational Vigor in Parkinson's Disease Requires the Short and Long Duration Response to Levodopa.
Mov Disord. 2023 Dec 7. doi: 10.1002/mds.29659.
PubMed Abstract available

FIORENZATO E, Moaveninejad S, Weis L, Biundo R, et al
Brain Dynamics Complexity as a Signature of Cognitive Decline in Parkinson's Disease.
Mov Disord. 2023 Dec 6. doi: 10.1002/mds.29678.
PubMed Abstract available

MULLER T, Kuhn W
An Indirect Proof for Levodopa-Induced Vitamin Deficiency in Parkinson's Disease.
Mov Disord. 2023;38:2319-2320.
PubMed

NAMBU A, Chiken S, Sano H, Hatanaka N, et al
Dynamic Activity Model of Movement Disorders: The Fundamental Role of the Hyperdirect Pathway.
Mov Disord. 2023;38:2145-2150.
PubMed Abstract available

ZHENG Y, Cai H, Wang X, Zhang N, et al
Erythrocytic alpha-Synuclein Species as Biomarkers for Isolated Rapid Eye Movement Sleep Behavior Disorder.
Mov Disord. 2023;38:2315-2317.
PubMed

November 2023

ANDREWS SV, Kukkle PL, Menon R, Geetha TS, et al
The Genetic Drivers of Juvenile, Young, and Early-Onset Parkinson's Disease in India.
Mov Disord. 2023 Nov 28. doi: 10.1002/mds.29676.
PubMed Abstract available

WANG J, Li H, Jia J, Shao X, et al
Progressive Cerebrovascular Reactivity Reduction Occurs in Parkinson's Disease: A Longitudinal Study.
Mov Disord. 2023 Nov 27. doi: 10.1002/mds.29671.
PubMed Abstract available

ONGARI G, Ghezzi C, Di Martino D, Pisani A, et al
Impaired Mitochondrial Respiration in REM-Sleep Behavior Disorder: A Biomarker of Parkinson's Disease?
Mov Disord. 2023 Nov 25. doi: 10.1002/mds.29643.
PubMed Abstract available

DI FOLCO C, Couronne R, Arnulf I, Mangone G, et al
Charting Disease Trajectories from Isolated REM Sleep Behavior Disorder to Parkinson's Disease.
Mov Disord. 2023 Nov 25. doi: 10.1002/mds.29662.
PubMed Abstract available

Correction to Excessive alpha-beta Oscillations Mark Enlarged Motor Sign Severity and Parkinson's Disease Duration.
Mov Disord. 2023 Nov 22. doi: 10.1002/mds.29660.
PubMed

MA DR, Li SJ, Shi JJ, Liang YY, et al
Shared Genetic Architecture between Parkinson's Disease and Brain Structural Phenotypes.
Mov Disord. 2023 Nov 21. doi: 10.1002/mds.29598.
PubMed Abstract available

KIM A, Martinez-Valbuena I, Keith JL, Kovacs GG, et al
Misfolded alpha-Synuclein Seeding Is Detected in Suspected LRRK2-Parkinson's Disease without Immunohistochemically Detectable alpha-Synuclein Pathology.
Mov Disord. 2023 Nov 20. doi: 10.1002/mds.29665.
PubMed

BOOGERS A, Fasano A
A Transatlantic Viewpoint on the Role of Pallidal Stimulation for Parkinson's Disease.
Mov Disord. 2023 Nov 15. doi: 10.1002/mds.29656.
PubMed

KERESTES R, Laansma MA, Owens-Walton C, Perry A, et al
Cerebellar Volume and Disease Staging in Parkinson's Disease: An ENIGMA-PD Study.
Mov Disord. 2023 Nov 14. doi: 10.1002/mds.29611.
PubMed Abstract available

OERTEL WH, Paule E, Hasemann T, Sittig E, et al
Reduced Gastric Contraction in Rapid-Eye-Movement Sleep Behavior Disorder and De Novo Parkinson's Disease.
Mov Disord. 2023 Nov 13. doi: 10.1002/mds.29652.
PubMed Abstract available

KONERU V, Espay AJ, Cole AJ, Weintraub D, et al
The Self-Administered Screening Questionnaire for Parkinson's Disease-Associated Psychosis (SASPAP).
Mov Disord. 2023 Nov 8. doi: 10.1002/mds.29627.
PubMed Abstract available

DAIDA K, Funayama M, Billingsley KJ, Malik L, et al
Long-Read Sequencing Resolves a Complex Structural Variant in PRKN Parkinson's Disease.
Mov Disord. 2023 Nov 5. doi: 10.1002/mds.29610.
PubMed Abstract available

SAFFIE AWAD P, Teixeira-Dos-Santos D, Santos-Lobato BL, Camargos S, et al
Frequency of Hereditary and GBA1-Related Parkinsonism in Latin America: A Systematic Review and Meta-Analysis.
Mov Disord. 2023 Nov 3. doi: 10.1002/mds.29614.
PubMed Abstract available

PAL GD, Corcos DM, Metman LV, Israel Z, et al
Cognitive Effects of Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease with GBA1 Pathogenic Variants.
Mov Disord. 2023 Nov 2. doi: 10.1002/mds.29647.
PubMed Abstract available

The Future of Parkinson's Disease: Improving Care & Driving Research.
Mov Disord. 2023;38 Suppl 2:S1-S21.
PubMed

BERGER SL, Seemiller J, Rosenthal LS
Synuclein Seed Amplification in the Cerebrospinal Fluid: Research and Clinical Implications.
Mov Disord. 2023;38:1990-1991.
PubMed

VASILEVSKAYA A, Martinez-Valbuena I, Anastassiadis C, Taghdiri F, et al
Misfolded alpha-Synuclein in Cerebrospinal Fluid of Contact Sport Athletes.
Mov Disord. 2023;38:2125-2131.
PubMed Abstract available

DI LUCA DG, Ramirez-Gomez C, Germann J, Santyr B, et al
Deep Brain Stimulation of the Globus Pallidus Internus and Externus in Multiple System Atrophy.
Mov Disord. 2023;38:2121-2125.
PubMed Abstract available

October 2023

OLANOW CW, Hauser RA, Burdick DJ, Dhall R, et al
A Randomized Phase 3 Study Comparing P2B001 to its Components (Low-Dose Extended-Release Rasagiline and Pramipexole) and to Optimized Doses of Marketed Extended-Release Pramipexole in Early Parkinson's Disease.
Mov Disord. 2023 Oct 27. doi: 10.1002/mds.29642.
PubMed Abstract available

PAHWA R, Merola A, Soileau M, Alobaidi A, et al
Cost-Effectiveness of Carbidopa-Levodopa Enteral Suspension for Advanced Parkinson's Disease in the United States.
Mov Disord. 2023 Oct 25. doi: 10.1002/mds.29624.
PubMed Abstract available

BOUGOU V, Vanhoyland M, Decramer T, Van Hoylandt A, et al
Active and Passive Cycling Decrease Subthalamic beta Oscillations in Parkinson's Disease.
Mov Disord. 2023 Oct 20. doi: 10.1002/mds.29632.
PubMed Abstract available

CONTI M, Guerra A, Pierantozzi M, Bovenzi R, et al
Band-Specific Altered Cortical Connectivity in Early Parkinson's Disease and its Clinical Correlates.
Mov Disord. 2023 Oct 20. doi: 10.1002/mds.29615.
PubMed Abstract available

ALBIN R, Grotewold N
What is the Parkinson Pandemic?
Mov Disord. 2023 Oct 20. doi: 10.1002/mds.29637.
PubMed

WOO KA, Joun JH, Yoon EJ, Lee CY, et al
Monoaminergic Degeneration and Ocular Motor Abnormalities in De Novo Parkinson's Disease.
Mov Disord. 2023 Oct 17. doi: 10.1002/mds.29623.
PubMed Abstract available

BUSCH JL, Kaplan J, Bahners BH, Roediger J, et al
Local Field Potentials Predict Motor Performance in Deep Brain Stimulation for Parkinson's Disease.
Mov Disord. 2023 Oct 12. doi: 10.1002/mds.29626.
PubMed Abstract available

SAMUEL N, Ding MYR, Sarica C, Darmani G, et al
Accelerated Transcranial Ultrasound Neuromodulation in Parkinson's Disease: A Pilot Study.
Mov Disord. 2023 Oct 9. doi: 10.1002/mds.29622.
PubMed Abstract available

YANG Y, Stewart T, Zhang C, Wang P, et al
Erythrocytic alpha-Synuclein and the Gut Microbiome: Kindling of the Gut-Brain Axis in Parkinson's Disease.
Mov Disord. 2023 Oct 5. doi: 10.1002/mds.29620.
PubMed Abstract available

WAN L, Fu Y, Chen Z, Long Z, et al
No Correlation between Plasma GPNMB Levels and Multiple System Atrophy in Chinese Cohorts.
Mov Disord. 2023;38:1956-1961.
PubMed Abstract available

HU Y, Ma TC, Alberico SL, Ding Y, et al
Substantia Nigra Pars Reticulata Projections to the Pedunculopontine Nucleus Modulate Dyskinesia.
Mov Disord. 2023;38:1850-1860.
PubMed Abstract available

GROSSMANN D, Malburg N, Glass H, Weeren V, et al
Mitochondria-Endoplasmic Reticulum Contact Sites Dynamics and Calcium Homeostasis Are Differentially Disrupted in PINK1-PD or PRKN-PD Neurons.
Mov Disord. 2023;38:1822-1836.
PubMed Abstract available

September 2023

JANSSEN DAALEN JM, Oosterhof TH, Bloem BR, Darweesh SKL, et al
Wearables for Parkinson's: Fast-Paced toward Novel Outcome Measures.
Mov Disord. 2023 Sep 29. doi: 10.1002/mds.29608.
PubMed

SATOH R, Weigand SD, Pham NTT, Ali F, et al
Magnetic Susceptibility in Progressive Supranuclear Palsy Variants, Parkinson's Disease, and Corticobasal Syndrome.
Mov Disord. 2023 Sep 29. doi: 10.1002/mds.29613.
PubMed Abstract available

DI FONZO A, Percetti M, Monfrini E, Palmieri I, et al
Harmonizing Genetic Testing for Parkinson's Disease: Results of the PARKNET Multicentric Study.
Mov Disord. 2023 Sep 26. doi: 10.1002/mds.29617.
PubMed Abstract available

TOFFOLI M, Schapira AHV, Proukakis C
Sex Distribution of GBA1 Variants Carriers with Dementia with Lewy Bodies and Parkinson's Disease.
Mov Disord. 2023 Sep 22. doi: 10.1002/mds.29609.
PubMed

NATALE G, Colella M, De Carluccio M, Lelli D, et al
Astrocyte Responses Influence Local Effects of Whole-Brain Magnetic Stimulation in Parkinsonian Rats.
Mov Disord. 2023 Sep 12. doi: 10.1002/mds.29599.
PubMed Abstract available

ZHAO Y, Ray A, Broberg K, Kippler M, et al
Prediagnostic Blood Metal Levels and the Risk of Parkinson's Disease: A Large European Prospective Cohort.
Mov Disord. 2023 Sep 7. doi: 10.1002/mds.29602.
PubMed Abstract available

BOOIJ J, Tellier SP, Seibyl J, Vriend C, et al
Dopamine Transporter Availability in Early Parkinson's Disease is Dependent on Sunlight Exposure.
Mov Disord. 2023 Sep 5. doi: 10.1002/mds.29597.
PubMed Abstract available

MARKAKI I, Paslawski W, Ntetsika T, Engesvik L, et al
Isolation of L1CAM-Extracellular Vesicles Reveals Signs of Insulin Resistance in Parkinson's Disease.
Mov Disord. 2023 Sep 5. doi: 10.1002/mds.29601.
PubMed

Correction to "Olfactory Neuron Substance P Is Overexpressed in Parkinson's Disease Reflecting Gut Dysfunction".
Mov Disord. 2023 Sep 5. doi: 10.1002/mds.29600.
PubMed

FINK A, Dodel R, Georges D, Doblhammer G, et al
The Impact of Sex-Specific Survival on the Incidence of Dementia in Parkinson's Disease.
Mov Disord. 2023 Sep 1. doi: 10.1002/mds.29596.
PubMed Abstract available

BOON LI, Buijink AWG
Parkinsonian Tremor: Shaking in Synchrony.
Mov Disord. 2023;38:1582-1584.
PubMed

GONZALEZ-LATAPI P, Lo RY
Bone First or Brain First: "Picking at the Bones" of Parkinson's Disease.
Mov Disord. 2023;38:1579-1581.
PubMed

ZHANG D, Zhou L, Yao J, Shi Y, et al
Increased Free Water in the Putamen in Idiopathic REM Sleep Behavior Disorder.
Mov Disord. 2023;38:1645-1654.
PubMed Abstract available

August 2023

SUN H, Gan C, Wang L, Ji M, et al
Cortical Disinhibition Drives Freezing of Gait in Parkinson's Disease and an Exploratory Repetitive Transcranial Magnetic Stimulation Study.
Mov Disord. 2023 Aug 30. doi: 10.1002/mds.29595.
PubMed Abstract available

TOTSUNE T, Baba T, Sugimura Y, Oizumi H, et al
Nuclear Imaging Data-Driven Classification of Parkinson's Disease.
Mov Disord. 2023 Aug 28. doi: 10.1002/mds.29582.
PubMed Abstract available

WEINTRAUB D
What's in a Name? The Time Has Come to Unify Parkinson's Disease and Dementia with Lewy Bodies.
Mov Disord. 2023 Aug 23. doi: 10.1002/mds.29590.
PubMed

ANDICA C, Kamagata K, Uchida W, Saito Y, et al
Fiber-Specific White Matter Alterations in Parkinson's Disease Patients with GBA Gene Mutations.
Mov Disord. 2023 Aug 22. doi: 10.1002/mds.29578.
PubMed Abstract available

PARK KY, Jung JH, Hwang HS, Park HK, et al
Bone Mineral Density and the Risk of Parkinson's Disease in Postmenopausal Women.
Mov Disord. 2023 Aug 21. doi: 10.1002/mds.29579.
PubMed Abstract available

TRESSERRA-RIMBAU A, Thompson AS, Bondonno N, Jennings A, et al
Plant-Based Dietary Patterns and Parkinson's Disease: A Prospective Analysis of the UK Biobank.
Mov Disord. 2023 Aug 21. doi: 10.1002/mds.29580.
PubMed Abstract available

DAI L, Wang J, Zhang X, Yan M, et al
27-Hydroxycholesterol Drives the Spread of alpha-Synuclein Pathology in Parkinson's Disease.
Mov Disord. 2023 Aug 18. doi: 10.1002/mds.29577.
PubMed Abstract available

BAR-ON M, Baharav S, Katzir Z, Mirelman A, et al
Task-Related Reorganization of Cognitive Network in Parkinson's Disease Using Electrophysiology.
Mov Disord. 2023 Aug 8. doi: 10.1002/mds.29571.
PubMed Abstract available

GAARE JJ, Brugger K, Nido GS, Tzoulis C, et al
DNA Methylation Age Acceleration Is Not Associated with Age of Onset in Parkinson's Disease.
Mov Disord. 2023 Aug 7. doi: 10.1002/mds.29574.
PubMed Abstract available

CHU Y, Kordower JH
Post-Mortem Studies of Neurturin Gene Therapy for Parkinson's Disease: Two Subjects with 10 Years CERE120 Delivery.
Mov Disord. 2023 Aug 6. doi: 10.1002/mds.29518.
PubMed Abstract available

TA M, Blauwendraat C, Antar T, Leonard HL, et al
Genome-Wide Meta-Analysis of Cerebrospinal Fluid Biomarkers in Alzheimer's Disease and Parkinson's Disease Cohorts.
Mov Disord. 2023 Aug 4. doi: 10.1002/mds.29511.
PubMed Abstract available

CHUA MMJ, Blitz SE, Ng PR, Segar DJ, et al
Focused Ultrasound Thalamotomy for Tremor in Parkinson's Disease: Outcomes in a Large, Prospective Cohort.
Mov Disord. 2023 Aug 4. doi: 10.1002/mds.29569.
PubMed Abstract available

TIAN Y, Ma G, Li H, Zeng Y, et al
Shared Genetics and Comorbid Genes of Amyotrophic Lateral Sclerosis and Parkinson's Disease.
Mov Disord. 2023 Aug 3. doi: 10.1002/mds.29572.
PubMed Abstract available

AQUINO C, Luo L, Agarwal P, Garg K, et al
Deep Brain Stimulation as an Exclusion Criteria in Parkinson's Disease Studies: Time to Rethink?
Mov Disord. 2023 Aug 2. doi: 10.1002/mds.29554.
PubMed

VIRAMETEEKUL S, de Pablo-Fernandez E
Variability in the Accuracy of Clinical Diagnosis of Early Parkinson's Disease.
Mov Disord. 2023;38:1574-1575.
PubMed

GOETZ CG, Zou H, Stebbins GT, Schrag A, et al
Reply to: Comment on "Summing MDS-UPDRS Parts 1 + 2 (Non-motor and Motor Experience of Daily Living): The Patient's Voice".
Mov Disord. 2023;38:1564.
PubMed

KOVACS N, Aschermann Z, Harmat M, Rohonczi M, et al
Comment on "Summing MDS-UPDRS Parts 1 + 2 (Nonmotor and Motor Experience of Daily Living): The Patient's Voice".
Mov Disord. 2023;38:1563-1564.
PubMed

BEACH TG, Adler CH, Shill HA, Zhang N, et al
Accuracy of the Early Diagnosis of Parkinson's Disease.
Mov Disord. 2023;38:1573-1574.
PubMed

KLIETZ M, Mahmoudi N, Maudsley AA, Sheriff S, et al
Whole-Brain Magnetic Resonance Spectroscopy Reveals Distinct Alterations in Neurometabolic Profile in Progressive Supranuclear Palsy.
Mov Disord. 2023;38:1503-1514.
PubMed Abstract available

AGIN-LIEBES J, Hickman RA, Vonsattel JP, Faust PL, et al
Patterns of TDP-43 Deposition in Brains with LRRK2 G2019S Mutations.
Mov Disord. 2023;38:1541-1545.
PubMed Abstract available

Abstracts of the 2023 International Congress of Parkinson's Disease and Movement Disorders.
Mov Disord. 2023;38 Suppl 1:S1-S871.
PubMed

ALBANESE A, Bhatia KP, Cardoso F, Comella C, et al
Isolated Cervical Dystonia: Diagnosis and Classification.
Mov Disord. 2023;38:1367-1378.
PubMed Abstract available

July 2023

LABRADOR-ESPINOSA MA, Silva-Rodriguez J, Reina-Castillo MI, Mir P, et al
Basal Forebrain Atrophy, Cortical Thinning, and Amyloid-beta Status in Parkinson's disease-Related Cognitive Decline.
Mov Disord. 2023 Jul 26. doi: 10.1002/mds.29564.
PubMed Abstract available

BORSCHE M, Berg D
Blood-Based alpha-Synuclein Seeding-A New Era for Identifying Parkinsonian Syndromes.
Mov Disord. 2023 Jul 25. doi: 10.1002/mds.29555.
PubMed

JEONG SH, Kim SH, Park CW, Lee HS, et al
Differential Implications of Cerebral Hypoperfusion and Hyperperfusion in Parkinson's Disease.
Mov Disord. 2023 Jul 25. doi: 10.1002/mds.29565.
PubMed Abstract available

LUTH T, Gabbert C, Koch S, Konig IR, et al
Interaction of Mitochondrial Polygenic Score and Lifestyle Factors in LRRK2 p.Gly2019Ser Parkinsonism.
Mov Disord. 2023 Jul 21. doi: 10.1002/mds.29563.
PubMed Abstract available

LEAL TP, Rao SC, French-Kwawu JN, Gouveia MH, et al
X-Chromosome Association Study in Latin American Cohorts Identifies New Loci in Parkinson's Disease.
Mov Disord. 2023 Jul 20. doi: 10.1002/mds.29508.
PubMed Abstract available

XYLAKI M, Chopra A, Weber S, Bartl M, et al
Extracellular Vesicles for the Diagnosis of Parkinson's Disease: Systematic Review and Meta-Analysis.
Mov Disord. 2023 Jul 14. doi: 10.1002/mds.29497.
PubMed Abstract available

TESSON C, Bouchetara MS, Ferrien M, Lesage S, et al
Identification of a DAGLB Mutation in a Non-Chinese Patient with Parkinson's Disease.
Mov Disord. 2023 Jul 11. doi: 10.1002/mds.29533.
PubMed

ZHUPARRIS A, Thijssen E, Elzinga WO, Makai-Boloni S, et al
Treatment Detection and Movement Disorder Society-Unified Parkinson's Disease Rating Scale, Part III Estimation Using Finger Tapping Tasks.
Mov Disord. 2023 Jul 4. doi: 10.1002/mds.29520.
PubMed Abstract available

ARSHAD U, Rahman F, Hanan N, Chen C, et al
Longitudinal Meta-Analysis of Historical Parkinson's Disease Trials to Inform Future Trial Design.
Mov Disord. 2023 Jul 3. doi: 10.1002/mds.29514.
PubMed Abstract available

TURNER TH, Hinson VK
Cognitive Safety of Cannabis Products in Parkinson's Disease: Need for Solid Scientific Evidence to Guide Clinicians and Patients Currently on Shaky Grounds.
Mov Disord. 2023;38:1125-1126.
PubMed

PU J, Lin L, Jiang H, Hu Z, et al
Parkin Maintains Robust Pacemaking in Human Induced Pluripotent Stem Cell-Derived A9 Dopaminergic Neurons.
Mov Disord. 2023;38:1273-1281.
PubMed Abstract available

ZOU H, Goetz CG, Stebbins GT, Schrag A, et al
Summing MDS-UPDRS Parts 1 + 2 (Non-motor and Motor Experience of Daily Living): The Patient's Voice.
Mov Disord. 2023;38:1363-1364.
PubMed

June 2023

SCHLIESSER P, Struebing FL, Northoff BH, Kurz A, et al
Detection of a Parkinson's Disease-Specific MicroRNA Signature in Nasal and Oral Swabs.
Mov Disord. 2023 Jun 29. doi: 10.1002/mds.29515.
PubMed Abstract available

VON BELOW D, Wallerstedt SM, Bergquist F
Validation of the Swedish Patient-Reported Outcomes in Parkinson's Disease Scale in Outpatients.
Mov Disord. 2023 Jun 29. doi: 10.1002/mds.29517.
PubMed Abstract available

SENKEVICH K, Beletskaia M, Dworkind A, Yu E, et al
Association of Rare Variants in ARSA with Parkinson's Disease.
Mov Disord. 2023 Jun 28. doi: 10.1002/mds.29521.
PubMed Abstract available

PAL G, Cook L, Schulze J, Verbrugge J, et al
Genetic Testing in Parkinson's Disease.
Mov Disord. 2023 Jun 27. doi: 10.1002/mds.29500.
PubMed Abstract available

DIRKX MF, Shine JM, Helmich RC
Integrative Brain States Facilitate the Expression of Parkinson's Tremor.
Mov Disord. 2023 Jun 26. doi: 10.1002/mds.29506.
PubMed Abstract available

VENUTO CS, Smith G, Herbst K, Zielinski R, et al
Predicting Ambulatory Capacity in Parkinson's Disease to Analyze Progression, Biomarkers, and Trial Design.
Mov Disord. 2023 Jun 26. doi: 10.1002/mds.29519.
PubMed Abstract available

LIN CP, Knoop LEJ, Frigerio I, Bol JGJM, et al
Nigral Pathology Contributes to Microstructural Integrity of Striatal and Frontal Tracts in Parkinson's Disease.
Mov Disord. 2023 Jun 22. doi: 10.1002/mds.29510.
PubMed Abstract available

SICILIANO M, De Micco R, Russo AG, Esposito F, et al
Memory Phenotypes In Early, De Novo Parkinson's Disease Patients with Mild Cognitive Impairment.
Mov Disord. 2023 Jun 15. doi: 10.1002/mds.29502.
PubMed Abstract available

HAMEDANI AG, Auinger P, Willis AW, Safarpour D, et al
Adjusting for Underrepresentation Reveals Widespread Underestimation of Parkinson's Disease Symptom Burden.
Mov Disord. 2023 Jun 15. doi: 10.1002/mds.29507.
PubMed Abstract available

SIMONET C, Mahlknecht P, Marini K, Seppi K, et al
The Emergence and Progression of Motor Dysfunction in Individuals at Risk of Parkinson's Disease.
Mov Disord. 2023 Jun 15. doi: 10.1002/mds.29496.
PubMed Abstract available

FLORES-TORRES MH, Bjornevik K, Hung AY, Healy BC, et al
Subjective Cognitive Decline in Women with Features Suggestive of Prodromal Parkinson's Disease.
Mov Disord. 2023 Jun 14. doi: 10.1002/mds.29503.
PubMed Abstract available

YASSINE S, Gschwandtner U, Auffret M, Duprez J, et al
Identification of Parkinson's Disease Subtypes from Resting-State Electroencephalography.
Mov Disord. 2023 Jun 13. doi: 10.1002/mds.29451.
PubMed Abstract available

SAUNDERS-PULLMAN R, Raymond D, Ortega RA, Shalash A, et al
International Genetic Testing and Counseling Practices for Parkinson's Disease.
Mov Disord. 2023 Jun 13. doi: 10.1002/mds.29442.
PubMed Abstract available

SCOTT GD, Neilson LE, Woltjer R, Quinn JF, et al
Lifelong Association of Disorders Related to Military Trauma with Subsequent Parkinson's Disease.
Mov Disord. 2023 Jun 13. doi: 10.1002/mds.29457.
PubMed Abstract available

GILES DORAN C, Wilson F, Goulding SR, Mazzocchi M, et al
Bioinformatics and Immunohistochemical Analyses Support Preserved Expression of Glial Cell Line-Derived Neurotrophic Factor Receptor RET in Parkinson's.
Mov Disord. 2023;38:1115-1116.
PubMed

WHONE A
Reply to: "Bioinformatics and Immunohistochemistry Show Preserved Expression of GDNF Receptor RET in Parkinson's".
Mov Disord. 2023;38:1117-1118.
PubMed

PAL GD, David FJ, Shils JL, Munoz MJ, et al
Subthalamic Physiology in Genetic Subtypes of Parkinson's Disease.
Mov Disord. 2023;38:1113-1114.
PubMed

WEILL C, Gallant A, Baker Erdman H, Abu Snineh M, et al
Reply to: "Subthalamic Physiology in Genetic Subtypes of Parkinson's Disease".
Mov Disord. 2023;38:1114.
PubMed

NEUMANN WJ, Gilron R, Little S, Tinkhauser G, et al
Adaptive Deep Brain Stimulation: From Experimental Evidence Toward Practical Implementation.
Mov Disord. 2023;38:937-948.
PubMed Abstract available

MARTINO D, Karnik V, Bhidayasiri R, Hall DA, et al
Scales for Antipsychotic-Associated Movement Disorders: Systematic Review, Critique, and Recommendations.
Mov Disord. 2023;38:1008-1026.
PubMed Abstract available

SCHIDLITZKI A, Stanojlovic M, Fournier C, Kaufer C, et al
Double-Edged Effects of Venglustat on Behavior and Pathology in Mice Overexpressing alpha-Synuclein.
Mov Disord. 2023;38:1044-1055.
PubMed Abstract available

STEFANI A, Serradell M, Holzknecht E, Gaig C, et al
Low Specificity of Rapid Eye Movement Sleep Behavior Disorder Questionnaires: Need for Better Screening Methods.
Mov Disord. 2023;38:1000-1007.
PubMed Abstract available

UEDA J, Uemura N, Ishimoto T, Taguchi T, et al
Ca(2+) -Calmodulin-Calcineurin Signaling Modulates alpha-Synuclein Transmission.
Mov Disord. 2023;38:1056-1067.
PubMed Abstract available

PEREZ-CARBONELL L, Simonet C, Chohan H, Gill A, et al
The Views of Patients with Isolated Rapid Eye Movement Sleep Behavior Disorder on Risk Disclosure.
Mov Disord. 2023;38:1089-1093.
PubMed Abstract available

KUZKINA A, Panzer C, Seger A, Schmitt D, et al
Dermal Real-Time Quaking-Induced Conversion Is a Sensitive Marker to Confirm Isolated Rapid Eye Movement Sleep Behavior Disorder as an Early alpha-Synucleinopathy.
Mov Disord. 2023;38:1077-1082.
PubMed Abstract available

May 2023

PAYNE T, Appleby M, Buckley E, van Gelder LMA, et al
A Double-Blind, Randomized, Placebo-Controlled Trial of Ursodeoxycholic Acid (UDCA) in Parkinson's Disease.
Mov Disord. 2023 May 29. doi: 10.1002/mds.29450.
PubMed Abstract available

GEORGIADES MJ, Shine JM, Gilat M, McMaster J, et al
Subthalamic Nucleus Activity during Cognitive Load and Gait Dysfunction in Parkinson's Disease.
Mov Disord. 2023 May 25. doi: 10.1002/mds.29455.
PubMed Abstract available

DOMEN CH, Sillau S, Liu Y, Adkins M, et al
Cognitive Safety Data from a Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase IIb Study of the Effects of a Cannabidiol and Delta9-Tetrahydrocannabinol Drug on Parkinson's Disease-Related Motor Symptoms.
Mov Disord. 2023 May 22. doi: 10.1002/mds.29447.
PubMed Abstract available

HUTTUNEN HJ, Booms S, Sjogren M, Kerstens V, et al
Intraputamenal Cerebral Dopamine Neurotrophic Factor in Parkinson's Disease: A Randomized, Double-Blind, Multicenter Phase 1 Trial.
Mov Disord. 2023 May 22. doi: 10.1002/mds.29426.
PubMed Abstract available

KROSCHE M, Kannenberg S, Butz M, Hartmann CJ, et al
Slowing of Frontal beta Oscillations in Atypical Parkinsonism.
Mov Disord. 2023 May 20. doi: 10.1002/mds.29378.
PubMed Abstract available

DEN HEIJER JM, Kruithof AC, Moerland M, Walker M, et al
A Phase 1B Trial in GBA1-Associated Parkinson's Disease of BIA-28-6156, a Glucocerebrosidase Activator.
Mov Disord. 2023 May 17. doi: 10.1002/mds.29346.
PubMed Abstract available

RAFEE S, Fearon C
Palmitoylation: A New Therapeutic Target for Parkinson's Disease?
Mov Disord. 2023 May 11. doi: 10.1002/mds.29418.
PubMed

MAMARIL-DAVIS JC, Gelb AW, Larson PS
Procedure-Related Complications in Sham Surgeries for Parkinson's Clinical Trials: A Meta-analysis.
Mov Disord. 2023 May 11. doi: 10.1002/mds.29406.
PubMed Abstract available

SCHIRINZI T, Maftei D, Grillo P, Bovenzi R, et al
Olfactory Neuron Substance P is Overexpressed in Parkinson's Disease Reflecting Gut Dysfunction.
Mov Disord. 2023 May 8. doi: 10.1002/mds.29433.
PubMed

BROWN GC, Camacho M, Williams-Gray CH
The Endotoxin Hypothesis of Parkinson's Disease.
Mov Disord. 2023 May 8. doi: 10.1002/mds.29432.
PubMed Abstract available

RYMAN SG, Shaff N, Dodd A, Nitschke S, et al
Reduced and Delayed Cerebrovascular Reactivity in Patients with Parkinson's Disease.
Mov Disord. 2023 May 8. doi: 10.1002/mds.29429.
PubMed Abstract available

OUTEIRO TF, Alcalay RN, Antonini A, Attems J, et al
Defining the Riddle in Order to Solve It: There Is More Than One "Parkinson's Disease".
Mov Disord. 2023 May 8. doi: 10.1002/mds.29419.
PubMed Abstract available

KOROS C, Brockmann K, Simitsi AM, Bougea A, et al
Impact of APOE Genotype on Cognition in Idiopathic and Genetic Forms of Parkinson's Disease.
Mov Disord. 2023 May 6. doi: 10.1002/mds.29399.
PubMed

SENKEVICH K, Alipour P, Chernyavskaya E, Yu E, et al
Potential Protective Link Between Type I Diabetes and Parkinson's Disease Risk and Progression.
Mov Disord. 2023 May 6. doi: 10.1002/mds.29424.
PubMed Abstract available

VALENTIJN PP, Eggers C, Bloem BR, Grimes D, et al
Validation of the Rainbow Model of Integrated Care Measurement Tool in Parkinson's Disease.
Mov Disord. 2023 May 6. doi: 10.1002/mds.29413.
PubMed Abstract available

NG J, Barral S, Waddington SN, Kurian MA, et al
Gene Therapy for Dopamine Dyshomeostasis: From Parkinson's to Primary Neurotransmitter Diseases.
Mov Disord. 2023 May 5. doi: 10.1002/mds.29416.
PubMed Abstract available

JOST ST, Kaldenbach MA, Antonini A, Martinez-Martin P, et al
Levodopa Dose Equivalency in Parkinson's Disease: Updated Systematic Review and Proposals.
Mov Disord. 2023 May 5. doi: 10.1002/mds.29410.
PubMed Abstract available

AVERNA A, Debove I, Nowacki A, Peterman K, et al
Spectral Topography of the Subthalamic Nucleus to Inform Next-Generation Deep Brain Stimulation.
Mov Disord. 2023;38:818-830.
PubMed Abstract available

LOFREDI R, Scheller U, Mindermann A, Feldmann LK, et al
Pallidal Beta Activity Is Linked to Stimulation-Induced Slowness in Dystonia.
Mov Disord. 2023;38:894-899.
PubMed Abstract available

ZHANG D, Shi Y, Yao J, Zhou L, et al
Free-Water Imaging of the Substantia Nigra in GBA Pathogenic Variant Carriers.
Mov Disord. 2023;38:764-773.
PubMed Abstract available

April 2023

MESTRE TA, McDermott MP, Lobo R, Ferreira JJ, et al
The Lessebo Effect in Disease Modification Trials in Parkinson's Disease.
Mov Disord. 2023 Apr 24. doi: 10.1002/mds.29414.
PubMed Abstract available

GEROIN C, Artusi CA, Nonnekes J, Aquino C, et al
Axial Postural Abnormalities in Parkinsonism: Gaps in Predictors, Pathophysiology, and Management.
Mov Disord. 2023 Apr 20. doi: 10.1002/mds.29377.
PubMed

LI C, Lin J, Jiang Q, Yang T, et al
Cross-Ethnic Variant Screening and Burden Analysis of PTPA in Parkinson's Disease.
Mov Disord. 2023 Apr 12. doi: 10.1002/mds.29411.
PubMed Abstract available

OH YS, Kim JS, Lyoo CH, Kim H, et al
Obstructive Sleep Apnea and Striatal Dopamine Availability in Parkinson's Disease.
Mov Disord. 2023 Apr 12. doi: 10.1002/mds.29402.
PubMed Abstract available

BELOVA E, Semenova U, Gamaleya A, Tomskiy A, et al
Excessive alpha-beta Oscillations Mark Enlarged Motor Sign Severity and Parkinson's Disease Duration.
Mov Disord. 2023 Apr 6. doi: 10.1002/mds.29393.
PubMed Abstract available

MULLER T, Kuhn W
Epigenetic Drug Effects in Levodopa-Treated Patients with Parkinson's Disease.
Mov Disord. 2023;38:710-711.
PubMed

THALER A, Mirelman A, Alcalay RN
Differences in Sex-Specific Frequency of Glucocerebrosidase Variant Carriers and Familial Parkinsonism.
Mov Disord. 2023;38:713-714.
PubMed

YANG X, Xiao Q
Reply to: "Epigenetic Drug Effects in Levodopa Treated Patients with Parkinson's Disease".
Mov Disord. 2023;38:711.
PubMed

LANG AE
Targeting alpha-Synuclein: A Further Viewpoint.
Mov Disord. 2023;38:715-716.
PubMed

POSTUMA RB, Lang AE
The Clinical Diagnosis of Parkinson's Disease-We Are Getting Better.
Mov Disord. 2023;38:515-517.
PubMed

ORTEGA RA, Bressman SB, Raymond D, Ozelius LJ, et al
Differences in Sex-Specific Frequency of Glucocerebrosidase Variant Carriers and Familial Parkinsonism.
Mov Disord. 2023;38:714-715.
PubMed

PERCETTI M, Monfrini E, Caporali L, Minardi R, et al
Reply to: "Lack of Association between TWNK Rare Variants and Parkinson's Disease in a Chinese Cohort".
Mov Disord. 2023;38:709-710.
PubMed

KRESOJEVIC N, Markovic V, Dobricic V, Stankovic I, et al
Reply to: "Differences in Sex-Specific Frequency of Glucocerebrosidase Variant Carriers and Familial Parkinsonism".
Mov Disord. 2023;38:712-713.
PubMed

LI C, Lin J, Jiang Q, Yang T, et al
Lack of Association between TWNK Rare Variants and Parkinson's Disease in a Chinese Cohort.
Mov Disord. 2023;38:708-709.
PubMed

BOLOGNA M, Espay AJ, Fasano A, Paparella G, et al
Redefining Bradykinesia.
Mov Disord. 2023;38:551-557.
PubMed

HUANG SY, Chen SF, Cui M, Zhao M, et al
Plasma Biomarkers and Positron Emission Tomography Tau Pathology in Progressive Supranuclear Palsy.
Mov Disord. 2023;38:676-682.
PubMed Abstract available

March 2023

BORSCHE M, Pratuseviciute N, Schaake S, Hinrichs F, et al
The New p.F1700L LRRK2 Variant Causes Parkinson's Disease by Extensively Increasing Kinase Activity.
Mov Disord. 2023 Mar 27. doi: 10.1002/mds.29385.
PubMed

ZENG R, Wang J, Zheng C, Jiang R, et al
Lack of Causal Associations of Inflammatory Bowel Disease with Parkinson's Disease and Other Neurodegenerative Disorders.
Mov Disord. 2023 Mar 23. doi: 10.1002/mds.29386.
PubMed Abstract available

ZHOU G, Ren J, Rong D, Zhou H, et al
Monitoring Substantia Nigra Degeneration Using Free Water Imaging across Prodromal and Clinical Parkinson's Disease.
Mov Disord. 2023 Mar 22. doi: 10.1002/mds.29366.
PubMed Abstract available

MESTRE TA, Schlossmacher MG
Target-Specific Strategies to Modify the Course of Parkinson's: Is Iron Chelation Safe?
Mov Disord. 2023 Mar 21. doi: 10.1002/mds.29382.
PubMed

FLORES-TORRES MH, Christine CW, Bjornevik K, Molsberry SA, et al
Long-Term Intake of Folate, Vitamin B6, and Vitamin B12 and the Incidence of Parkinson's Disease in a Sample of U.S. Women and Men.
Mov Disord. 2023 Mar 20. doi: 10.1002/mds.29383.
PubMed Abstract available

DEN HEIJER JM, Cullen VC, Pereira DR, Yavuz Y, et al
A Biomarker Study in Patients with GBA1-Parkinson's Disease and Healthy Controls.
Mov Disord. 2023 Mar 14. doi: 10.1002/mds.29360.
PubMed Abstract available

MUNOZ-DELGADO L, Labrador-Espinosa MA, Macias-Garcia D, Jesus S, et al
Peripheral Inflammation Is Associated with Dopaminergic Degeneration in Parkinson's Disease.
Mov Disord. 2023 Mar 13. doi: 10.1002/mds.29369.
PubMed Abstract available

KAMATH T, Macosko EZ
Insights into Neurodegeneration in Parkinson's Disease from Single-Cell and Spatial Genomics.
Mov Disord. 2023 Mar 7. doi: 10.1002/mds.29374.
PubMed Abstract available

DORSEY ER, Ray A
Paraquat, Parkinson's Disease, and Agnotology.
Mov Disord. 2023 Mar 6. doi: 10.1002/mds.29371.
PubMed

BLAUWENDRAAT C, Tayebi N, Woo EG, Lopez G, et al
Polygenic Parkinson's Disease Genetic Risk Score as Risk Modifier of Parkinsonism in Gaucher Disease.
Mov Disord. 2023 Mar 3. doi: 10.1002/mds.29342.
PubMed Abstract available

MARSILI L, Duque KR, Gregor N, Abdelghany E, et al
Bradykinesia in Neurodegenerative Disorders: A Blinded Video Analysis of Pathology-Proven Cases.
Mov Disord. 2023;38:496-501.
PubMed Abstract available

JENSEN PH, Schlossmacher MG, Stefanis L
Who Ever Said It Would Be Easy? Reflecting on Two Clinical Trials Targeting alpha-Synuclein.
Mov Disord. 2023;38:378-384.
PubMed Abstract available

VIRAMETEEKUL S, Revesz T, Jaunmuktane Z, Warner TT, et al
Pathological Validation of the MDS Criteria for the Diagnosis of Multiple System Atrophy.
Mov Disord. 2023;38:444-452.
PubMed Abstract available

WANG EW, Brown GL, Lewis MM, Jellen LC, et al
Susceptibility Magnetic Resonance Imaging Correlates with Glial Density and Tau in the Substantia Nigra Pars Compacta.
Mov Disord. 2023;38:464-473.
PubMed Abstract available

TAN C, Nawaz H, Lageman SK, Cloud LJ, et al
Cholinergic Nucleus 4 Degeneration and Cognitive Impairment in Isolated Rapid Eye Movement Sleep Behavior Disorder.
Mov Disord. 2023;38:474-479.
PubMed Abstract available

WIEST C, Morgante F, Torrecillos F, Pogosyan A, et al
Subthalamic Nucleus Stimulation-Induced Local Field Potential Changes in Dystonia.
Mov Disord. 2023;38:423-434.
PubMed Abstract available

ROSSI M, Hamed M, Rodriguez-Antiguedad J, Cornejo-Olivas M, et al
Genotype-Phenotype Correlations for ATX-TBP (SCA17): MDSGene Systematic Review.
Mov Disord. 2023;38:368-377.
PubMed Abstract available

February 2023

YACOUBIAN TA, Fang YD, Gerstenecker A, Amara A, et al
Brain and Systemic Inflammation in De Novo Parkinson's Disease.
Mov Disord. 2023 Feb 28. doi: 10.1002/mds.29363.
PubMed Abstract available

EMMI A, Sandre M, Russo FP, Tombesi G, et al
Duodenal alpha-Synuclein Pathology and Enteric Gliosis in Advanced Parkinson's Disease.
Mov Disord. 2023 Feb 27. doi: 10.1002/mds.29358.
PubMed Abstract available

SCIACCA G, Mostile G, Disilvestro I, Donzuso G, et al
Long-Duration Response to Levodopa, Motor Learning, and Neuroplasticity in Early Parkinson's Disease.
Mov Disord. 2023 Feb 25. doi: 10.1002/mds.29344.
PubMed Abstract available

JUNG JH, Na HK, Jeong SH, Chung SJ, et al
Effects of Dihydropyridines on the Motor and Cognitive Outcomes of Patients with Parkinson's Disease.
Mov Disord. 2023 Feb 24. doi: 10.1002/mds.29367.
PubMed Abstract available

LANDELLE C, Dahlberg LS, Lungu O, Misic B, et al
Altered Spinal Cord Functional Connectivity Associated with Parkinson's Disease Progression.
Mov Disord. 2023 Feb 21. doi: 10.1002/mds.29354.
PubMed Abstract available

MANCINI A, Stoops E, Demeyer L, Bellomo G, et al
LRRK2 Quantification in Cerebrospinal Fluid of Patients with Parkinson's Disease and Atypical Parkinsonian Syndromes.
Mov Disord. 2023 Feb 18. doi: 10.1002/mds.29336.
PubMed Abstract available

JENNINGS D, Huntwork-Rodriguez S, Vissers MFJM, Daryani VM, et al
LRRK2 Inhibition by BIIB122 in Healthy Participants and Patients with Parkinson's Disease.
Mov Disord. 2023 Feb 18. doi: 10.1002/mds.29297.
PubMed Abstract available

SU D, Gan Y, Zhang Z, Cui Y, et al
Multimodal Imaging of Substantia Nigra in Parkinson's Disease with Levodopa-Induced Dyskinesia.
Mov Disord. 2023 Feb 17. doi: 10.1002/mds.29320.
PubMed Abstract available

SUGIER PE, Lucotte EA, Domenighetti C, Law MH, et al
Investigation of Shared Genetic Risk Factors Between Parkinson's Disease and Cancers.
Mov Disord. 2023 Feb 14. doi: 10.1002/mds.29337.
PubMed Abstract available

NGUYEN TTH, Fournier A, Courtois E, Artaud F, et al
Statin Use and Incidence of Parkinson's Disease in Women from the French E3N Cohort Study.
Mov Disord. 2023 Feb 14. doi: 10.1002/mds.29349.
PubMed Abstract available

AZIZ NA, Wullner U
Genetic Variants in Sulfonylurea Targets Affect Parkinson's Disease Risk: A Two-Sample Mendelian Randomization Study.
Mov Disord. 2023 Feb 13. doi: 10.1002/mds.29341.
PubMed

CONCHA-MARAMBIO L, Weber S, Farris CM, Dakna M, et al
Accurate Detection of alpha-Synuclein Seeds in Cerebrospinal Fluid from Isolated Rapid Eye Movement Sleep Behavior Disorder and Patients with Parkinson's Disease in the DeNovo Parkinson (DeNoPa) Cohort.
Mov Disord. 2023 Feb 13. doi: 10.1002/mds.29329.
PubMed Abstract available

BECKER-COHEN M, Zimran A, Arkadir D, Revel-Vilk S, et al
Has Parkinson Disease Gone to the Dogs?
Mov Disord. 2023;38:358.
PubMed

GAO CQ, Zhang XX, Wang MM, Guo JF, et al
Reply to: Has Parkinson Disease Gone to the Dogs?
Mov Disord. 2023;38:359.
PubMed

GOETZ CG, Choi D, Guo Y, Stebbins GT, et al
It Is as It Was: MDS-UPDRS Part III Scores Cannot Be Combined with Other Parts to Give a Valid Sum.
Mov Disord. 2023;38:342-347.
PubMed Abstract available

GARRIDO A, Fairfoul G, Tolosa E, Marti MJ, et al
Brain and Cerebrospinal Fluid alpha-Synuclein Real-Time Quaking-Induced Conversion Identifies Lewy Body Pathology in LRRK2-PD.
Mov Disord. 2023;38:333-338.
PubMed Abstract available

OLSEN AL, Clemens SG, Feany MB
Nicotine-Mediated Rescue of alpha-Synuclein Toxicity Requires Synaptic Vesicle Glycoprotein 2 in Drosophila.
Mov Disord. 2023;38:244-255.
PubMed Abstract available

January 2023

FELDMANN LK, Lofredi R, Al-Fatly B, Busch JL, et al
Christmas-Related Reduction in Beta Activity in Parkinson's Disease.
Mov Disord. 2023 Jan 31. doi: 10.1002/mds.29334.
PubMed Abstract available

STREUBEL-GALLASCH L, Seibler P
Neuron-Derived Misfolded alpha-Synuclein in Blood: A Potential Biomarker for Parkinson's Disease?
Mov Disord. 2023 Jan 31. doi: 10.1002/mds.29331.
PubMed

BORSCHE M, Martens A, Hormann P, Bruckmann T, et al
In Vivo Investigation of Glucose Metabolism in Idiopathic and PRKN-Related Parkinson's Disease.
Mov Disord. 2023 Jan 30. doi: 10.1002/mds.29333.
PubMed Abstract available

KIM J, Inbo H, Kim HS, Kim W, et al
First Clinical Report on the Treatment of Parkinson's Disease with Fetal Midbrain Precursor Cells.
Mov Disord. 2023 Jan 24. doi: 10.1002/mds.29316.
PubMed Abstract available

VOLLSTEDT EJ, Schaake S, Lohmann K, Padmanabhan S, et al
Embracing Monogenic Parkinson's Disease: The MJFF Global Genetic PD Cohort.
Mov Disord. 2023 Jan 24. doi: 10.1002/mds.29288.
PubMed Abstract available

BOKTOR JC, Sharon G, Verhagen Metman LA, Hall DA, et al
Integrated Multi-Cohort Analysis of the Parkinson's Disease Gut Metagenome.
Mov Disord. 2023 Jan 24. doi: 10.1002/mds.29300.
PubMed Abstract available

KAASINEN V, Luo S, Martinez-Martin P, Goetz CG, et al
Cross-Cultural Differences in Patient Perceptions of Dyskinesia in Parkinson's Disease.
Mov Disord. 2023 Jan 20. doi: 10.1002/mds.29335.
PubMed Abstract available

WEILL C, Gallant A, Baker Erdman H, Abu Snineh M, et al
The Genetic Etiology of Parkinson's Disease Does Not Robustly Affect Subthalamic Physiology.
Mov Disord. 2023 Jan 9. doi: 10.1002/mds.29310.
PubMed Abstract available

GUO Y, Goetz CG, Stebbins GT, Mestre TA, et al
Using Movement Disorder Society Unified Parkinson's Disease Rating Scale Parts 2 and 3 Simultaneously: Combining the Patient Voice with Clinician Ratings.
Mov Disord. 2023 Jan 9. doi: 10.1002/mds.29308.
PubMed Abstract available

ABDELHAFEEZ M, Elsayed I
In Situ Global Structural Proteome Analysis Identifies Potential Biomarkers for Parkinson's Disease.
Mov Disord. 2023 Jan 9. doi: 10.1002/mds.29315.
PubMed

VIRAMETEEKUL S, Revesz T, Jaunmuktane Z, Warner TT, et al
Clinical Diagnostic Accuracy of Parkinson's Disease: Where Do We Stand?
Mov Disord. 2023 Jan 5. doi: 10.1002/mds.29317.
PubMed Abstract available

PARLAR SC, Grenn FP, Kim JJ, Baluwendraat C, et al
Classification of GBA1 Variants in Parkinson's Disease: The GBA1-PD Browser.
Mov Disord. 2023 Jan 4. doi: 10.1002/mds.29314.
PubMed Abstract available

NOBILEAU A, Gaurav R, Chougar L, Faucher A, et al
Neuromelanin-Sensitive Magnetic Resonance Imaging Changes in the Locus Coeruleus/Subcoeruleus Complex in Patients with Typical and Atypical Parkinsonism.
Mov Disord. 2023 Jan 2. doi: 10.1002/mds.29309.
PubMed Abstract available

LLOYD K, Lawton M, Whone A
Practically Defined Off-State Dyskinesia Following Repeated Intraputamenal Glial Cell Line-Derived Neurotrophic Factor Administration.
Mov Disord. 2023;38:104-112.
PubMed Abstract available

BRINK-KJAER A, Gupta N, Marin E, Zitser J, et al
Ambulatory Detection of Isolated Rapid-Eye-Movement Sleep Behavior Disorder Combining Actigraphy and Questionnaire.
Mov Disord. 2023;38:82-91.
PubMed Abstract available

ZHANG D, Zhou L, Shi Y, Liu J, et al
Increased Free Water in the Substantia Nigra in Asymptomatic LRRK2 G2019S Mutation Carriers.
Mov Disord. 2023;38:138-142.
PubMed Abstract available

MATTIOLI P, Orso B, Liguori C, Fama F, et al
Derivation and Validation of a Phenoconversion-Related Pattern in Idiopathic Rapid Eye Movement Behavior Disorder.
Mov Disord. 2023;38:57-67.
PubMed Abstract available

December 2022

CULLINANE PW, de Pablo Fernandez E, Konig A, Outeiro TF, et al
Type 2 Diabetes and Parkinson's Disease: A Focused Review of Current Concepts.
Mov Disord. 2022 Dec 26. doi: 10.1002/mds.29298.
PubMed Abstract available

BAIK K, Kim HR, Park M, Lee Y, et al
Effect of Amyloid on Cognitive Performance in Parkinson's Disease and Dementia with Lewy Bodies.
Mov Disord. 2022 Dec 17. doi: 10.1002/mds.29295.
PubMed Abstract available

PALERMO G, Ceravolo R
Clues to Reshaping Anti-alpha-Synuclein Immunotherapy in Early Parkinson's Disease Patients.
Mov Disord. 2022 Dec 15. doi: 10.1002/mds.29294.
PubMed

NILSSON J, Constantinescu J, Nellgard B, Jakobsson P, et al
Cerebrospinal Fluid Biomarkers of Synaptic Dysfunction Are Altered in Parkinson's Disease and Related Disorders.
Mov Disord. 2022 Dec 12. doi: 10.1002/mds.29287.
PubMed Abstract available

PINTO S, Nebel A, Rau J, Espesser R, et al
Results of a Randomized Clinical Trial of Speech after Early Neurostimulation in Parkinson's Disease.
Mov Disord. 2022 Dec 3. doi: 10.1002/mds.29282.
PubMed Abstract available

RUSSO MJ, MacLeod K, Lamoureux J, Lebovitz R, et al
Aggregation-Seeding Forms of alpha-Synuclein Are Not Detected in Acute Coronavirus Disease 2019 Cerebrospinal Fluid.
Mov Disord. 2022;37:2462-2463.
PubMed

LORENZO-BETANCOR O, Galosi L, Bonfili L, Eleuteri AM, et al
Homozygous CADPS2 Mutations Cause Neurodegenerative Disease with Lewy Body-like Pathology in Parrots.
Mov Disord. 2022;37:2345-2354.
PubMed Abstract available

November 2022

DARMANI G, Drummond NM, Ramezanpour H, Saha U, et al
Long-Term Recording of Subthalamic Aperiodic Activities and Beta Bursts in Parkinson's Disease.
Mov Disord. 2022 Nov 24. doi: 10.1002/mds.29276.
PubMed Abstract available

TALEBI AH, Ypinga JHL, De Vries NM, Nonnekes J, et al
Specialized Versus Generic Allied Health Therapy and the Risk of Parkinson's Disease Complications.
Mov Disord. 2022 Nov 24. doi: 10.1002/mds.29274.
PubMed Abstract available

TANG Y, Li L, Hu T, Jiao F, et al
In Vivo (18) F-Florzolotau Tau Positron Emission Tomography Imaging in Parkinson's Disease Dementia.
Mov Disord. 2022 Nov 11. doi: 10.1002/mds.29273.
PubMed Abstract available

KRAINC T, Monje MHG, Kinsinger M, Bustos BI, et al
Melanin and Neuromelanin: Linking Skin Pigmentation and Parkinson's Disease.
Mov Disord. 2022 Nov 9. doi: 10.1002/mds.29260.
PubMed Abstract available

LEDONNE A, Massaro Cenere M, Paldino E, D'Angelo V, et al
Morpho-Functional Changes of Nigral Dopamine Neurons in an alpha-Synuclein Model of Parkinson's Disease.
Mov Disord. 2022 Nov 9. doi: 10.1002/mds.29269.
PubMed Abstract available

HOENIG MC, Dzialas V, Drzezga A, van Eimeren T, et al
The Concept of Motor Reserve in Parkinson's Disease: New Wine in Old Bottles?
Mov Disord. 2022 Nov 7. doi: 10.1002/mds.29266.
PubMed

TROCHE MS, Curtis JA, Sevitz JS, Dakin AE, et al
Rehabilitating Cough Dysfunction in Parkinson's Disease: A Randomized Controlled Trial.
Mov Disord. 2022 Nov 7. doi: 10.1002/mds.29268.
PubMed Abstract available

PIZARRO GALLEGUILLOS BM, Mohamed W, Perinan MT
The Glycoprotein GPNMB: A Secret Ingredient for Understanding Parkinson's Disease Etiology?
Mov Disord. 2022 Nov 2. doi: 10.1002/mds.29264.
PubMed

BOHNEN NI, Kanel P, van Emde Boas M, Roytman S, et al
Vestibular Sensory Conflict During Postural Control, Freezing of Gait, and Falls in Parkinson's Disease.
Mov Disord. 2022;37:2257-2262.
PubMed Abstract available

PERCETTI M, Monfrini E, Caporali L, Minardi R, et al
Reply to: No Association between Rare TWNK Variants and Parkinson's Disease in European Cohorts.
Mov Disord. 2022;37:2319-2320.
PubMed

SOTIRAKIS C, Conway N, Su Z, Villarroel M, et al
Longitudinal Monitoring of Progressive Supranuclear Palsy using Body-Worn Movement Sensors.
Mov Disord. 2022;37:2263-2271.
PubMed Abstract available

LEYS F, Eschlbock S, Campese N, Mahlknecht P, et al
Family History for Neurodegeneration in Multiple System Atrophy: Does it Indicate Susceptibility?
Mov Disord. 2022;37:2310-2312.
PubMed

October 2022

BARTL M, Dakna M, Schade S, Otte B, et al
Blood Markers of Inflammation, Neurodegeneration, and Cardiovascular Risk in Early Parkinson's Disease.
Mov Disord. 2022 Oct 20. doi: 10.1002/mds.29257.
PubMed Abstract available

VIVACQUA G, Mason M, De Bartolo MI, Wegrzynowicz M, et al
Salivary alpha-Synuclein RT-QuIC Correlates with Disease Severity in de novo Parkinson's Disease.
Mov Disord. 2022 Oct 19. doi: 10.1002/mds.29246.
PubMed

HULZINGA F, Seuthe J, D'Cruz N, Ginis P, et al
Split-Belt Treadmill Training to Improve Gait Adaptation in Parkinson's Disease.
Mov Disord. 2022 Oct 14. doi: 10.1002/mds.29238.
PubMed Abstract available

CLERET DE LANGAVANT L, Roze E, Petit A, Tressieres B, et al
Annonaceae Consumption Worsens Disease Severity and Cognitive Deficits in Degenerative Parkinsonism.
Mov Disord. 2022 Oct 10. doi: 10.1002/mds.29222.
PubMed Abstract available

ZIMPRICH A
LRRK2 PROTAC Degraders as a Potential Novel Targeting Strategy for Parkinson's Disease?
Mov Disord. 2022 Oct 5. doi: 10.1002/mds.29243.
PubMed

KIM R, Kim H, Kim YK, Yoon EJ, et al
Brain Metabolic Correlates of Dopaminergic Denervation in Prodromal and Early Parkinson's Disease.
Mov Disord. 2022;37:2099-2109.
PubMed Abstract available

SAWAMURA M, Onoe H, Tsukada H, Isa K, et al
Lewy Body Disease Primate Model with alpha-Synuclein Propagation from the Olfactory Bulb.
Mov Disord. 2022;37:2033-2044.
PubMed Abstract available

SOTO M, Iranzo A, Lahoz S, Fernandez M, et al
Serum MicroRNAs Predict Isolated Rapid Eye Movement Sleep Behavior Disorder and Lewy Body Diseases.
Mov Disord. 2022;37:2086-2098.
PubMed Abstract available

September 2022

DANG X, Zhang Z, Luo XJ
Mendelian Randomization Study Using Dopaminergic Neuron-Specific eQTL Nominates Potential Causal Genes for Parkinson's Disease.
Mov Disord. 2022 Sep 29. doi: 10.1002/mds.29239.
PubMed Abstract available

PAULY C, Glaab E, Hansen M, Martin-Gallausiaux C, et al
Disease Progression, Resilience, and Inflammation Markers During the Coronavirus Disease 2019 Pandemic in Parkinson's Disease.
Mov Disord. 2022 Sep 23. doi: 10.1002/mds.29212.
PubMed

WILHELM E, Quoilin C, Derosiere G, Paco S, et al
Corticospinal Suppression Underlying Intact Movement Preparation Fades in Parkinson's Disease.
Mov Disord. 2022 Sep 19. doi: 10.1002/mds.29214.
PubMed Abstract available

CHOU KL, Dayalu P, Koeppe RA, Gilman S, et al
Serotonin Transporter Imaging in Multiple System Atrophy and Parkinson's Disease.
Mov Disord. 2022 Sep 14. doi: 10.1002/mds.29220.
PubMed Abstract available

MILLS KA, Pontone GM
The Dawn of Precision Medicine for Deep Brain Stimulation in Parkinson's Disease?
Mov Disord. 2022 Sep 14. doi: 10.1002/mds.29224.
PubMed

MENG Y, Pople CB, Huang Y, Jones RM, et al
Putaminal Recombinant Glucocerebrosidase Delivery with Magnetic Resonance-Guided Focused Ultrasound in Parkinson's Disease: A Phase I Study.
Mov Disord. 2022 Sep 11. doi: 10.1002/mds.29190.
PubMed Abstract available

LANSBURY P
The Sphingolipids Clearly Play a Role in Parkinson's Disease, but Nature Has Made it Complicated.
Mov Disord. 2022 Sep 10. doi: 10.1002/mds.29204.
PubMed

LUO J, Wu H, Li J, Xian W, et al
Joint Modeling Study Identifies Blood-Based Transcripts Link to Cognitive Decline in Parkinson's Disease.
Mov Disord. 2022 Sep 10. doi: 10.1002/mds.29213.
PubMed Abstract available

ZHANG X, Xu J, Liu Y, Chen S, et al
Diet Quality is Associated with Prodromal Parkinson's Disease Features in Chinese Adults.
Mov Disord. 2022 Sep 7. doi: 10.1002/mds.29208.
PubMed Abstract available

SENKEVICH K, Gan-Or Z
No Association Between Rare TWNK Variants and Parkinson's Disease in European Cohorts.
Mov Disord. 2022 Sep 4. doi: 10.1002/mds.29216.
PubMed

SEIFAR F, Dinasarapu AR, Jinnah HA
Uric Acid in Parkinson's Disease: What Is the Connection?
Mov Disord. 2022 Sep 3. doi: 10.1002/mds.29209.
PubMed Abstract available

HARIZ M, Bronstein JM, Cosgrove GR, de Bie RMA, et al
European Academy of Neurology/Movement Disorder Society-European Section Guidelines on Pallidotomy for Parkinson's Disease: Let's Be Accurate.
Mov Disord. 2022 Sep 1. doi: 10.1002/mds.29210.
PubMed

August 2022

FERREIRA JJ, Poewe W, Rascol O, Stocchi F, et al
Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's Disease.
Mov Disord. 2022 Aug 31. doi: 10.1002/mds.29193.
PubMed Abstract available

COURTOIS E, Nguyen TTH, Fournier A, Carcaillon-Bentata L, et al
Identifying Protective Drugs for Parkinson's Disease in Health-Care Databases Using Machine Learning.
Mov Disord. 2022 Aug 29. doi: 10.1002/mds.29205.
PubMed Abstract available

LI D, Mastaglia FL, Yau WY, Chen S, et al
Targeted Molecular Therapeutics for Parkinson's Disease: A Role for Antisense Oligonucleotides?
Mov Disord. 2022 Aug 29. doi: 10.1002/mds.29201.
PubMed

GOLFRE ANDREASI N, Cilia R, Romito LM, Bonvegna S, et al
Magnetic Resonance-Guided Focused Ultrasound Thalamotomy May Spare Dopaminergic Therapy in Early-Stage Tremor-Dominant Parkinson's Disease: A Pilot Study.
Mov Disord. 2022 Aug 29. doi: 10.1002/mds.29200.
PubMed Abstract available

ORTEGA RA, Bressman SB, Raymond D, Ozelius LJ, et al
Differences in Sex-Specific Frequency of Glucocerebrosidase Variant Carriers and Familial Parkinsonism.
Mov Disord. 2022 Aug 27. doi: 10.1002/mds.29197.
PubMed Abstract available

GAO CQ, Wang SN, Wang MM, Li JJ, et al
Sensitivity of Sniffer Dogs for a Diagnosis of Parkinson's Disease: A Diagnostic Accuracy Study.
Mov Disord. 2022 Aug 25. doi: 10.1002/mds.29180.
PubMed Abstract available

RUS T, Schindlbeck KA, Tang CC, Vo A, et al
Stereotyped Relationship Between Motor and Cognitive Metabolic Networks in Parkinson's Disease.
Mov Disord. 2022 Aug 23. doi: 10.1002/mds.29188.
PubMed Abstract available

SIMMERING JE, Welsh MJ, Schultz J, Narayanan NS, et al
Use of Glycolysis-Enhancing Drugs and Risk of Parkinson's Disease.
Mov Disord. 2022 Aug 22. doi: 10.1002/mds.29184.
PubMed Abstract available

STEFANO DP, Franciotti R, Chiacchiaretta P, Ferretti A, et al
Altered Medial Prefrontal Connectivity in Parkinson's Disease Patients with Somatic Symptoms.
Mov Disord. 2022 Aug 22. doi: 10.1002/mds.29187.
PubMed Abstract available

YUAN X, Yang Y, Liu C, Tian Y, et al
Fine Particulate Matter Triggers alpha-Synuclein Fibrillization and Parkinson-like Neurodegeneration.
Mov Disord. 2022 Aug 22. doi: 10.1002/mds.29181.
PubMed Abstract available

REYES CJ, Asano K, Todd PK, Klein C, et al
Repeat-Associated Non-AUG Translation of AGAGGG Repeats that Cause X-Linked Dystonia-Parkinsonism.
Mov Disord. 2022 Aug 16. doi: 10.1002/mds.29183.
PubMed Abstract available

SAFARPOUR D, Brumbach BH, Arena M, Quinn J, et al
Gastrointestinal Motility and Response to Levodopa in Parkinson's Disease: A Proof-of-Concept Study.
Mov Disord. 2022 Aug 15. doi: 10.1002/mds.29176.
PubMed Abstract available

SMIT JW, Basile P, Prato MK, Detalle L, et al
Phase 1/1b Studies of UCB0599, an Oral Inhibitor of alpha-Synuclein Misfolding, Including a Randomized Study in Parkinson's Disease.
Mov Disord. 2022 Aug 12. doi: 10.1002/mds.29170.
PubMed Abstract available

BANWINKLER M, Dzialas V, Hoenig MC, van Eimeren T, et al
Gray Matter Volume Loss in Proposed Brain-First and Body-First Parkinson's Disease Subtypes.
Mov Disord. 2022 Aug 9. doi: 10.1002/mds.29172.
PubMed Abstract available

MCKEE KE, Gilbert RM, Spigle WA, Tilley BC, et al
Inclusion of Non-English-Speaking Participants in Studies of Parkinson's Disease: A Call to Action.
Mov Disord. 2022 Aug 5. doi: 10.1002/mds.29179.
PubMed

TANG X, Gonzalez-Latapi P, Marras C, Visanji NP, et al
Epigenetic Clock Acceleration Is Linked to Age at Onset of Parkinson's Disease.
Mov Disord. 2022 Aug 3. doi: 10.1002/mds.29157.
PubMed Abstract available

SURFACE M, Balwani M, Waters C, Haimovich A, et al
Reply to: "Could Blood Hexosylsphingosine Be a Marker for Parkinson's Disease Linked with GBA1 Mutations"?
Mov Disord. 2022;37:1782.
PubMed

GLEASON AM, Tayebi N, Lopez GJ, Sidransky E, et al
Reply to: "Overlapping Ranges in Levels Indicate That Hexosylsphingosine Is Not a Clinically Relevant Biomarker for GBA1-Associated Parkinson's Disease".
Mov Disord. 2022;37:1781-1782.
PubMed

LI C, Lin J, Gu X, Hou Y, et al
Mutation Screening of TFG in alpha-Synucleinopathy and Amyotrophic Lateral Sclerosis.
Mov Disord. 2022;37:1756-1761.
PubMed Abstract available

PAZ RM, Stahl AM, Rela L, Murer MG, et al
D1/D5 Inverse Agonists Restore Striatal Cholinergic Interneuron Physiology in Dyskinetic Mice.
Mov Disord. 2022;37:1693-1706.
PubMed Abstract available

July 2022

DAIDA K, Shimonaka S, Shiba-Fukushima K, Ogata J, et al
alpha-Synuclein V15A Variant in Familial Parkinson's Disease Exhibits a Weaker Lipid-Binding Property.
Mov Disord. 2022 Jul 27. doi: 10.1002/mds.29162.
PubMed Abstract available

TE VRUCHTE D, Sturchio A, Priestman DA, Tsitsi P, et al
Glycosphingolipid Changes in Plasma in Parkinson's Disease Independent of Glucosylceramide Levels.
Mov Disord. 2022 Jul 25. doi: 10.1002/mds.29163.
PubMed Abstract available

SCHUMACHER-SCHUH AF, Bieger A, Okunoye O, Mok KY, et al
Underrepresented Populations in Parkinson's Genetics Research: Current Landscape and Future Directions.
Mov Disord. 2022 Jul 22. doi: 10.1002/mds.29126.
PubMed Abstract available

RAJAN R, Garg K, Srivastava AK, Singh M, et al
Device-Assisted and Neuromodulatory Therapies for Parkinson's Disease: A Network Meta-Analysis.
Mov Disord. 2022 Jul 22. doi: 10.1002/mds.29160.
PubMed Abstract available

BILLINGSLEY KJ, Alvarez Jerez P, Grenn FP, Bandres-Ciga S, et al
Profiling the NOTCH2NLC GGC Repeat Expansion in Parkinson's Disease in the European Population.
Mov Disord. 2022 Jul 22. doi: 10.1002/mds.29155.
PubMed

LIU FT, Li XY, Lu JY, Wu P, et al
(18) F-Florzolotau Tau Positron Emission Tomography Imaging in Patients with Multiple System Atrophy-Parkinsonian Subtype.
Mov Disord. 2022 Jul 21. doi: 10.1002/mds.29159.
PubMed Abstract available

MARANO M, Anzini G, Musumeci G, Magliozzi A, et al
Transcutaneous Auricular Vagus Stimulation Improves Gait and Reaction Time in Parkinson's Disease.
Mov Disord. 2022 Jul 21. doi: 10.1002/mds.29166.
PubMed

ILIEVA NM, De Miranda BR
Rest and Digest-The Basal Role of Autophagy in Neurons and Its Relevance to Parkinson's Disease.
Mov Disord. 2022 Jul 20. doi: 10.1002/mds.29165.
PubMed

LU J, Ge J, Chen K, Sun Y, et al
Consistent Abnormalities in Metabolic Patterns of Lewy Body Dementias.
Mov Disord. 2022 Jul 20. doi: 10.1002/mds.29138.
PubMed Abstract available

PEREZ-OLIVEIRA S, Alvarez I, Rosas I, Menendez-Gonzalez M, et al
Intermediate and Expanded HTT Alleles and the Risk for alpha-Synucleinopathies.
Mov Disord. 2022 Jul 19. doi: 10.1002/mds.29153.
PubMed Abstract available

LUO S, Zou H, Stebbins GT, Schwarzschild MA, et al
Dissecting the Domains of Parkinson's Disease: Insights from Longitudinal Item Response Theory Modeling.
Mov Disord. 2022 Jul 16. doi: 10.1002/mds.29154.
PubMed Abstract available

DELVA A, Van Laere K, Vandenberghe W
Longitudinal Positron Emission Tomography Imaging of Presynaptic Terminals in Early Parkinson's Disease.
Mov Disord. 2022 Jul 12. doi: 10.1002/mds.29148.
PubMed Abstract available

DOMENIGHETTI C, Douillard V, Sugier PE, Sreelatha AAK, et al
The Interaction between HLA-DRB1 and Smoking in Parkinson's Disease Revisited.
Mov Disord. 2022 Jul 10. doi: 10.1002/mds.29133.
PubMed Abstract available

SUBERT M, Simek M, Novotny M, Tykalova T, et al
Linguistic Abnormalities in Isolated Rapid Eye Movement Sleep Behavior Disorder.
Mov Disord. 2022 Jul 7. doi: 10.1002/mds.29140.
PubMed Abstract available

PERCETTI M, Franco G, Monfrini E, Caporali L, et al
TWNK in Parkinson's Disease: A Movement Disorder and Mitochondrial Disease Center Perspective Study.
Mov Disord. 2022 Jul 6. doi: 10.1002/mds.29139.
PubMed Abstract available

KOPYTOVA AE, Usenko TS, Baydakova GV, Nikolaev MA, et al
Could Blood Hexosylsphingosine Be a Marker for Parkinson's Disease Linked with GBA1 Mutations?
Mov Disord. 2022 Jul 6. doi: 10.1002/mds.29132.
PubMed

DEUSCHL G, Antonini A, Costa J, Smilowska K, et al
European Academy of Neurology/Movement Disorder Society-European Section Guideline on the Treatment of Parkinson's Disease: I. Invasive Therapies.
Mov Disord. 2022 Jul 6. doi: 10.1002/mds.29066.
PubMed Abstract available

VIJIARATNAM N, Lawton M, Real R, Heslegrave AJ, et al
Diabetes and Neuroaxonal Damage in Parkinson's Disease.
Mov Disord. 2022;37:1568-1569.
PubMed

BUHMANN C, Potter-Nerger M, Schulz R, Gerloff C, et al
Reply to: "Diabetes and Neuroaxonal Damage in Parkinson's Disease".
Mov Disord. 2022;37:1569-1570.
PubMed

COCHEN DE COCK V, Dotov D, Damm L, Janaqi S, et al
Reply to: "Is Gait Dysfunction Prominent Sign of Isolated Rapid Eye Movement Sleep Behavior Disorder?"
Mov Disord. 2022;37:1576-1577.
PubMed

KLARENDIC M, Kojovic M
Reply to: "Neither Friend Nor Foe: Beekeeping and Parkinson's Disease".
Mov Disord. 2022;37:1575.
PubMed

NETUKOVA S, Rusz J, Ruzicka E, Krupicka R, et al
Is Gait Dysfunction a Prominent Sign of Isolated Rapid Eye Movement Sleep Behavior Disorder?
Mov Disord. 2022;37:1575-1576.
PubMed

WASNER K, Smajic S, Ghelfi J, Delcambre S, et al
Parkin Deficiency Impairs Mitochondrial DNA Dynamics and Propagates Inflammation.
Mov Disord. 2022;37:1405-1415.
PubMed Abstract available

YU HJ, Thijssen E, van Brummelen E, van der Plas JL, et al
A Randomized First-in-Human Study With UB-312, a UBITh(R) alpha-Synuclein Peptide Vaccine.
Mov Disord. 2022;37:1416-1424.
PubMed Abstract available

TAYLOR NL, Wainstein G, Quek D, Lewis SJG, et al
The Contribution of Noradrenergic Activity to Anxiety-Induced Freezing of Gait.
Mov Disord. 2022;37:1432-1443.
PubMed Abstract available

June 2022

LABANDEIRA-GARCIA JL, Parga JA
Nigral Neurons Degenerating in Parkinson's Disease Express the Angiotensin Receptor Type 1 Gene.
Mov Disord. 2022 Jun 29. doi: 10.1002/mds.29137.
PubMed Abstract available

PINEDA-PARDO JA, Gasca-Salas C, Fernandez-Rodriguez B, Rodriguez-Rojas R, et al
Striatal Blood-Brain Barrier Opening in Parkinson's Disease Dementia: A Pilot Exploratory Study.
Mov Disord. 2022 Jun 28. doi: 10.1002/mds.29134.
PubMed Abstract available

POHL EDR, Upadhyay N, Kobeleva X, Purrer V, et al
Coherent Structural and Functional Network Changes after Thalamic Lesions in Essential Tremor.
Mov Disord. 2022 Jun 23. doi: 10.1002/mds.29130.
PubMed Abstract available

WANG P, Pan J, Luo Q, Chen J, et al
A 10-Year Community-Based Study of Leucine-Rich Repeat Kinase 2 G2385R Carriers' Conversion to Parkinson's Disease.
Mov Disord. 2022 Jun 22. doi: 10.1002/mds.29127.
PubMed Abstract available

STRAKA I, Svantnerova J, Minar M, Stankova S, et al
Neurodevelopmental Gene-Related Dystonia-Parkinsonism with Onset in Adults: A Case with NAA15 Variant.
Mov Disord. 2022 Jun 22. doi: 10.1002/mds.29125.
PubMed

XIE A, Ensink E, Li P, Gordevicius J, et al
Bacterial Butyrate in Parkinson's Disease Is Linked to Epigenetic Changes and Depressive Symptoms.
Mov Disord. 2022 Jun 20. doi: 10.1002/mds.29128.
PubMed Abstract available

LUO S, Goetz CG, Choi D, Aggarwal S, et al
Resolving Missing Data from the Movement Disorder Society Unified Parkinson's Disease Rating Scale: Implications for Telemedicine.
Mov Disord. 2022 Jun 18. doi: 10.1002/mds.29129.
PubMed Abstract available

COKU I, Mutez E, Eddarkaoui S, Carrier S, et al
Functional Analyses of Two Novel LRRK2 Pathogenic Variants in Familial Parkinson's Disease.
Mov Disord. 2022 Jun 16. doi: 10.1002/mds.29124.
PubMed Abstract available

OLSON JW, Nakhmani A, Irwin ZT, Edwards LJ, et al
Cortical and Subthalamic Nucleus Spectral Changes During Limb Movements in Parkinson's Disease Patients with and Without Dystonia.
Mov Disord. 2022 Jun 14. doi: 10.1002/mds.29057.
PubMed Abstract available

ATHAUDA D, Evans J, Wernick A, Virdi G, et al
The Impact of Type 2 Diabetes in Parkinson's Disease.
Mov Disord. 2022 Jun 14. doi: 10.1002/mds.29122.
PubMed Abstract available

AJALIN RM, Al-Abdulrasul H, Tuisku JM, Hirvonen JES, et al
Cannabinoid Receptor Type 1 in Parkinson's Disease: A Positron Emission Tomography Study with [(18) F]FMPEP-d2.
Mov Disord. 2022 Jun 8. doi: 10.1002/mds.29117.
PubMed Abstract available

RINNE JO, Jucaite A, Cselenyi Z, Farde L, et al
Glia Imaging Shows Clinical Utility in Differentiating Parkinson's Disease from Multiple System Atrophy.
Mov Disord. 2022 Jun 6. doi: 10.1002/mds.29078.
PubMed

The PSG 32nd Annual Symposium on Etiology, Pathogenesis, and Treatment of Parkinson Disease and Other Movement Disorders.
Mov Disord. 2022;37 Suppl 1:S1-S36.
PubMed

SCHAEFFER E, Toedt I, Kohler S, Rogge A, et al
Reply to: "Risk Disclosure in Prodromal Parkinson's Disease".
Mov Disord. 2022;37:1327.
PubMed

MORRIS LA, O'Callaghan C, Le Heron C
Disordered Decision Making: A Cognitive Framework for Apathy and Impulsivity in Huntington's Disease.
Mov Disord. 2022;37:1149-1163.
PubMed Abstract available

May 2022

HOBSON DE, Del Bigio MR
Beekeeper Parkinsonism.
Mov Disord. 2022 May 31. doi: 10.1002/mds.29076.
PubMed

LI C, Hou Y, Ou R, Gu X, et al
Genetic Determinants of Survival in Parkinson's Disease in the Asian Population.
Mov Disord. 2022 May 26. doi: 10.1002/mds.29069.
PubMed Abstract available

DU G, Wang E, Sica C, Chen H, et al
Dynamics of Nigral Iron Accumulation in Parkinson's Disease: From Diagnosis to Late Stage.
Mov Disord. 2022 May 25. doi: 10.1002/mds.29062.
PubMed Abstract available

YANG X, Ai P, He X, Mo C, et al
Parkinson's Disease Is Associated with Impaired Gut-Blood Barrier for Short-Chain Fatty Acids.
Mov Disord. 2022 May 24. doi: 10.1002/mds.29063.
PubMed Abstract available

KIM R, Kim HJ, Shin JH, Lee CY, et al
Serum Inflammatory Markers and Progression of Nonmotor Symptoms in Early Parkinson's Disease.
Mov Disord. 2022 May 21. doi: 10.1002/mds.29056.
PubMed Abstract available

SMEYNE RJ, Eells JB, Chatterjee D, Byrne M, et al
COVID-19 infection enhances susceptibility to oxidative-stress induced parkinsonism.
Mov Disord. 2022 May 17. doi: 10.1002/mds.29116.
PubMed Abstract available

YE R, O'Callaghan C, Rua C, Hezemans FH, et al
Locus Coeruleus Integrity from 7 T MRI Relates to Apathy and Cognition in Parkinsonian Disorders.
Mov Disord. 2022 May 16. doi: 10.1002/mds.29072.
PubMed Abstract available

MAHLKNECHT P, Foltynie T, Limousin P, Poewe W, et al
How Does Deep Brain Stimulation Change the Course of Parkinson's Disease?
Mov Disord. 2022 May 12. doi: 10.1002/mds.29052.
PubMed Abstract available

YAMASHITA R, Beck G, Yonenobu Y, Inoue K, et al
TDP-43 Proteinopathy Presenting with Typical Symptoms of Parkinson's Disease.
Mov Disord. 2022 May 9. doi: 10.1002/mds.29048.
PubMed Abstract available

SOSSI V, Patterson JR, McCormick S, Kemp CJ, et al
Dopaminergic Positron Emission Tomography Imaging in the Alpha-Synuclein Preformed Fibril Model Reveals Similarities to Early Parkinson's Disease.
Mov Disord. 2022 May 7. doi: 10.1002/mds.29051.
PubMed Abstract available

WANG S, Unnithan S, Bryant N, Chang A, et al
Elevated Urinary Rab10 Phosphorylation in Idiopathic Parkinson Disease.
Mov Disord. 2022 May 6. doi: 10.1002/mds.29043.
PubMed Abstract available

PAN Y, Xue J, Chen J, Zhang X, et al
Assessment of GGC Repeat Expansion in GIPC1 in Patients with Parkinson's Disease.
Mov Disord. 2022 May 6. doi: 10.1002/mds.29041.
PubMed

FILIPPI M, Balestrino R, Basaia S, Agosta F, et al
Neuroimaging in Glucocerebrosidase-Associated Parkinsonism: A Systematic Review.
Mov Disord. 2022 May 6. doi: 10.1002/mds.29047.
PubMed Abstract available

ZHOU X, Liu Z, Zhou X, Xiang Y, et al
The Chinese Parkinson's Disease Registry (CPDR): Study Design and Baseline Patient Characteristics.
Mov Disord. 2022 May 3. doi: 10.1002/mds.29037.
PubMed Abstract available

STEINHARDT J, Hanssen H, Heldmann M, Sprenger A, et al
Prodromal X-Linked Dystonia-Parkinsonism is Characterized by a Subclinical Motor Phenotype.
Mov Disord. 2022 May 2. doi: 10.1002/mds.29033.
PubMed Abstract available

MACIAS-GARCIA D, Perinan MT, Munoz-Delgado L, Jesus S, et al
Reply to: "Increased Stroke Risk in Patients with Parkinson's Disease with LRRK2 Mutations".
Mov Disord. 2022;37:1119-1120.
PubMed

GRISANTI S, Ferri L, Cavallieri F, Fioravanti V, et al
Increased Stroke Risk in Patients with Parkinson's Disease with LRRK2 Mutations.
Mov Disord. 2022;37:1117-1118.
PubMed

LAANSMA MA, Bright JK, Jahanshad N, Thompson PM, et al
Reply to: "Parkinson's Disease, Premature Mortality, and Amygdala".
Mov Disord. 2022;37:1111-1112.
PubMed

RAO SC, Pattipati S, Salim A, Gutierrez N, et al
Promoting Gender Inclusivity: A Questionnaire for Women's Health Factors in Parkinson's Disease.
Mov Disord. 2022;37:1112-1113.
PubMed

SCORZA FA, de Almeida AG, Scorza CA, Finsterer J, et al
Parkinson's Disease, Premature Mortality, and Amygdala.
Mov Disord. 2022;37:1110-1111.
PubMed

DARWEESH SKL, Vermeulen R, Bloem BR, Peters S, et al
Exposure to Pesticides Predicts Prodromal Feature of Parkinson's Disease: Public Health Implications.
Mov Disord. 2022;37:883-885.
PubMed

SUBRAMANIAN I, Mathur S, Oosterbaan A, Flanagan R, et al
Reply to: "Promoting Gender Inclusivity: A questionnaire for Women's Health Factors in Parkinson's Disease".
Mov Disord. 2022;37:1113.
PubMed

FOFFANI G
An Exponential Rather Than Multistep Model of Parkinson's Disease Pathogenesis.
Mov Disord. 2022;37:1105-1106.
PubMed

ALZGHOOL OM, van Dongen G, van de Giessen E, Schoonmade L, et al
alpha-Synuclein Radiotracer Development and In Vivo Imaging: Recent Advancements and New Perspectives.
Mov Disord. 2022;37:936-948.
PubMed Abstract available

GANAPATHY S R, Levova K, Kotackova L, Trnka J, et al
Increased Transferrin Sialylation Predicts Phenoconversion in Isolated REM Sleep Behavior Disorder.
Mov Disord. 2022;37:983-992.
PubMed Abstract available

TODISCO M, Cosentino G, Scardina S, Fresia M, et al
Diagnostic and Prognostic Value of External Anal Sphincter EMG Patterns in Multiple System Atrophy.
Mov Disord. 2022;37:1069-1074.
PubMed Abstract available

GAURAV R, Pyatigorskaya N, Biondetti E, Valabregue R, et al
Deep Learning-Based Neuromelanin MRI Changes of Isolated REM Sleep Behavior Disorder.
Mov Disord. 2022;37:1064-1069.
PubMed Abstract available

April 2022

BANDRES-CIGA S
Black and African American Connections to Parkinson's Disease Study: Addressing Missing Diversity in Parkinson's Disease Genetics.
Mov Disord. 2022 Apr 30. doi: 10.1002/mds.29042.
PubMed

TANIMURA A, Shen W, Wokosin D, Surmeier DJ, et al
Pathway-Specific Remodeling of Thalamostriatal Synapses in a Mouse Model of Parkinson's Disease.
Mov Disord. 2022 Apr 29. doi: 10.1002/mds.29030.
PubMed Abstract available

KARAGIANIS JL
Re: Risk Disclosure in Prodromal Parkinson's Disease.
Mov Disord. 2022 Apr 28. doi: 10.1002/mds.29038.
PubMed

LANGE LM, Gonzalez-Latapi P, Rajalingam R, Tijssen MAJ, et al
Nomenclature of Genetic Movement Disorders: Recommendations of the International Parkinson and Movement Disorder Society Task Force - An Update.
Mov Disord. 2022 Apr 28. doi: 10.1002/mds.28982.
PubMed Abstract available

KOLMANCIC K, Zupancic NK, Trost M, Flisar D, et al
Continuous Dopaminergic Stimulation Improves Cortical Maladaptive Changes in Advanced Parkinson's Disease.
Mov Disord. 2022 Apr 18. doi: 10.1002/mds.29028.
PubMed Abstract available

YASSINE S, Gschwandtner U, Auffret M, Achard S, et al
Functional Brain Dysconnectivity in Parkinson's Disease: A 5-Year Longitudinal Study.
Mov Disord. 2022 Apr 14. doi: 10.1002/mds.29026.
PubMed Abstract available

RAMIREZ J, Berberian SA, Breen DP, Gao F, et al
Small and Large Magnetic Resonance Imaging-Visible Perivascular Spaces in the Basal Ganglia of Parkinson's Disease Patients.
Mov Disord. 2022 Apr 11. doi: 10.1002/mds.29010.
PubMed Abstract available

QUATTRONE A, Bianco MG, Antonini A, Vaillancourt DE, et al
Development and Validation of Automated Magnetic Resonance Parkinsonism Index 2.0 to Distinguish Progressive Supranuclear Palsy-Parkinsonism From Parkinson's Disease.
Mov Disord. 2022 Apr 11. doi: 10.1002/mds.28992.
PubMed Abstract available

UYAR M, Lezius S, Buhmann C, Potter-Nerger M, et al
Diabetes, Glycated Hemoglobin (HbA1c), and Neuroaxonal Damage in Parkinson's Disease (MARK-PD Study).
Mov Disord. 2022 Apr 6. doi: 10.1002/mds.29009.
PubMed Abstract available

BARBA L, Paolini Paoletti F, Bellomo G, Gaetani L, et al
Alpha and Beta Synucleins: From Pathophysiology to Clinical Application as Biomarkers.
Mov Disord. 2022;37:669-683.
PubMed Abstract available

THIJSSEN E, den Heijer J, Puibert D, Moss L, et al
A Randomized Trial Assessing the Safety, Pharmacokinetics, and Efficacy During Morning Off of AZ-009.
Mov Disord. 2022;37:790-798.
PubMed Abstract available

GRIJALVA RM, Pham NTT, Huang Q, Martin PR, et al
Brainstem Biomarkers of Clinical Variant and Pathology in Progressive Supranuclear Palsy.
Mov Disord. 2022;37:702-712.
PubMed Abstract available

March 2022

CHOUGAR L, Arsovic E, Gaurav R, Biondetti E, et al
Regional Selectivity of Neuromelanin Changes in the Substantia Nigra in Atypical Parkinsonism.
Mov Disord. 2022 Mar 29. doi: 10.1002/mds.28988.
PubMed Abstract available

LE HERON C, MacAskill MR, Myall DJ
Reply to: "An Exponential Rather Than Multistep Model of Parkinson's Disease Pathogenesis".
Mov Disord. 2022 Mar 28. doi: 10.1002/mds.28989.
PubMed

XU Y, Feeney MP, Surface M, Novak D, et al
Attitudes Toward Telehealth Services Among People Living With Parkinson's Disease: A Survey Study.
Mov Disord. 2022 Mar 26. doi: 10.1002/mds.28990.
PubMed Abstract available

SIGURDSSON HP, Yarnall AJ, Galna B, Lord S, et al
Gait-Related Metabolic Covariance Networks at Rest in Parkinson's Disease.
Mov Disord. 2022 Mar 14. doi: 10.1002/mds.28977.
PubMed Abstract available

NAKANO Y, Hirano S, Kojima K, Li H, et al
Dopaminergic Correlates of Regional Cerebral Blood Flow in Parkinsonian Disorders.
Mov Disord. 2022 Mar 14. doi: 10.1002/mds.28981.
PubMed Abstract available

LUAN M, Sun Y, Chen J, Jiang Y, et al
Diagnostic Value of Salivary Real-Time Quaking-Induced Conversion in Parkinson's Disease and Multiple System Atrophy.
Mov Disord. 2022 Mar 12. doi: 10.1002/mds.28976.
PubMed Abstract available

MURTOMAKI K, Mertsalmi T, Jaakkola E, Makinen E, et al
Gastrointestinal Symptoms and Dopamine Transporter Asymmetry in Early Parkinson's Disease.
Mov Disord. 2022 Mar 11. doi: 10.1002/mds.28986.
PubMed Abstract available

STRANIERO L, Rimoldi V, Monfrini E, Bonvegna S, et al
Role of Lysosomal Gene Variants in Modulating GBA-Associated Parkinson's Disease Risk.
Mov Disord. 2022 Mar 9. doi: 10.1002/mds.28987.
PubMed Abstract available

KUSTERS CDJ, Paul KC, Duarte Folle A, Keener AM, et al
Erratum to "Increased Menopausal Age Reduces the Risk of Parkinson's Disease: A Mendelian Approach".
Mov Disord. 2022 Mar 4. doi: 10.1002/mds.28974.
PubMed

PRANGE S, Metereau E, Maillet A, Klinger H, et al
Limbic Serotonergic Plasticity Contributes to the Compensation of Apathy in Early Parkinson's Disease.
Mov Disord. 2022 Mar 3. doi: 10.1002/mds.28971.
PubMed Abstract available

OLSZEWSKA DA, Lang AE
The Role of Insular Cortex in Gut-Inflammation Memory: What Does It Mean for Parkinson's Disease?
Mov Disord. 2022 Mar 1. doi: 10.1002/mds.28975.
PubMed

LIN CH, Lin HY, Ho EP, Ke YC, et al
Reply to: Mild Chronic Colitis Triggers Parkinsonism in LRRK2 Mutant Mice through Activating TNF-alpha Pathway.
Mov Disord. 2022;37:665-666.
PubMed

SAMBIN S, Menon PJ, Ihle J, Mariani LL, et al
Down-Regulation of Dopamine Transporter in Early Premotor Phases.
Mov Disord. 2022;37:663-664.
PubMed

LINARD M, Ravier A, Mougue L, Grgurina I, et al
Infectious Agents as Potential Drivers of alpha-Synucleinopathies.
Mov Disord. 2022;37:464-477.
PubMed Abstract available

ROEDIGER J, Dembek TA, Wenzel G, Butenko K, et al
StimFit-A Data-Driven Algorithm for Automated Deep Brain Stimulation Programming.
Mov Disord. 2022;37:574-584.
PubMed Abstract available

JANZEN A, Kogan RV, Meles SK, Sittig E, et al
Rapid Eye Movement Sleep Behavior Disorder: Abnormal Cardiac Image and Progressive Abnormal Metabolic Brain Pattern.
Mov Disord. 2022;37:624-629.
PubMed Abstract available

February 2022

RAO SC, Sanyaolu AO
Breaking Barriers: Modeling the Blood-Brain Barrier in Parkinson's Disease Using a Human-Brain-Chip.
Mov Disord. 2022 Feb 28. doi: 10.1002/mds.28968.
PubMed

RASCOL O, Medori R, Baayen C, Such P, et al
A Randomized, Double-Blind, Controlled Phase II Study of Foliglurax in Parkinson's Disease.
Mov Disord. 2022 Feb 26. doi: 10.1002/mds.28970.
PubMed Abstract available

KHALIL H, Aldaajani ZF, Aldughmi M, Al-Sharman A, et al
Validation of the Arabic Version of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale.
Mov Disord. 2022 Feb 26. doi: 10.1002/mds.28905.
PubMed Abstract available

CORNEJO-OLIVAS M, Wu L, Noyce A
Disruption of Mitochondrial Complex I Induces Progressive Parkinsonism.
Mov Disord. 2022 Feb 22. doi: 10.1002/mds.28961.
PubMed

XING Y, Sapuan AH, Martin-Bastida A, Naidu S, et al
Neuromelanin-MRI to Quantify and Track Nigral Depigmentation in Parkinson's Disease: A Multicenter Longitudinal Study Using Template-Based Standardized Analysis.
Mov Disord. 2022 Feb 15. doi: 10.1002/mds.28934.
PubMed Abstract available

LIZARRAGA KJ, Gnanamanogaran B, Al-Ozzi TM, Cohn M, et al
Lateralized Subthalamic Stimulation for Axial Dysfunction in Parkinson's Disease: A Randomized Trial.
Mov Disord. 2022 Feb 13. doi: 10.1002/mds.28953.
PubMed Abstract available

MAGRINELLI F, Rajapaksha I, Kobylecki C, Latorre A, et al
Reply to: Juvenile PLA2G6-parkinsonism due to Indian 'Asian' p.R741Q mutation, and response to STN DBS.
Mov Disord. 2022 Feb 13. doi: 10.1002/mds.28955.
PubMed

AYTON S, Hall S, Janelidze S, Kalinowski P, et al
The Neuroinflammatory Acute Phase Response in Parkinsonian-Related Disorders.
Mov Disord. 2022 Feb 8. doi: 10.1002/mds.28958.
PubMed Abstract available

PRASUHN J, Gottlich M, Grosser SS, Reuther K, et al
In Vivo Brain Sodium Disequilibrium in ATP1A3-Related Rapid-Onset Dystonia-Parkinsonism.
Mov Disord. 2022 Feb 7. doi: 10.1002/mds.28954.
PubMed

MADELUNG CF, Meder D, Fuglsang SA, Marques MM, et al
Locus Coeruleus Shows a Spatial Pattern of Structural Disintegration in Parkinson's Disease.
Mov Disord. 2022 Feb 3. doi: 10.1002/mds.28945.
PubMed Abstract available

RAVAT P, Shinde S, Shinde SR, Bangar S, et al
Juvenile PLA2G6-Parkinsonism Due to Indian 'Asian' p.R741Q Mutation, and Response to STN DBS.
Mov Disord. 2022 Feb 3. doi: 10.1002/mds.28950.
PubMed

SZWEDO AA, Dalen I, Pedersen KF, Camacho M, et al
GBA and APOE Impact Cognitive Decline in Parkinson's Disease: A 10-Year Population-Based Study.
Mov Disord. 2022 Feb 2. doi: 10.1002/mds.28932.
PubMed Abstract available

ORTEGA RA, Bodamer O, Peake RWA, Raymond D, et al
Assessment of Glucocerebrosidase Enzyme Activity in Parkinson Disease Using Multiple Approaches.
Mov Disord. 2022 Feb 1. doi: 10.1002/mds.28951.
PubMed

AAMODT WW, Chen-Plotkin AS
Reply to: "Age-Adjusted Serum Neurofilament Predicts Cognitive Decline in Parkinson's Disease (MARK-PD)".
Mov Disord. 2022;37:436-437.
PubMed

TODT I, Al-Fatly B, Granert O, Kuhn AA, et al
The Contribution of Subthalamic Nucleus Deep Brain Stimulation to the Improvement in Motor Functions and Quality of Life.
Mov Disord. 2022;37:291-301.
PubMed Abstract available

D'CRUZ N, Seuthe J, De Somer C, Hulzinga F, et al
Dual Task Turning in Place: A Reliable, Valid, and Responsive Outcome Measure of Freezing of Gait.
Mov Disord. 2022;37:269-278.
PubMed Abstract available

ZIRRA A, Huxford B
CD4(+) T Cells Contribute to Neurodegeneration in Lewy Body Dementia.
Mov Disord. 2022;37:268.
PubMed

January 2022

DERKINDEREN P, de Guilhem de Lataillade A, Neunlist M, Rolli-Derkinderen M, et al
Mild Chronic Colitis Triggers Parkinsonism in LRRK2 Mutant Mice through Activating TNF-alpha Pathway.
Mov Disord. 2022 Jan 31. doi: 10.1002/mds.28948.
PubMed

SURFACE M, Balwani M, Waters C, Haimovich A, et al
Reply to: No Evidence that Glucosylsphingosine Is a Biomarker for Parkinson Disease.
Mov Disord. 2022 Jan 29. doi: 10.1002/mds.28936.
PubMed

LIU W, Yu Y
Single-Trajectory Multiple Target for Parkinsonian Mobility and Cognition? An Inadvisable Idea.
Mov Disord. 2022 Jan 28. doi: 10.1002/mds.28949.
PubMed

GLEASON A, Tayebi N, Lopez G, Sidransky E, et al
No Evidence That Glucosylsphingosine Is a Biomarker for Parkinson's Disease: Statistical Differences Do Not Necessarily Indicate Biological Significance.
Mov Disord. 2022 Jan 24. doi: 10.1002/mds.28935.
PubMed

OMER N, Giladi N, Gurevich T, Bar-Shira A, et al
Glucocerebrosidase Activity Is Not Associated with Parkinson's Disease Risk or Severity.
Mov Disord. 2022 Jan 22. doi: 10.1002/mds.28929.
PubMed

GARRIDO A, Santamaria E, Fernandez-Irigoyen J, Soto M, et al
Differential Phospho-Signatures in Blood Cells Identify LRRK2 G2019S Carriers in Parkinson's Disease.
Mov Disord. 2022 Jan 20. doi: 10.1002/mds.28927.
PubMed Abstract available

SUBRAMANIAN I, Mathur S, Oosterbaan A, Flanagan R, et al
Unmet Needs of Women Living with Parkinson's Disease: Gaps and Controversies.
Mov Disord. 2022 Jan 20. doi: 10.1002/mds.28921.
PubMed Abstract available

MURATA H, Barnhill LM, Bronstein JM
Air Pollution and the Risk of Parkinson's Disease: A Review.
Mov Disord. 2022 Jan 19. doi: 10.1002/mds.28922.
PubMed Abstract available

BUHMANN C, Lezius S, Potter-Nerger M, Gerloff C, et al
Age-Adjusted Serum Neurofilament Predicts Cognitive Decline in Parkinson's Disease (MARK-PD).
Mov Disord. 2022 Jan 17. doi: 10.1002/mds.28909.
PubMed

COCHEN DE COCK V, Dotov D, Lacombe S, Picot MC, et al
Classifying Idiopathic Rapid Eye Movement Sleep Behavior Disorder, Controls, and Mild Parkinson's Disease Using Gait Parameters.
Mov Disord. 2022 Jan 17. doi: 10.1002/mds.28894.
PubMed Abstract available

VAN DER ZEE S, Kanel P, Gerritsen MJJ, Boertien JM, et al
Altered Cholinergic Innervation in De Novo Parkinson's Disease with and without Cognitive Impairment.
Mov Disord. 2022 Jan 17. doi: 10.1002/mds.28913.
PubMed Abstract available

MARTINEZ-VALBUENA I, Visanji NP, Olszewska DA, Sousa M, et al
Combining Skin alpha-Synuclein Real-Time Quaking-Induced Conversion and Circulating Neurofilament Light Chain to Distinguish Multiple System Atrophy and Parkinson's Disease.
Mov Disord. 2022 Jan 12. doi: 10.1002/mds.28912.
PubMed

ISHIBASHI K, Miura Y, Wagatsuma K, Toyohara J, et al
Adenosine A2A Receptor Occupancy by Caffeine After Coffee Intake in Parkinson's Disease.
Mov Disord. 2022 Jan 9. doi: 10.1002/mds.28897.
PubMed Abstract available

LEODORI G, De Bartolo MI, Guerra A, Fabbrini A, et al
Motor Cortical Network Excitability in Parkinson's Disease.
Mov Disord. 2022 Jan 9. doi: 10.1002/mds.28914.
PubMed Abstract available

DOMENIGHETTI C, Sugier PE, Ashok Kumar Sreelatha A, Schulte C, et al
Dairy Intake and Parkinson's Disease: A Mendelian Randomization Study.
Mov Disord. 2022 Jan 8. doi: 10.1002/mds.28902.
PubMed Abstract available

VANEGAS-ARROYAVE N, Chen DF, Lauro PM, Norato G, et al
Where Do Parkinson's Disease Patients Look while Walking?
Mov Disord. 2022 Jan 8. doi: 10.1002/mds.28917.
PubMed Abstract available

MERCHANT K, Sullivan J
c-Abl Inhibitors as Disease-Modifying Therapies for Parkinson's Disease: Gaps and Opportunities.
Mov Disord. 2022;37:3-5.
PubMed

LA MORGIA C, Romagnoli M, Pizza F, Biscarini F, et al
Chromatic Pupillometry in Isolated Rapid Eye Movement Sleep Behavior Disorder.
Mov Disord. 2022;37:205-210.
PubMed Abstract available

December 2021

LEWIS SJG, Factor SA, Giladi N, Hallett M, et al
Addressing the Challenges of Clinical Research for Freezing of Gait in Parkinson's Disease.
Mov Disord. 2021 Dec 22. doi: 10.1002/mds.28837.
PubMed

BOHNEN NI, Costa RM, Dauer WT, Factor SA, et al
Discussion of Research Priorities for Gait Disorders in Parkinson's Disease.
Mov Disord. 2021 Dec 22. doi: 10.1002/mds.28883.
PubMed Abstract available

GUTTUSO T JR, Sirica D, Tosun D, Zivadinov R, et al
Thalamic Dorsomedial Nucleus Free Water Correlates with Cognitive Decline in Parkinson's Disease.
Mov Disord. 2021 Dec 22. doi: 10.1002/mds.28886.
PubMed Abstract available

BOSHKOVSKI T, Cohen-Adad J, Misic B, Arnulf I, et al
The Myelin-Weighted Connectome in Parkinson's Disease.
Mov Disord. 2021 Dec 22. doi: 10.1002/mds.28891.
PubMed Abstract available

DEVIGNES Q, Bordier C, Viard R, Defebvre L, et al
Resting-State Functional Connectivity in Frontostriatal and Posterior Cortical Subtypes in Parkinson's Disease-Mild Cognitive Impairment.
Mov Disord. 2021 Dec 17. doi: 10.1002/mds.28888.
PubMed Abstract available

LIN CH, Lin HY, Ho EP, Ke YC, et al
Mild Chronic Colitis Triggers Parkinsonism in LRRK2 Mutant Mice Through Activating TNF-alpha Pathway.
Mov Disord. 2021 Dec 17. doi: 10.1002/mds.28890.
PubMed Abstract available

ZOLFAGHARI S, Thomann AE, Lewandowski N, Trundell D, et al
Self-Report versus Clinician Examination in Early Parkinson's Disease.
Mov Disord. 2021 Dec 13. doi: 10.1002/mds.28884.
PubMed Abstract available

BRUNO MK, Watanabe G, Ishikawa K, Chen JJ, et al
Geographic Variation in Prescription Patterns of Parkinson's Disease Medications.
Mov Disord. 2021 Dec 3. doi: 10.1002/mds.28880.
PubMed

RODRIGUEZ-ROJAS R, Pineda-Pardo JA, Manez-Miro J, Sanchez-Turel A, et al
Functional Topography of the Human Subthalamic Nucleus: Relevance for Subthalamotomy in Parkinson's Disease.
Mov Disord. 2021 Dec 3. doi: 10.1002/mds.28862.
PubMed Abstract available

MACIAS-GARCIA D, Perinan MT, Munoz-Delgado L, Jesus S, et al
Increased Stroke Risk in Patients with Parkinson's Disease with LRRK2 Mutations.
Mov Disord. 2021 Dec 2. doi: 10.1002/mds.28863.
PubMed

GHIGLIERI V, Natale G
Reply to: Rewiring Brains in Parkinson's Disease: The New Era of Brain Stimulation.
Mov Disord. 2021;36:2979-2980.
PubMed

GARCIA AM, Orozco-Arroyave JR
Reply to: "Does Cognitive Impairment Influence Motor Speech Performance in De Novo Parkinson's Disease".
Mov Disord. 2021;36:2982-2983.
PubMed

RUSZ J, Tykalova T
Does Cognitive Impairment Influence Motor Speech Performance in De Novo Parkinson's Disease?
Mov Disord. 2021;36:2980-2982.
PubMed

SUPPA A
Rewiring Brains in Parkinson's Disease: The New Era of Brain Stimulation.
Mov Disord. 2021;36:2979.
PubMed

YSSELSTEIN D, Young TJ, Nguyen M, Padmanabhan S, et al
Evaluation of Strategies for Measuring Lysosomal Glucocerebrosidase Activity.
Mov Disord. 2021;36:2719-2730.
PubMed Abstract available

VERHAGEN METMAN L, Slavin KV, Rosenow JM, Vitek JL, et al
More Than Just the Level of Consciousness: Comparing Asleep and Awake Deep Brain Stimulation.
Mov Disord. 2021;36:2763-2766.
PubMed

FOIS AF, Mahant N, Vucic S, Fung VSC, et al
Measuring Tremor-A Comparison of Automated Video Analysis, Neurophysiology, and Clinical Rating.
Mov Disord. 2021;36:2962-2963.
PubMed

November 2021

WERNER MH, Olanow CW
Parkinson's Disease Modification through Abl Kinase Inhibition: An Opportunity.
Mov Disord. 2021 Nov 23. doi: 10.1002/mds.28858.
PubMed Abstract available

SCAMARCIA PG, Agosta F, Spinelli EG, Basaia S, et al
Longitudinal White Matter Damage Evolution in Parkinson's Disease.
Mov Disord. 2021 Nov 22. doi: 10.1002/mds.28864.
PubMed Abstract available

SASIKUMAR S, Cohn M, Harmsen IE, Loh A, et al
Single-Trajectory Multiple-Target Deep Brain Stimulation for Parkinsonian Mobility and Cognition.
Mov Disord. 2021 Nov 22. doi: 10.1002/mds.28870.
PubMed Abstract available

CHEN C, Mossman E, Malko P, McDonald D, et al
Astrocytic Changes in Mitochondrial Oxidative Phosphorylation Protein Levels in Parkinson's Disease.
Mov Disord. 2021 Nov 15. doi: 10.1002/mds.28849.
PubMed Abstract available

COSENTINO C, Torres L, Velez M, Nunez Y, et al
SARS-CoV-2 Vaccines and Motor Symptoms in Parkinson's Disease.
Mov Disord. 2021 Nov 14. doi: 10.1002/mds.28851.
PubMed

VOGEL A, Claus I, Ahring S, Gruber D, et al
Endoscopic Characteristics of Dysphagia in Multiple System Atrophy Compared to Parkinson's Disease.
Mov Disord. 2021 Nov 13. doi: 10.1002/mds.28854.
PubMed Abstract available

LANE EL, Harrison DJ, Ramos-Varas E, Hills R, et al
Spontaneous Graft-Induced Dyskinesias Are Independent of 5-HT Neurons and Levodopa Priming in a Model of Parkinson's Disease.
Mov Disord. 2021 Nov 12. doi: 10.1002/mds.28856.
PubMed Abstract available

SURMEIER DJ, Nguyen JT, Lancki N, Venuto CS, et al
Re-Analysis of the STEADY-PD II Trial-Evidence for Slowing the Progression of Parkinson's Disease.
Mov Disord. 2021 Nov 12. doi: 10.1002/mds.28850.
PubMed Abstract available

SURFACE M, Balwani M, Waters C, Haimovich A, et al
Plasma Glucosylsphingosine in GBA1 Mutation Carriers with and without Parkinson's Disease.
Mov Disord. 2021 Nov 6. doi: 10.1002/mds.28846.
PubMed Abstract available

ARPIN DJ, Mitchell T, Archer DB, Burciu RG, et al
Diffusion Magnetic Resonance Imaging Detects Progression in Parkinson's Disease: A Placebo-Controlled Trial of Rasagiline.
Mov Disord. 2021 Nov 1. doi: 10.1002/mds.28838.
PubMed Abstract available

LESCHZINER AE, Reck-Peterson SL
Structural Biology of LRRK2 and its Interaction with Microtubules.
Mov Disord. 2021;36:2494-2504.
PubMed Abstract available

MANOR B, Dagan M, Herman T, Gouskova NA, et al
Multitarget Transcranial Electrical Stimulation for Freezing of Gait: A Randomized Controlled Trial.
Mov Disord. 2021;36:2693-2698.
PubMed Abstract available

LERCHE S, Sjodin S, Brinkmalm A, Blennow K, et al
CSF Protein Level of Neurotransmitter Secretion, Synaptic Plasticity, and Autophagy in PD and DLB.
Mov Disord. 2021;36:2595-2604.
PubMed Abstract available

BORDERS JC, Sevitz JS, Curtis JA, Vanegas-Arroyave N, et al
Sensorimotor Cough Dysfunction Is Prevalent and Pervasive in Progressive Supranuclear Palsy.
Mov Disord. 2021;36:2624-2633.
PubMed Abstract available

October 2021

CORVOL JC, Azulay JP, Bosse B, Dauvilliers Y, et al
THN 102 for Excessive Daytime Sleepiness Associated with Parkinson's Disease: A Phase 2a Trial.
Mov Disord. 2021 Oct 28. doi: 10.1002/mds.28840.
PubMed Abstract available

CHARISIS S, Ntanasi E, Stamelou M, Xiromerisiou G, et al
Plasma Glutathione and Prodromal Parkinson's Disease Probability.
Mov Disord. 2021 Oct 25. doi: 10.1002/mds.28826.
PubMed Abstract available

VAN RENSBURG ZJ, Abrahams S, Chetty D, Step K, et al
The South African Parkinson's Disease Study Collection.
Mov Disord. 2021 Oct 22. doi: 10.1002/mds.28828.
PubMed Abstract available

SAMBIN S, Lavisse S, Decaix C, Pyatigorskaya N, et al
Compensatory Mechanisms Nine Years Before Parkinson's Disease Conversion in a LRRK2 R1441H Family.
Mov Disord. 2021 Oct 20. doi: 10.1002/mds.28833.
PubMed

KLARENDIC M, Kirbis M, Mojsovska E, Kavcic M, et al
Bee Venom Does Not Reduce the Risk for Parkinson's Disease: Epidemiological Study among Beekeepers.
Mov Disord. 2021 Oct 16. doi: 10.1002/mds.28820.
PubMed Abstract available

TSUKITA K, Sakamaki-Tsukita H, Takahashi R
Lower Circulating Lymphocyte Count Predicts ApoE epsilon4-Related Cognitive Decline in Parkinson's Disease.
Mov Disord. 2021 Oct 13. doi: 10.1002/mds.28799.
PubMed

HUXFORD B, Haque T, Joseph AB, Simonet C, et al
Parkinson's Disease and Type 2 Diabetes: HbA1c Is Associated with Motor and Cognitive Severity.
Mov Disord. 2021 Oct 13. doi: 10.1002/mds.28829.
PubMed

JARAZO J, Barmpa K, Modamio J, Saraiva C, et al
Parkinson's Disease Phenotypes in Patient Neuronal Cultures and Brain Organoids Improved by 2-Hydroxypropyl-beta-Cyclodextrin Treatment.
Mov Disord. 2021 Oct 12. doi: 10.1002/mds.28810.
PubMed Abstract available

SCHIRINZI T, Maftei D, Ralli M, Greco A, et al
Serum Substance P Is Increased in Parkinson's Disease and Correlates with Motor Impairment.
Mov Disord. 2021 Oct 8. doi: 10.1002/mds.28824.
PubMed

MAGRINELLI F, Mehta S, Di Lazzaro G, Latorre A, et al
Dissecting the Phenotype and Genotype of PLA2G6-Related Parkinsonism.
Mov Disord. 2021 Oct 8. doi: 10.1002/mds.28807.
PubMed Abstract available

PU JL, Jin CY, Wang ZX, Fang Y, et al
Apolipoprotein E Genotype Contributes to Motor Progression in Parkinson's Disease.
Mov Disord. 2021 Oct 6. doi: 10.1002/mds.28805.
PubMed Abstract available

PIHLSTROM L, Fan CC, Frei O, Tan M, et al
Genetic Stratification of Age-Dependent Parkinson's Disease Risk by Polygenic Hazard Score.
Mov Disord. 2021 Oct 6. doi: 10.1002/mds.28808.
PubMed Abstract available

JUCAITE A, Cselenyi Z, Kreisl WC, Rabiner EA, et al
Glia Imaging Differentiates Multiple System Atrophy from Parkinson's Disease: A Positron Emission Tomography Study with [(11) C]PBR28 and Machine Learning Analysis.
Mov Disord. 2021 Oct 5. doi: 10.1002/mds.28814.
PubMed Abstract available

GULER S, Gul T, Guler S, Haerle MC, et al
Early-Onset Parkinson's Disease: A Novel Deletion Comprising the DJ-1 and TNFRSF9 Genes.
Mov Disord. 2021 Oct 3. doi: 10.1002/mds.28812.
PubMed Abstract available

CAMINITI SP, Carli G, Avenali M, Blandini F, et al
Clinical and Dopamine Transporter Imaging Trajectories in a Cohort of Parkinson's Disease Patients with GBA Mutations.
Mov Disord. 2021 Oct 1. doi: 10.1002/mds.28818.
PubMed Abstract available

KANG X, Ploner A, Roelstraete B, Khalili H, et al
Reply to: "Association between Microscopic Colitis and Parkinson's Disease in a Swedish Population".
Mov Disord. 2021;36:2453.
PubMed

ONG TL, Dal S, Williams LJ, Morales-Briceno H, et al
\Association between Microscopic Colitis and Parkinson's Disease in a Swedish Population.
Mov Disord. 2021;36:2452.
PubMed

GAN-OR Z, Wood NW
Mendelian Randomization Studies: A Path to Better Understand Sex and Gender Differences in Parkinson's Disease?
Mov Disord. 2021;36:2220-2222.
PubMed

NAMBU A
Distinct Roles of the Dorsal Versus Ventral Subthalamic Nucleus.
Mov Disord. 2021;36:2223.
PubMed

ERRO R, Mencacci NE, Bhatia KP
The Emerging Role of Phosphodiesterases in Movement Disorders.
Mov Disord. 2021;36:2225-2243.
PubMed Abstract available

CAMACHO M, Greenland JC, Williams-Gray CH
The Gastrointestinal Dysfunction Scale for Parkinson's Disease.
Mov Disord. 2021;36:2358-2366.
PubMed Abstract available

September 2021

REYES-PEREZ P, Bandres-Ciga S
Identifying Genetic Markers Associated with the Progression of Cognitive Decline in Parkinson's Disease: A Call Out for Replication.
Mov Disord. 2021 Sep 30. doi: 10.1002/mds.28798.
PubMed

MILANOWSKI LM, Oshinaike O, Walton RL, Soto-Beasley AI, et al
Screening of GBA Mutations in Nigerian Patients with Parkinson's Disease.
Mov Disord. 2021 Sep 29. doi: 10.1002/mds.28803.
PubMed

EVIDENTE VGH, Evidente DH, Ortega SC, Levine TD, et al
X-Linked Dystonia-Parkinsonism ("Lubag") May Present with Peripheral Synucleinopathy.
Mov Disord. 2021 Sep 28. doi: 10.1002/mds.28801.
PubMed Abstract available

REN Y, Jiang H, Pu J, Li L, et al
Molecular Features of Parkinson's Disease in Patient-Derived Midbrain Dopaminergic Neurons.
Mov Disord. 2021 Sep 26. doi: 10.1002/mds.28786.
PubMed Abstract available

BUCHANAN SM, Richards M, Schott JM, Schrag A, et al
Mild Parkinsonian Signs: A Systematic Review of Clinical, Imaging, and Pathological Associations.
Mov Disord. 2021 Sep 25. doi: 10.1002/mds.28777.
PubMed Abstract available

MAASS F, Michalke B, Willkommen D, Canaslan S, et al
Cerebrospinal Fluid Iron-Ferritin Ratio as a Potential Progression Marker for Parkinson's Disease.
Mov Disord. 2021 Sep 23. doi: 10.1002/mds.28790.
PubMed Abstract available

OMER N, Giladi N, Gurevich T, Bar-Shira A, et al
Glucocerebrosidase Activity is not Associated with Parkinson's Disease Risk or Severity.
Mov Disord. 2021 Sep 22. doi: 10.1002/mds.28792.
PubMed Abstract available

LAKE J, Reed X, Langston RG, Nalls MA, et al
Coding and Noncoding Variation in LRRK2 and Parkinson's Disease Risk.
Mov Disord. 2021 Sep 20. doi: 10.1002/mds.28787.
PubMed Abstract available

RENNER H, Scholer HR, Bruder JM
Combining Automated Organoid Workflows With Artificial Intelligence-Based Analyses: Opportunities to Build a New Generation of Interdisciplinary High-Throughput Screens for Parkinson's Disease and Beyond.
Mov Disord. 2021 Sep 8. doi: 10.1002/mds.28775.
PubMed Abstract available

POEWE W, Stocchi F, Arkadir D, Ebersbach G, et al
Subcutaneous Levodopa Infusion for Parkinson's Disease: 1-Year Data from the Open-Label BeyoND Study.
Mov Disord. 2021 Sep 8. doi: 10.1002/mds.28758.
PubMed Abstract available

MAILLET A, Metereau E, Tremblay L, Favre E, et al
Serotonergic and Dopaminergic Lesions Underlying Parkinsonian Neuropsychiatric Signs.
Mov Disord. 2021 Sep 8. doi: 10.1002/mds.28722.
PubMed Abstract available

AAMODT WW, Waligorska T, Shen J, Tropea TF, et al
Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease.
Mov Disord. 2021 Sep 4. doi: 10.1002/mds.28779.
PubMed Abstract available

LIN ZH, Zhang BR
Striking While the Iron is Hot: The Role of Prosaposin (PSAP) in Parkinson's Disease.
Mov Disord. 2021 Sep 3. doi: 10.1002/mds.28781.
PubMed

ELSAYED I, Foote IF
Improving Diversity in Parkinson's Disease Genetics: Findings from the First-Ever Genome-Wide Association Study in Latinos.
Mov Disord. 2021 Sep 2. doi: 10.1002/mds.28782.
PubMed

TERRACCIANO A, Aschwanden D, Stephan Y, Cerasa A, et al
Reply to: "Is Conscientiousness Related to the Risk of Parkinson's Disease?"
Mov Disord. 2021;36:2216.
PubMed

LUCA A, Nicoletti A, Zappia M
Neuroticism and Risk of Parkinson's Disease: A Meta-Analysis.
Mov Disord. 2021;36:2215.
PubMed

QUATTRONE A, Antonini A, Vaillancourt DE, Seppi K, et al
Reply to: "Experience with a New Index to Differentiate Parkinson's Disease and Progressive Supranuclear Palsy".
Mov Disord. 2021;36:2208-2209.
PubMed

LIU H, Koros C, Stefanis L, Gasser T, et al
Reply to: "alpha-Synuclein (SNCA) A30G Mutation as a Cause of a Complex Phenotype Without Parkinsonism".
Mov Disord. 2021;36:2212-2213.
PubMed

RAU A, Jost WH, von der Warth R, Urbach H, et al
Experience with a New Index to Differentiate Parkinson's Disease and Progressive Supranuclear Palsy.
Mov Disord. 2021;36:2207-2208.
PubMed

TAN S, Baggio D, Shortt J, Ko B, et al
Cardiovascular Safety of Nilotinib in Parkinson's Disease.
Mov Disord. 2021;36:2217.
PubMed

SOKRATOUS M, Breza M, Senkevich K, Gan-Or Z, et al
alpha-Synuclein (SNCA) A30G Mutation as a Cause of a Complex Phenotype Without Parkinsonism.
Mov Disord. 2021;36:2209-2212.
PubMed

ISHIMOTO T, Yamakado H
Membranes and Organelle in Lewy Bodies: The Mastermind or the Bystander?
Mov Disord. 2021;36:2026.
PubMed

MAJBOUR NK, Abdi IY, Dakna M, Wicke T, et al
Cerebrospinal alpha-Synuclein Oligomers Reflect Disease Motor Severity in DeNoPa Longitudinal Cohort.
Mov Disord. 2021;36:2048-2056.
PubMed Abstract available

ANDERSEN KB, Hansen AK, Damholdt MF, Horsager J, et al
Reduced Synaptic Density in Patients with Lewy Body Dementia: An [(11) C]UCB-J PET Imaging Study.
Mov Disord. 2021;36:2057-2065.
PubMed Abstract available

August 2021

LIU Y, Lawton MA, Lo C, Bowring F, et al
Longitudinal Changes in Parkinson's Disease Symptoms with and Without Rapid Eye Movement Sleep Behavior Disorder: The Oxford Discovery Cohort Study.
Mov Disord. 2021 Aug 26. doi: 10.1002/mds.28763.
PubMed Abstract available

KAINAGA M, Shirota Y, Kodama S, Toda T, et al
Effects of the Coronavirus Disease 2019 Pandemic on Motor Symptoms in Parkinson's Disease: An Observational Study.
Mov Disord. 2021 Aug 25. doi: 10.1002/mds.28766.
PubMed

ONOFRJ M, Di Iorio A, Carrarini C, Russo M, et al
Preexisting Bipolar Disorder Influences the Subsequent Phenotype of Parkinson's Disease.
Mov Disord. 2021 Aug 24. doi: 10.1002/mds.28745.
PubMed Abstract available

KUSTERS CDJ, Paul KC, Duarte Folle A, Keener AM, et al
Increased Menopausal Age Reduces the Risk of Parkinson's Disease: A Mendelian Randomization Approach.
Mov Disord. 2021 Aug 23. doi: 10.1002/mds.28760.
PubMed Abstract available

CAMPESE N, Goebel G, Leys F, Ndayisaba JP, et al
Orthostatic Hypotension in Parkinson's Disease: Do Height and Weight Matter?
Mov Disord. 2021 Aug 23. doi: 10.1002/mds.28768.
PubMed

O'SHEA SA, Hickman RA, Cortes E, Vonsattel JP, et al
Neuropathological Findings in a Case of Parkinsonism and Developmental Delay Associated with a Monoallelic Variant in PLXNA1.
Mov Disord. 2021 Aug 20. doi: 10.1002/mds.28756.
PubMed Abstract available

CIRNARU MD, Creus-Muncunill J, Nelson S, Lewis T, et al
Striatal Cholinergic Dysregulation after Neonatal Decrease in X-Linked Dystonia Parkinsonism-Related TAF1 Isoforms.
Mov Disord. 2021 Aug 17. doi: 10.1002/mds.28750.
PubMed Abstract available

SIA MW, Foo JN, Saffari SE, Wong AS, et al
Polygenic Risk Scores in a Prospective Parkinson's Disease Cohort.
Mov Disord. 2021 Aug 17. doi: 10.1002/mds.28761.
PubMed Abstract available

QI S, Yin P, Wang L, Qu M, et al
Prevalence of Parkinson's Disease: A Community-Based Study in China.
Mov Disord. 2021 Aug 14. doi: 10.1002/mds.28762.
PubMed Abstract available

GARCIA AM, Arias-Vergara T, C Vasquez-Correa J, Noth E, et al
Cognitive Determinants of Dysarthria in Parkinson's Disease: An Automated Machine Learning Approach.
Mov Disord. 2021 Aug 14. doi: 10.1002/mds.28751.
PubMed Abstract available

LE HERON C, MacAskill M, Mason D, Dalrymple-Alford J, et al
A Multi-Step Model of Parkinson's Disease Pathogenesis.
Mov Disord. 2021 Aug 10. doi: 10.1002/mds.28719.
PubMed Abstract available

ERRO R, Buonomo AR, Barone P, Pellecchia MT, et al
Severe dyskinesia after administration of SARS-CoV2 mRNA vaccine in Parkinson Disease.
Mov Disord. 2021 Aug 9. doi: 10.1002/mds.28772.
PubMed

OLANOW CW, Poewe W, Rascol O, Stocchi F, et al
On-Demand Therapy for OFF Episodes in Parkinson's Disease.
Mov Disord. 2021 Aug 7. doi: 10.1002/mds.28726.
PubMed Abstract available

SCHAEFFER E, Toedt I, Kohler S, Rogge A, et al
Risk Disclosure in Prodromal Parkinson's Disease.
Mov Disord. 2021 Aug 5. doi: 10.1002/mds.28723.
PubMed Abstract available

OKUNOYE O, Horsfall L, Marston L, Walters K, et al
Mortality of People with Parkinson's Disease in a Large UK-Based Cohort Study: Time Trends and Relationship to Disease Duration.
Mov Disord. 2021 Aug 5. doi: 10.1002/mds.28727.
PubMed Abstract available

MARKAKI I, Ntetsika T, Svenningsson P
Reply to: "HbA1c and Motor Outcome in Parkinson's Disease in the Mark-PD Study".
Mov Disord. 2021;36:1993.
PubMed

MONJE MHG, Sanchez-Ferro A, Pineda-Pardo JA, Vela-Desojo L, et al
Reply to: Motor Features in a Peruvian Cohort of Parkinson's Disease Patients.
Mov Disord. 2021;36:1994-1995.
PubMed

TORRES L, Velez M, Suarez R, Nunez Y, et al
Motor Features in a Peruvian Cohort of Parkinson's Disease Patients.
Mov Disord. 2021;36:1994.
PubMed

ZITTEL S, Uyar M, Lezius S, Gerloff C, et al
HbA1c and Motor Outcome in Parkinson's Disease in the Mark-PD Study.
Mov Disord. 2021;36:1991-1992.
PubMed

ZECH M, Jech R, Boesch S, Skorvanek M, et al
Scoring Algorithm-Based Genomic Testing in Dystonia: A Prospective Validation Study.
Mov Disord. 2021;36:1959-1964.
PubMed Abstract available

KOSS DJ, Campesan S, Giorgini F, Outeiro TF, et al
Dysfunction of RAB39B-Mediated Vesicular Trafficking in Lewy Body Diseases.
Mov Disord. 2021;36:1744-1758.
PubMed Abstract available

FASANO A, Gurevich T, Jech R, Kovacs N, et al
Concomitant Medication Usage with Levodopa-Carbidopa Intestinal Gel: Results from the COSMOS Study.
Mov Disord. 2021;36:1853-1862.
PubMed Abstract available

KIM R, Lee JY, Kim YK, Kim H, et al
Longitudinal Changes in Isolated Rapid Eye Movement Sleep Behavior Disorder-Related Metabolic Pattern Expression.
Mov Disord. 2021;36:1889-1898.
PubMed Abstract available

July 2021

REN X, Lin J, Stebbins GT, Goetz CG, et al
Prognostic Modeling of Parkinson's Disease Progression Using Early Longitudinal Patterns of Change.
Mov Disord. 2021 Jul 30. doi: 10.1002/mds.28730.
PubMed Abstract available

LAANSMA MA, Bright JK, Al-Bachari S, Anderson TJ, et al
International Multicenter Analysis of Brain Structure Across Clinical Stages of Parkinson's Disease.
Mov Disord. 2021 Jul 20. doi: 10.1002/mds.28706.
PubMed Abstract available

SARASSO E, Agosta F, Piramide N, Gardoni A, et al
Action Observation and Motor Imagery Improve Dual Task in Parkinson's Disease: A Clinical/fMRI Study.
Mov Disord. 2021 Jul 19. doi: 10.1002/mds.28717.
PubMed Abstract available

GROS P, Wang X, Guan J, Lang AE, et al
Exposure to Phosphoglycerate Kinase 1 Activators and Incidence of Parkinson's Disease.
Mov Disord. 2021 Jul 9. doi: 10.1002/mds.28712.
PubMed Abstract available

CONCHA-MARAMBIO L, Farris CM, Holguin B, Ma Y, et al
Seed Amplification Assay to Diagnose Early Parkinson's and Predict Dopaminergic Deficit Progression.
Mov Disord. 2021 Jul 8. doi: 10.1002/mds.28715.
PubMed

FREIRE-ALVAREZ E, Kurca E, Lopez Manzanares L, Pekkonen E, et al
Levodopa-Carbidopa Intestinal Gel Reduces Dyskinesia in Parkinson's Disease in a Randomized Trial.
Mov Disord. 2021 Jul 8. doi: 10.1002/mds.28703.
PubMed Abstract available

MULLER-NEDEBOCK AC, Komolafe MA, Fawale MB, Carr JA, et al
Copy Number Variation in Parkinson's Disease: An Update from Sub-Saharan Africa.
Mov Disord. 2021 Jul 6. doi: 10.1002/mds.28710.
PubMed

SCHILLING M, Lill CM
MicroRNAs as Molecular Biomarkers for Parkinson's Disease Progression.
Mov Disord. 2021 Jul 5. doi: 10.1002/mds.28700.
PubMed

CHOONG CJ, Kimura Y, Mochizuki H
Disturbed Mitochondria-Lysosome Crosstalk in GBA1-Associated Parkinson's Disease.
Mov Disord. 2021 Jul 1. doi: 10.1002/mds.28693.
PubMed

RASCOL O, Cochen de Cock V, Pavy-Le Traon A, Foubert-Samier A, et al
Fluoxetine for the Symptomatic Treatment of Multiple System Atrophy: The MSA-FLUO Trial.
Mov Disord. 2021;36:1704-1711.
PubMed Abstract available

SHILL HA, Zhang N, Driver-Dunckley E, Mehta S, et al
Olfaction in Neuropathologically Defined Progressive Supranuclear Palsy.
Mov Disord. 2021;36:1700-1704.
PubMed Abstract available

PERKINS JE, Janzen A, Bernhard FP, Wilhelm K, et al
Saccade, Pupil, and Blink Responses in Rapid Eye Movement Sleep Behavior Disorder.
Mov Disord. 2021;36:1720-1726.
PubMed Abstract available

DE ALMEIDA CMO, Brito MMC, Bosaipo NB, Pimentel AV, et al
Cannabidiol for Rapid Eye Movement Sleep Behavior Disorder.
Mov Disord. 2021;36:1711-1715.
PubMed Abstract available

WITTKE C, Petkovic S, Dobricic V, Schaake S, et al
Genotype-Phenotype Relations for the Atypical Parkinsonism Genes: MDSGene Systematic Review.
Mov Disord. 2021;36:1499-1510.
PubMed Abstract available

June 2021

VIDENOVIC A, Amara AW, Comella C, Schweitzer PK, et al
Solriamfetol for Excessive Daytime Sleepiness in Parkinson's Disease: Phase 2 Proof-of-Concept Trial.
Mov Disord. 2021 Jun 30. doi: 10.1002/mds.28702.
PubMed Abstract available

PATEL SG, Buchanan CM, Mulroy E, Simpson M, et al
Potential PINK1 Founder Effect in Polynesia Causing Early-Onset Parkinson's Disease.
Mov Disord. 2021 Jun 22. doi: 10.1002/mds.28665.
PubMed

FIORENZATO E, Antonini A, Bisiacchi P, Weis L, et al
Asymmetric Dopamine Transporter Loss Affects Cognitive and Motor Progression in Parkinson's Disease.
Mov Disord. 2021 Jun 14. doi: 10.1002/mds.28682.
PubMed Abstract available

NIGAM M, Ayadi I, Noiray C, Branquino-Bras AC, et al
Sweet or Bland Dreams? Taste Loss in Isolated REM-Sleep Behavior Disorder and Parkinson's Disease.
Mov Disord. 2021 Jun 12. doi: 10.1002/mds.28692.
PubMed Abstract available

GELPI E, Haberler C, Micko A, Polt A, et al
Focal Subthalamic Atrophy After Long-Term Deep Brain Stimulation in Parkinson's Disease.
Mov Disord. 2021 Jun 12. doi: 10.1002/mds.28653.
PubMed

MAITI B, Rawson KS, Tanenbaum AB, Koller JM, et al
Functional Connectivity of Vermis Correlates with Future Gait Impairments in Parkinson's Disease.
Mov Disord. 2021 Jun 10. doi: 10.1002/mds.28684.
PubMed Abstract available

MUNOZ-DELGADO L, Macias-Garcia D, Jesus S, Martin-Rodriguez JF, et al
Peripheral Immune Profile and Neutrophil-to-Lymphocyte Ratio in Parkinson's Disease.
Mov Disord. 2021 Jun 8. doi: 10.1002/mds.28685.
PubMed Abstract available

SEGER AD, Farrher E, Doppler CEJ, Gogishvili A, et al
Putaminal y-Aminobutyric Acid Modulates Motor Response to Dopaminergic Therapy in Parkinson's Disease.
Mov Disord. 2021 Jun 7. doi: 10.1002/mds.28674.
PubMed Abstract available

HAMID E, Ayele BA, Massi DG, Ben Sassi S, et al
Availability of Therapies and Services for Parkinson's Disease in Africa: A Continent-Wide Survey.
Mov Disord. 2021 Jun 3. doi: 10.1002/mds.28669.
PubMed Abstract available

ISONAKA R, Goldstein DS, Zhu W, Yoon E, et al
alpha-Synuclein Deposition in Sympathetic Nerve Fibers in Genetic Forms of Parkinson's Disease.
Mov Disord. 2021 Jun 2. doi: 10.1002/mds.28667.
PubMed Abstract available

MATHUR S
Counting What Counts: How to Reach Outcomes That Truly Matter to Parkinson's Patients.
Mov Disord. 2021;36:1290-1292.
PubMed

May 2021

CARVALHO V, Ferreira JJ, Correia Guedes L
Tremor and Parkinsonism in Chromosomopathies - A Systematic Review.
Mov Disord. 2021 May 31. doi: 10.1002/mds.28663.
PubMed Abstract available

CONEYS R, Storm CS, Kia DA, Almramhi M, et al
Mendelian Randomisation Finds No Causal Association between Urate and Parkinson's Disease Progression.
Mov Disord. 2021 May 31. doi: 10.1002/mds.28662.
PubMed Abstract available

FEARON C, Mikulis DJ, Lang AE
Parkinsonism as a Sequela of SARS-CoV-2 Infection: Pure Hypoxic Injury or Additional COVID-19-Related Response?
Mov Disord. 2021 May 27. doi: 10.1002/mds.28656.
PubMed

BOUALI-BENAZZOUZ R, Benazzouz A
Covid-19 Infection and Parkinsonism: Is There a Link?
Mov Disord. 2021 May 27. doi: 10.1002/mds.28680.
PubMed Abstract available

ORSO B, Arnaldi D, Girtler N, Brugnolo A, et al
Dopaminergic and Serotonergic Degeneration and Cortical [(18) F]Fluorodeoxyglucose Positron Emission Tomography in De Novo Parkinson's Disease.
Mov Disord. 2021 May 22. doi: 10.1002/mds.28654.
PubMed Abstract available

DEAN DN, Lee JC
Linking Parkinson's Disease and Melanoma: Interplay Between alpha-Synuclein and Pmel17 Amyloid Formation.
Mov Disord. 2021 May 22. doi: 10.1002/mds.28655.
PubMed Abstract available

SCHWEDHELM E, Englisch C, Niemann L, Lezius S, et al
Sphingosine-1-Phosphate, Motor Severity, and Progression in Parkinson's Disease (MARK-PD).
Mov Disord. 2021 May 19. doi: 10.1002/mds.28652.
PubMed Abstract available

TOFFOLI M, Higgins A, Lee C, Koletsi S, et al
Intronic Haplotypes in the GBA Gene Do Not Predict Age at Diagnosis of Parkinson's Disease.
Mov Disord. 2021 May 19. doi: 10.1002/mds.28616.
PubMed Abstract available

STUENDL A, Kraus T, Chatterjee M, Zapke B, et al
alpha-Synuclein in Plasma-Derived Extracellular Vesicles Is a Potential Biomarker of Parkinson's Disease.
Mov Disord. 2021 May 18. doi: 10.1002/mds.28639.
PubMed Abstract available

O'SULLIVAN JM, den Heijer JM, Groeneveld GJ, Cooper AA, et al
Intronic Haplotypes in GBA Modify Age at Diagnosis of Parkinson's: Replication in a Subgroup.
Mov Disord. 2021 May 18. doi: 10.1002/mds.28620.
PubMed

HAN F, Brown GL, Zhu Y, Belkin-Rosen AE, et al
Decoupling of Global Brain Activity and Cerebrospinal Fluid Flow in Parkinson's Disease Cognitive Decline.
Mov Disord. 2021 May 17. doi: 10.1002/mds.28643.
PubMed Abstract available

MORLEY D, Dummett S, Kelly L, Jenkinson C, et al
Development of an Exercise-Specific Parkinson's Disease Questionnaire: The PDQ-Exercise.
Mov Disord. 2021 May 15. doi: 10.1002/mds.28644.
PubMed Abstract available

MARRAS C, Mills KA, Eberly S, Oakes D, et al
Longitudinal Change in Quality of Life in Neurological Disorders Measures Over 3 Years in Patients With Early Parkinson's Disease.
Mov Disord. 2021 May 13. doi: 10.1002/mds.28641.
PubMed Abstract available

RICCIARDI L, Fischer P, Mostofi A, Tinkhauser G, et al
Neurophysiological Correlates of Trait Impulsivity in Parkinson's Disease.
Mov Disord. 2021 May 13. doi: 10.1002/mds.28625.
PubMed Abstract available

ESTIAR MA, Senkevich K, Yu E, Varghaei P, et al
Lack of Causal Effects or Genetic Correlation between Restless Legs Syndrome and Parkinson's Disease.
Mov Disord. 2021 May 11. doi: 10.1002/mds.28640.
PubMed Abstract available

COLLOBY SJ, Nathan PJ, Bakker G, Lawson RA, et al
Spatial Covariance of Cholinergic Muscarinic M1 /M4 Receptors in Parkinson's Disease.
Mov Disord. 2021 May 11. doi: 10.1002/mds.28564.
PubMed Abstract available

NAITO T, Satake W, Ogawa K, Suzuki K, et al
Trans-Ethnic Fine-Mapping of the Major Histocompatibility Complex Region Linked to Parkinson's Disease.
Mov Disord. 2021 May 11. doi: 10.1002/mds.28583.
PubMed Abstract available

BARBUTI PA, Barker RA, Brundin P, Przedborski S, et al
Recent Advances in the Development of Stem-Cell-Derived Dopaminergic Neuronal Transplant Therapies for Parkinson's Disease.
Mov Disord. 2021 May 8. doi: 10.1002/mds.28628.
PubMed Abstract available

IWAKI H, Leonard HL, Makarious MB, Bookman M, et al
Accelerating Medicines Partnership: Parkinson's Disease. Genetic Resource.
Mov Disord. 2021 May 7. doi: 10.1002/mds.28549.
PubMed Abstract available

DI LAZZARO G, Magrinelli F, Estevez-Fraga C, Valente EM, et al
X-Linked Parkinsonism: Phenotypic and Genetic Heterogeneity.
Mov Disord. 2021 May 7. doi: 10.1002/mds.28565.
PubMed Abstract available

MCINTOSH E, Kent S, Gray A, Clarke CE, et al
Cost-Effectiveness of Dopamine Agonists and Monoamine Oxidase B Inhibitors in Early Parkinson's Disease.
Mov Disord. 2021 May 7. doi: 10.1002/mds.28623.
PubMed Abstract available

MIRELMAN A, Ben Or Frank M, Melamed M, Granovsky L, et al
Detecting Sensitive Mobility Features for Parkinson's Disease Stages Via Machine Learning.
Mov Disord. 2021 May 6. doi: 10.1002/mds.28631.
PubMed Abstract available

KAASINEN V, Vahlberg T, Stoessl AJ, Strafella AP, et al
Dopamine Receptors in Parkinson's Disease: A Meta-Analysis of Imaging Studies.
Mov Disord. 2021 May 6. doi: 10.1002/mds.28632.
PubMed Abstract available

KREMER T, Taylor KI, Siebourg-Polster J, Gerken T, et al
Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease.
Mov Disord. 2021 May 4. doi: 10.1002/mds.28608.
PubMed Abstract available

SCHERBAUM R, Kwon EH, Richter D, Bartig D, et al
Clinical Profiles and Mortality of COVID-19 Inpatients with Parkinson's Disease in Germany.
Mov Disord. 2021 May 4. doi: 10.1002/mds.28586.
PubMed Abstract available

MESTRE TA, Macklin EA, Ascherio A, Ferreira JJ, et al
Expectations of Benefit in a Trial of a Candidate Disease-Modifying Treatment for Parkinson Disease.
Mov Disord. 2021 May 4. doi: 10.1002/mds.28630.
PubMed Abstract available

SCOTT GD, Lim MM, Drake MG, Woltjer R, et al
Onset of Skin, Gut, and Genitourinary Prodromal Parkinson's Disease: A Study of 1.5 Million Veterans.
Mov Disord. 2021 May 3. doi: 10.1002/mds.28636.
PubMed Abstract available

KIEBURTZ K, Olanow CW
Reply to: "A New Approach to the Development of Disease-Modifying Therapies for PD".
Mov Disord. 2021;36:1281-1282.
PubMed

SIMON DK
A New Approach to the Development of Disease-Modifying Therapies for PD.
Mov Disord. 2021;36:1281.
PubMed

LERCHE S, Schulte C, Wurster I, Machetanz G, et al
The Mutation Matters: CSF Profiles of GCase, Sphingolipids, alpha-Synuclein in PDGBA.
Mov Disord. 2021;36:1216-1228.
PubMed Abstract available

April 2021

YILMAZ R, Suenkel U, Postuma RB, Heinzel S, et al
Comparing the Two Prodromal Parkinson's Disease Research Criteria-Lessons for Future Studies.
Mov Disord. 2021 Apr 30. doi: 10.1002/mds.28637.
PubMed

SARANZA G, Villanueva EQ 3rd, Lang AE
Preferences for Communication About End-of-Life Care in Atypical Parkinsonism.
Mov Disord. 2021 Apr 28. doi: 10.1002/mds.28633.
PubMed Abstract available

HUYNH B, Fu Y, Kirik D, Shine JM, et al
Comparison of Locus Coeruleus Pathology with Nigral and Forebrain Pathology in Parkinson's Disease.
Mov Disord. 2021 Apr 26. doi: 10.1002/mds.28615.
PubMed Abstract available

TSUNEMI T, Oyama G, Saiki S, Hatano T, et al
Intrajejunal Infusion of Levodopa/Carbidopa for Advanced Parkinson's Disease: A Systematic Review.
Mov Disord. 2021 Apr 25. doi: 10.1002/mds.28595.
PubMed Abstract available

LETA V, Rodriguez-Violante M, Abundes A, Rukavina K, et al
Parkinson's disease and Post-COVID-19 syndrome: The Parkinson's Long-COVID spectrum.
Mov Disord. 2021 Apr 22. doi: 10.1002/mds.28622.
PubMed

LI C, Ou R, Chen Y, Gu X, et al
Genetic Modifiers of Age at Onset for Parkinson's Disease in Asians: A Genome-Wide Association Study.
Mov Disord. 2021 Apr 21. doi: 10.1002/mds.28621.
PubMed Abstract available

CHEN Y, Wu W, Zhao S, Lv X, et al
Increased Accumulation of alpha-Synuclein in Inflamed Appendices of Parkinson's Disease Patients.
Mov Disord. 2021 Apr 20. doi: 10.1002/mds.28553.
PubMed Abstract available

JOHNSON LA, Aman JE, Yu Y, Escobar Sanabria D, et al
High-Frequency Oscillations in the Pallidum: A Pathophysiological Biomarker in Parkinson's Disease?
Mov Disord. 2021 Apr 13. doi: 10.1002/mds.28566.
PubMed Abstract available

SOARES C, Carneiro DR, Dias R, Ferreira D, et al
Behind the mask: recognizing facial features of Parkinson's disease during the COVID-19 pandemic.
Mov Disord. 2021 Apr 9. doi: 10.1002/mds.28619.
PubMed

ZAHED H, Zuzuarregui JRP, Gilron R, Denison T, et al
The Neurophysiology of Sleep in Parkinson's Disease.
Mov Disord. 2021 Apr 7. doi: 10.1002/mds.28562.
PubMed Abstract available

LIM SH, Ferdousi M, Kalteniece A, Mahfoud ZR, et al
Corneal Confocal Microscopy Identifies Parkinson's Disease with More Rapid Motor Progression.
Mov Disord. 2021 Apr 7. doi: 10.1002/mds.28602.
PubMed Abstract available

JIANG C, Hopfner F, Berg D, Hu MT, et al
Validation of alpha-Synuclein in L1CAM-Immunocaptured Exosomes as a Biomarker for the Stratification of Parkinsonian Syndromes.
Mov Disord. 2021 Apr 7. doi: 10.1002/mds.28591.
PubMed Abstract available

KOOHI N, Bancroft MJ, Patel J, Castro P, et al
Saccadic Bradykinesia in Parkinson's Disease: Preliminary Observations.
Mov Disord. 2021 Apr 6. doi: 10.1002/mds.28609.
PubMed

TERRACCIANO A, Aschwanden D, Stephan Y, Cerasa A, et al
Neuroticism and Risk of Parkinson's Disease: A Meta-Analysis.
Mov Disord. 2021 Apr 4. doi: 10.1002/mds.28575.
PubMed Abstract available

UEDA J, Uemura N, Sawamura M, Taguchi T, et al
Perampanel Inhibits alpha-Synuclein Transmission in Parkinson's Disease Models.
Mov Disord. 2021 Apr 4. doi: 10.1002/mds.28558.
PubMed Abstract available

NIJHUIS FAP, Esselink R, de Bie RMA, Groenewoud H, et al
Translating Evidence to Advanced Parkinson's Disease Patients: A Systematic Review and Meta-Analysis.
Mov Disord. 2021 Apr 2. doi: 10.1002/mds.28599.
PubMed Abstract available

HELMICH RC, Van den Berg KRE, Panyakaew P, Cho HJ, et al
Cerebello-Cortical Control of Tremor Rhythm and Amplitude in Parkinson's Disease.
Mov Disord. 2021 Apr 1. doi: 10.1002/mds.28603.
PubMed

GUTTLER C, Nikulin VV, van Riesen C
Reply to: "Levodopa-Induced Dyskinesia Is Mediated by Cortical Gamma Oscillations in Experimental Parkinsonism".
Mov Disord. 2021;36:1045-1047.
PubMed

SCHMIDT SL, Grill WM
Levodopa-Induced Dyskinesia Is Mediated by Cortical Gamma Oscillations in Experimental Parkinsonism.
Mov Disord. 2021;36:1044-1045.
PubMed

NEUMANN WJ, Rodriguez-Oroz MC
Machine Learning Will Extend the Clinical Utility of Adaptive Deep Brain Stimulation.
Mov Disord. 2021;36:796-799.
PubMed

RUSZ J, Tykalova T, Ramig LO, Tripoliti E, et al
Guidelines for Speech Recording and Acoustic Analyses in Dysarthrias of Movement Disorders.
Mov Disord. 2021;36:803-814.
PubMed Abstract available

GEORGIEV D, Roskar S, Cus A, Wilkinson L, et al
STN-DBS Increases Proactive but Not Retroactive Interference During Verbal Learning in PD.
Mov Disord. 2021;36:1010-1015.
PubMed Abstract available

OSHIMA S, Fushimi Y, Okada T, Nakajima S, et al
Neuromelanin-Sensitive Magnetic Resonance Imaging Using DANTE Pulse.
Mov Disord. 2021;36:874-882.
PubMed Abstract available

BOOTH S, Ramadan A, Zhang D, Lu L, et al
The Vasomotor Response to Dopamine Is Altered in the Rat Model of l-dopa-Induced Dyskinesia.
Mov Disord. 2021;36:938-947.
PubMed Abstract available

March 2021

VISANJI NP, Lang AE
Call the Plumber: Impaired Meningeal Lymphatic Drainage in Parkinson's Disease.
Mov Disord. 2021 Mar 30. doi: 10.1002/mds.28590.
PubMed

KLUGER BM, Dolhun R, Sumrall M, Hall K, et al
Palliative Care and Parkinson's Disease: Time to Move Beyond Cancer.
Mov Disord. 2021 Mar 30. doi: 10.1002/mds.28556.
PubMed

SCHIESS M, Suescun J, Doursout MF, Adams C, et al
Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Safety in Idiopathic Parkinson's Disease.
Mov Disord. 2021 Mar 27. doi: 10.1002/mds.28582.
PubMed Abstract available

KANG X, Ploner A, Roelstraete B, Khalili H, et al
Association between Microscopic Colitis and Parkinson's Disease in a Swedish Population.
Mov Disord. 2021 Mar 25. doi: 10.1002/mds.28594.
PubMed Abstract available

GROVER S, Kumar-Sreelatha AA, Bobbili DR, May P, et al
Replication of a Novel Parkinson's Locus in a European Ancestry Population.
Mov Disord. 2021 Mar 24. doi: 10.1002/mds.28546.
PubMed Abstract available

ABRAHAM DS, Pham Nguyen TP, Willis AW
Claims-Based Frailty and Outcomes: Applying an Aging Measure to Older Adults with Parkinson's Disease.
Mov Disord. 2021 Mar 23. doi: 10.1002/mds.28561.
PubMed Abstract available

YAO CW, Saha-Chaudhuri P, Zolfaghari S, Pelletier A, et al
Phenoconversion from Possible REM Sleep Behavior to Parkinsonism in the Population-Based CLSA.
Mov Disord. 2021 Mar 22. doi: 10.1002/mds.28571.
PubMed

SALARI M, Etemadifar M, Zali A, Medghalchi A, et al
Seroprevalence of SARS-CoV-2 in Parkinson's Disease Patients: A Case-Control Study.
Mov Disord. 2021 Mar 17. doi: 10.1002/mds.28580.
PubMed

MARINI K, Seppi K, Tschiderer L, Kiechl S, et al
Application of the Updated Movement Disorder Society Criteria for Prodromal Parkinson's Disease to a Population-Based 10-Year Study.
Mov Disord. 2021 Mar 17. doi: 10.1002/mds.28570.
PubMed

CANONICO M, Pesce G, Bonaventure A, Le Noan-Laine M, et al
Increased Risk of Parkinson's Disease in Women after Bilateral Oophorectomy.
Mov Disord. 2021 Mar 16. doi: 10.1002/mds.28563.
PubMed Abstract available

DOBKIN RD, Mann SL, Weintraub D, Rodriguez KM, et al
Innovating Parkinson's Care: A Randomized Controlled Trial of Telemedicine Depression Treatment.
Mov Disord. 2021 Mar 12. doi: 10.1002/mds.28548.
PubMed Abstract available

GAURAV R, Yahia-Cherif L, Pyatigorskaya N, Mangone G, et al
Longitudinal Changes in Neuromelanin MRI Signal in Parkinson's Disease: A Progression Marker.
Mov Disord. 2021 Mar 10. doi: 10.1002/mds.28531.
PubMed Abstract available

CHOHAN H, Senkevich K, Patel RK, Bestwick JP, et al
Type 2 Diabetes as a Determinant of Parkinson's Disease Risk and Progression.
Mov Disord. 2021 Mar 8. doi: 10.1002/mds.28551.
PubMed Abstract available

DUYSENS J, Nonnekes J
Parkinson's Kinesia Paradoxa Is Not a Paradox.
Mov Disord. 2021 Mar 3. doi: 10.1002/mds.28550.
PubMed

CLAUS I, Muhle P, Czechowski J, Ahring S, et al
Expiratory Muscle Strength Training for Therapy of Pharyngeal Dysphagia in Parkinson's Disease.
Mov Disord. 2021 Mar 2. doi: 10.1002/mds.28552.
PubMed Abstract available

FEARON C, Lang AE, Espay AJ
The Logic and Pitfalls of Parkinson's Disease as "Brain-First" Versus "Body-First" Subtypes.
Mov Disord. 2021;36:594-598.
PubMed

BORGHAMMER P, Horsager J
The Logic and Pitfalls of Parkinson's as Brain- Versus Body-First Subtypes.
Mov Disord. 2021;36:785-786.
PubMed

FEARON C, Lang AE, J Espay A
Reply to: "The Logic and Pitfalls of Parkinson's as Brain- Versus Body-First Subtypes".
Mov Disord. 2021;36:786-787.
PubMed

SARTER M, Avila C, Kucinski A, Donovan E, et al
Make a Left Turn: Cortico-Striatal Circuitry Mediating the Attentional Control of Complex Movements.
Mov Disord. 2021;36:535-546.
PubMed Abstract available

YOUNCE JR, Campbell MC, Hershey T, Tanenbaum AB, et al
Resting-State Functional Connectivity Predicts STN DBS Clinical Response.
Mov Disord. 2021;36:662-671.
PubMed Abstract available

POLISSIDIS A, Koronaiou M, Kollia V, Koronaiou E, et al
Psychosis-Like Behavior and Hyperdopaminergic Dysregulation in Human alpha-Synuclein BAC Transgenic Rats.
Mov Disord. 2021;36:716-728.
PubMed Abstract available

HANSS Z, Larsen SB, Antony P, Mencke P, et al
Mitochondrial and Clearance Impairment in p.D620N VPS35 Patient-Derived Neurons.
Mov Disord. 2021;36:704-715.
PubMed Abstract available

February 2021

DE MICCO R, Agosta F, Basaia S, Siciliano M, et al
Functional Connectomics and Disease Progression in Drug-Naive Parkinson's Disease Patients.
Mov Disord. 2021 Feb 27. doi: 10.1002/mds.28541.
PubMed Abstract available

BURTSCHER J, Syed MMK, Lashuel HA, Millet GP, et al
Hypoxia Conditioning as a Promising Therapeutic Target in Parkinson's Disease?
Mov Disord. 2021 Feb 27. doi: 10.1002/mds.28544.
PubMed Abstract available

MARKAKI I, Ntetsika T, Sorjonen K, Svenningsson P, et al
Euglycemia Indicates Favorable Motor Outcome in Parkinson's Disease.
Mov Disord. 2021 Feb 26. doi: 10.1002/mds.28545.
PubMed Abstract available

CHAHINE LM, Zhu X, Ehrenkranz R, Chen H, et al
Changes in Self-Reported Energy Levels in Prodromal Parkinson's Disease.
Mov Disord. 2021 Feb 26. doi: 10.1002/mds.28535.
PubMed

KAKAR RS, Pastor JV, Moe OW, Ambrosio F, et al
Peripheral Klotho and Parkinson's Disease.
Mov Disord. 2021 Feb 25. doi: 10.1002/mds.28530.
PubMed

MOONEN AJH, Mulders AEP, Defebvre L, Duits A, et al
Cognitive Behavioral Therapy for Anxiety in Parkinson's Disease: A Randomized Controlled Trial.
Mov Disord. 2021 Feb 22. doi: 10.1002/mds.28533.
PubMed Abstract available

AVENALI M, Cerri S, Ongari G, Ghezzi C, et al
Profiling the Biochemical Signature of GBA-Related Parkinson's Disease in Peripheral Blood Mononuclear Cells.
Mov Disord. 2021 Feb 22. doi: 10.1002/mds.28496.
PubMed Abstract available

LIU H, Koros C, Strohaker T, Schulte C, et al
A Novel SNCA A30G Mutation Causes Familial Parkinson's Disease.
Mov Disord. 2021 Feb 22. doi: 10.1002/mds.28534.
PubMed Abstract available

SONG S, Luo Z, Li C, Huang X, et al
Changes in Body Composition Before and After Parkinson's Disease Diagnosis.
Mov Disord. 2021 Feb 22:e28536. doi: 10.1002/mds.28536.
PubMed Abstract available

AEED F, Cermak N, Schiller J, Schiller Y, et al
Intrinsic Disruption of the M1 Cortical Network in a Mouse Model of Parkinson's Disease.
Mov Disord. 2021 Feb 19. doi: 10.1002/mds.28538.
PubMed Abstract available

KLEINER G, Fernandez HH, Chou KL, Fasano A, et al
Non-Motor Fluctuations in Parkinson's Disease: Validation of the Non-Motor Fluctuation Assessment Questionnaire.
Mov Disord. 2021 Feb 15. doi: 10.1002/mds.28507.
PubMed Abstract available

GALPER J, Balwani M, Fahn S, Waters C, et al
Cytokines and Gaucher Biomarkers in Glucocerebrosidase Carriers With and Without Parkinson Disease.
Mov Disord. 2021 Feb 11. doi: 10.1002/mds.28525.
PubMed Abstract available

BRIGHT JM, Carlisle HJ, Toda AMA, Murphy M, et al
Differential Inhibition of LRRK2 in Parkinson's Disease Patient Blood by a G2019S Selective LRRK2 Inhibitor.
Mov Disord. 2021 Feb 11. doi: 10.1002/mds.28490.
PubMed Abstract available

PAZ RM, Tubert C, Stahl AM, Amarillo Y, et al
Levodopa Causes Striatal Cholinergic Interneuron Burst-Pause Activity in Parkinsonian Mice.
Mov Disord. 2021 Feb 6. doi: 10.1002/mds.28516.
PubMed Abstract available

ANTAR T, Iwaki H, B Singleton A
Reply to: 'Letter to the Editor on "Sex Differences in Parkinson's Disease Phenotype and Caregiving Disparities"'.
Mov Disord. 2021;36:527-528.
PubMed

OUTEIRO TF, Krisko A
Reply to: "Parkinson's Disease and COVID-19: Do We Need to Be More Patient?"
Mov Disord. 2021;36:278-279.
PubMed

GONZALEZ-LATAPI P, Fearon C, Fasano A, Lang AE, et al
Parkinson's Disease and COVID-19: Do We Need to Be More Patient?
Mov Disord. 2021;36:277.
PubMed

DE LA ROSA T, Amado Scerni D, Scorza FA
Sex Differences in Parkinson's Disease Phenotype and Caregiving Disparities.
Mov Disord. 2021;36:526.
PubMed

HO GPH, Ramalingam N, Imberdis T, Wilkie EC, et al
Upregulation of Cellular Palmitoylation Mitigates alpha-Synuclein Accumulation and Neurotoxicity.
Mov Disord. 2021;36:348-359.
PubMed Abstract available

January 2021

MULLER-NEDEBOCK AC, van der Westhuizen FH, Koks S, Bardien S, et al
Nuclear Genes Associated with Mitochondrial DNA Processes as Contributors to Parkinson's Disease Risk.
Mov Disord. 2021 Jan 29. doi: 10.1002/mds.28475.
PubMed Abstract available

JEONG SH, Lee HS, Jung JH, Baik K, et al
White Matter Hyperintensities, Dopamine Loss, and Motor Deficits in De Novo Parkinson's Disease.
Mov Disord. 2021 Jan 29. doi: 10.1002/mds.28510.
PubMed Abstract available

GP2: The Global Parkinson's Genetics Program.
Mov Disord. 2021 Jan 29. doi: 10.1002/mds.28494.
PubMed

KIM JJ, Makarious MB, Bandres-Ciga S, Gibbs JR, et al
The Parkinson's Disease DNA Variant Browser.
Mov Disord. 2021 Jan 26. doi: 10.1002/mds.28488.
PubMed Abstract available

MONJE MHG, Sanchez-Ferro A, Pineda-Pardo JA, Vela-Desojo L, et al
Motor Onset Topography and Progression in Parkinson's Disease: the Upper Limb Is First.
Mov Disord. 2021 Jan 20. doi: 10.1002/mds.28462.
PubMed Abstract available

DONAHUE EK, Murdos A, Jakowec MW, Sheikh-Bahaei N, et al
Global and Regional Changes in Perivascular Space in Idiopathic and Familial Parkinson's Disease.
Mov Disord. 2021 Jan 20. doi: 10.1002/mds.28473.
PubMed Abstract available

WELTON T, Tan EK
Applying Artificial Intelligence to Multi-Omic Data: New Functional Variants in Parkinson's Disease.
Mov Disord. 2021 Jan 17. doi: 10.1002/mds.28481.
PubMed

MICHELI F, Vissani M, Pecchioli G, Terenzi F, et al
Impulsivity Markers in Parkinsonian Subthalamic Single-Unit Activity.
Mov Disord. 2021 Jan 16. doi: 10.1002/mds.28497.
PubMed Abstract available

AVRAM CM, Brumbach BH, Hiller AL
A Report of Tamoxifen and Parkinson's Disease in a US Population and a Review of the Literature.
Mov Disord. 2021 Jan 15. doi: 10.1002/mds.28471.
PubMed Abstract available

LIN CH, Chang CH, Tai CH, Cheng MF, et al
A Double-Blind, Randomized, Controlled Trial of Lovastatin in Early-Stage Parkinson's Disease.
Mov Disord. 2021 Jan 15. doi: 10.1002/mds.28474.
PubMed Abstract available

RAVANIDIS S, Bougea A, Karampatsi D, Papagiannakis N, et al
Differentially Expressed Circular RNAs in Peripheral Blood Mononuclear Cells of Patients with Parkinson's Disease.
Mov Disord. 2021 Jan 12. doi: 10.1002/mds.28467.
PubMed Abstract available

HERZ DM, Meder D, Camilleri JA, Eickhoff SB, et al
Brain Motor Network Changes in Parkinson's Disease: Evidence from Meta-Analytic Modeling.
Mov Disord. 2021 Jan 11. doi: 10.1002/mds.28468.
PubMed Abstract available

VILA-VICOSA D, Clemente A, Pona-Ferreira F, Leitao M, et al
Unsupervised walking activity assessment reveals COVID-19 impact on Parkinson's disease patients.
Mov Disord. 2021 Jan 11. doi: 10.1002/mds.28514.
PubMed

ZARKALI A, McColgan P, Leyland LA, Lees AJ, et al
Visual Dysfunction Predicts Cognitive Impairment and White Matter Degeneration in Parkinson's Disease.
Mov Disord. 2021 Jan 9. doi: 10.1002/mds.28477.
PubMed Abstract available

KUUSIMAKI T, Al-Abdulrasul H, Kurki S, Hietala J, et al
Increased Risk of Parkinson's Disease in Patients With Schizophrenia Spectrum Disorders.
Mov Disord. 2021 Jan 6. doi: 10.1002/mds.28484.
PubMed Abstract available

CHEN L, Bedard P, Hallett M, Horovitz SG, et al
Dynamics of Top-Down Control and Motor Networks in Parkinson's Disease.
Mov Disord. 2021 Jan 6. doi: 10.1002/mds.28461.
PubMed Abstract available

SCHIRINZI T, Maftei D, Pieri M, Bernardini S, et al
Increase of Prokineticin-2 in Serum of Patients with Parkinson's Disease.
Mov Disord. 2021 Jan 6. doi: 10.1002/mds.28458.
PubMed

METCALFE-ROACH A, Yu AC, Golz E, Cirstea M, et al
MIND and Mediterranean Diets Associated with Later Onset of Parkinson's Disease.
Mov Disord. 2021 Jan 6. doi: 10.1002/mds.28464.
PubMed Abstract available

BAUMGARTNER AJ, Press DZ, Simon DK
The Relationship Between Olfactory Dysfunction and Constipation in Early Parkinson's Disease.
Mov Disord. 2021 Jan 6. doi: 10.1002/mds.28483.
PubMed

CHOE CU, Potter-Nerger M, Buhmann C, Blankenberg S, et al
Reply to: "Parkin Deficiency Appears Not to Be Associated with Cardiac Damage in Parkinson's Disease".
Mov Disord. 2021;36:273-274.
PubMed

TRILCK-WINKLER M, Borsche M, Konig IR, Balck A, et al
Parkin Deficiency Appears Not to Be Associated with Cardiac Damage in Parkinson's Disease.
Mov Disord. 2021;36:271-273.
PubMed

WITT K
The Impact of the Basal Ganglia on Working Memory: Evidence from Parkinson's Disease.
Mov Disord. 2021;36:13-15.
PubMed

FULLER RLM, Sanchez-Ferro A, Goetz CG, Martinez-Martin P, et al
In Support of Electronic Versions of Movement Disorder Society Rating Scales.
Mov Disord. 2021;36:270-271.
PubMed

TURNER TH, Dale ML
Reply to: "In Support of Electronic Versions of Movement Disorder Society Rating Scales".
Mov Disord. 2021;36:271.
PubMed

SARANZA G, Lang AE
Inhaled Levodopa as a Potential Treatment for Diphasic Dyskinesia.
Mov Disord. 2021;36:265-266.
PubMed

KIEBURTZ K, Katz R, McGarry A, Olanow CW, et al
A New Approach to the Development of Disease-Modifying Therapies for PD; Fighting Another Pandemic.
Mov Disord. 2021;36:59-63.
PubMed Abstract available

VIEIRA-YANO B, Martini DN, Horak FB, de Lima-Pardini A, et al
The Adapted Resistance Training with Instability Randomized Controlled Trial for Gait Automaticity.
Mov Disord. 2021;36:152-163.
PubMed Abstract available

December 2020

WILSON J, Yarnall AJ, Craig CE, Galna B, et al
Cholinergic Basal Forebrain Volumes Predict Gait Decline in Parkinson's Disease.
Mov Disord. 2020 Dec 31. doi: 10.1002/mds.28453.
PubMed Abstract available

DUITS AA, Boots LMM, Mulders AEP, Moonen AJH, et al
Covid Proof Self-Management Training for Caregivers of Patients with Parkinson's Disease.
Mov Disord. 2020 Dec 27. doi: 10.1002/mds.28457.
PubMed

FILIPPOU P, Outeiro TF
Cancer and Parkinson's Disease: Common Targets, Emerging Hopes.
Mov Disord. 2020 Dec 21. doi: 10.1002/mds.28425.
PubMed Abstract available

NISSEN SK, Ferreira SA, Nielsen MC, Schulte C, et al
Soluble CD163 Changes Indicate Monocyte Association With Cognitive Deficits in Parkinson's Disease.
Mov Disord. 2020 Dec 17. doi: 10.1002/mds.28424.
PubMed Abstract available

ZOON TJC, van Rooijen G, Balm GMFC, Bergfeld IO, et al
Apathy Induced by Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease: A Meta-Analysis.
Mov Disord. 2020 Dec 16. doi: 10.1002/mds.28390.
PubMed Abstract available

SKRAHINA V, Gaber H, Vollstedt EJ, Forster TM, et al
The Rostock International Parkinson's Disease (ROPAD) Study: Protocol and Initial Findings.
Mov Disord. 2020 Dec 14. doi: 10.1002/mds.28416.
PubMed Abstract available

KLINE EM, Houser MC, Herrick MK, Seibler P, et al
Genetic and Environmental Factors in Parkinson's Disease Converge on Immune Function and Inflammation.
Mov Disord. 2020 Dec 14. doi: 10.1002/mds.28411.
PubMed Abstract available

ELFIL M, Bahbah EI, Attia MM, Eldokmak M, et al
Impact of Obstructive Sleep Apnea on Cognitive and Motor Functions in Parkinson's Disease.
Mov Disord. 2020 Dec 9. doi: 10.1002/mds.28412.
PubMed Abstract available

MULLIN S, Stokholm MG, Hughes D, Mehta A, et al
Brain Microglial Activation Increased in Glucocerebrosidase (GBA) Mutation Carriers without Parkinson's disease.
Mov Disord. 2020 Dec 5. doi: 10.1002/mds.28375.
PubMed Abstract available

CAREY G, Gormezoglu M, de Jong JJA, Hofman PAM, et al
Neuroimaging of Anxiety in Parkinson's Disease: A Systematic Review.
Mov Disord. 2020 Dec 2. doi: 10.1002/mds.28404.
PubMed Abstract available

OLSZEWSKA DA, Lang AE
"Opening" New Insights Into LRRK2 Conformation and the Microtubule.
Mov Disord. 2020;35:2162-2163.
PubMed

November 2020

MARTIN WRW, Miles M, Zhong Q, Hartlein J, et al
Is Levodopa Response a Valid Indicator of Parkinson's Disease?
Mov Disord. 2020 Nov 30. doi: 10.1002/mds.28406.
PubMed Abstract available

GUTTLER C, Altschuler J, Tanev K, Bockmann S, et al
Levodopa-Induced Dyskinesia Are Mediated by Cortical Gamma Oscillations in Experimental Parkinsonism.
Mov Disord. 2020 Nov 28. doi: 10.1002/mds.28403.
PubMed Abstract available

PORTLEY MK, Scholz SW
Hot Topic: Epigenetics in Parkinson's Disease: A New Frontier for Disease-Modifying Therapies.
Mov Disord. 2020 Nov 27. doi: 10.1002/mds.28410.
PubMed

SANTOS-GARCIA D, Pozojevic J, de Deus Fonticoba T, Kurtis M, et al
First Case of Parkinsonian-Pyramidal Syndrome Associated with a TBK1 Mutation.
Mov Disord. 2020 Nov 27. doi: 10.1002/mds.28405.
PubMed

WALDTHALER J, Stock L, Sommerkorn J, Kruger-Zechlin C, et al
Antisaccade Latency Is Sensitive to Longitudinal Change of Motor and Cognitive Symptoms in Parkinson's Disease.
Mov Disord. 2020 Nov 25. doi: 10.1002/mds.28374.
PubMed

AL-QASSABI A, Tsao TS, Racolta A, Kremer T, et al
Immunohistochemical Detection of Synuclein Pathology in Skin in Idiopathic Rapid Eye Movement Sleep Behavior Disorder and Parkinsonism.
Mov Disord. 2020 Nov 24. doi: 10.1002/mds.28399.
PubMed Abstract available

JAAKKOLA E, Huovinen A, Kaasinen V, Joutsa J, et al
No Change in Prevalence of Impulse Control Disorder Behaviors in Parkinson's Disease During the Last Decade.
Mov Disord. 2020 Nov 24. doi: 10.1002/mds.28400.
PubMed

GARCIA-SANZ P, M F G Aerts J, Moratalla R
The Role of Cholesterol in alpha-Synuclein and Lewy Body Pathology in GBA1 Parkinson's Disease.
Mov Disord. 2020 Nov 21. doi: 10.1002/mds.28396.
PubMed Abstract available

PAGAN FL, Wilmarth B, Torres-Yaghi Y, Hebron ML, et al
Long-Term Safety and Clinical Effects of Nilotinib in Parkinson's Disease.
Mov Disord. 2020 Nov 20. doi: 10.1002/mds.28389.
PubMed Abstract available

ERREA O, Rodriguez-Oroz MC
Oligodendrocytes, a New Player in the Etiology of Parkinson's Disease.
Mov Disord. 2020 Nov 18. doi: 10.1002/mds.28393.
PubMed

OJUKWU DI, Andruska KM, Halpern CH
Lessons From George Floyd: Racial Inequalities in the Treatment of Parkinson's Disease.
Mov Disord. 2020 Nov 17. doi: 10.1002/mds.28388.
PubMed

ISHIBASHI K, Miura Y, Wagatsuma K, Toyohara J, et al
Adenosine A2A Receptor Occupancy by Long-Term Istradefylline Administration in Parkinson's Disease.
Mov Disord. 2020 Nov 16. doi: 10.1002/mds.28378.
PubMed

OUTEIRO TF, Heutink P, Bezard E, Cenci AM, et al
From iPS Cells to Rodents and Nonhuman Primates: Filling Gaps in Modeling Parkinson's Disease.
Mov Disord. 2020 Nov 16. doi: 10.1002/mds.28387.
PubMed Abstract available

VIGNATELLI L, Zenesini C, Belotti LMB, Baldin E, et al
Risk of hospitalization and death for COVID-19 in people with Parkinson's disease or parkinsonism.
Mov Disord. 2020 Nov 16. doi: 10.1002/mds.28408.
PubMed Abstract available

MAETZLER W, Rochester L, Bhidayasiri R, Espay AJ, et al
Modernizing Daily Function Assessment in Parkinson's Disease Using Capacity, Perception, and Performance Measures.
Mov Disord. 2020 Nov 15. doi: 10.1002/mds.28377.
PubMed Abstract available

DEVOS D, Hirsch E, Wyse R
Seven Solutions for Neuroprotection in Parkinson's Disease.
Mov Disord. 2020 Nov 13. doi: 10.1002/mds.28379.
PubMed Abstract available

DE MICCO R, Satolli S, Siciliano M, Di Nardo F, et al
Connectivity Correlates of Anxiety Symptoms in Drug-Naive Parkinson's Disease Patients.
Mov Disord. 2020 Nov 10. doi: 10.1002/mds.28372.
PubMed Abstract available

PICILLO M, Phokaewvarangkul O, Poon YY, McIntyre CC, et al
Levodopa Versus Dopamine Agonist After Subthalamic Stimulation in Parkinson's Disease.
Mov Disord. 2020 Nov 9. doi: 10.1002/mds.28382.
PubMed Abstract available

QUATTRONE A, Antonini A, Vaillancourt DE, Seppi K, et al
A New MRI Measure to Early Differentiate Progressive Supranuclear Palsy From De Novo Parkinson's Disease in Clinical Practice: An International Study.
Mov Disord. 2020 Nov 5. doi: 10.1002/mds.28364.
PubMed Abstract available

SARIHAN EI, Perez-Palma E, Niestroj LM, Loesch D, et al
Genome-Wide Analysis of Copy Number Variation in Latin American Parkinson's Disease Patients.
Mov Disord. 2020 Nov 5. doi: 10.1002/mds.28353.
PubMed Abstract available

VAN DER ZEE S, Muller MLTM, Kanel P, van Laar T, et al
Cholinergic Denervation Patterns Across Cognitive Domains in Parkinson's Disease.
Mov Disord. 2020 Nov 2. doi: 10.1002/mds.28360.
PubMed Abstract available

CHOUGAR L, Faouzi J, Pyatigorskaya N, Yahia-Cherif L, et al
Automated Categorization of Parkinsonian Syndromes Using Magnetic Resonance Imaging in a Clinical Setting.
Mov Disord. 2020 Nov 2. doi: 10.1002/mds.28348.
PubMed Abstract available

DORSEY ER, Bloem BR, Okun MS
A New Day: The Role of Telemedicine in Reshaping Care for Persons With Movement Disorders.
Mov Disord. 2020;35:1897-1902.
PubMed Abstract available

HERRINGTON TM, Schweitzer J, Henchcliffe C, Carter BS, et al
Toward a Personalized Approach to Parkinson's Cell Therapy.
Mov Disord. 2020;35:2119-2120.
PubMed

SILVA-BATISTA C, M Corcos D, B Horak F, Ugrinowitsch C, et al
Reply to: 'Letter to the Editor on "A Randomized Controlled Trial of Exercise for Parkinsonian Individuals With Freezing of Gait"'.
Mov Disord. 2020;35:2123-2124.
PubMed

KORDOWER JH, Okun MS, Jankovic J
Reply to: "Toward a Personalized Approach to Parkinson's Cell Therapy".
Mov Disord. 2020;35:2120-2121.
PubMed

NONNEKES J, Gilat M, D'Cruz N, Dijkstra BW, et al
Letter to the Editor on "A Randomized, Controlled Trial of Exercise for Parkinsonian Individuals With Freezing of Gait".
Mov Disord. 2020;35:2122-2123.
PubMed

October 2020

TAN MMX, Lawton MA, Jabbari E, Reynolds RH, et al
Genome-Wide Association Studies of Cognitive and Motor Progression in Parkinson's Disease.
Mov Disord. 2020 Oct 28. doi: 10.1002/mds.28342.
PubMed Abstract available

SUN YM, Yu HL, Zhou XY, Xiong WX, et al
Disease Progression in Patients with Parkin-Related Parkinson's Disease in a Longitudinal Cohort.
Mov Disord. 2020 Oct 27. doi: 10.1002/mds.28349.
PubMed Abstract available

MENOZZI E, Macnaughtan J, Schapira AHV
LRRK2 Parkinsonism: Does the Response to Gut Bacteria Mitigate the Neurological Picture?
Mov Disord. 2020 Oct 27. doi: 10.1002/mds.28347.
PubMed

VAN DEN HEUVEL L, Evers L, Meinders M, Post B, et al
Estimating the Effect of Early Treatment Initiation in Parkinson's Disease Using Observational Data.
Mov Disord. 2020 Oct 27. doi: 10.1002/mds.28339.
PubMed Abstract available

BEYLERGIL SB, Petersen M, Gupta P, Elkasaby M, et al
Severity-Dependent Effects of Parkinson's Disease on Perception of Visual and Vestibular Heading.
Mov Disord. 2020 Oct 26. doi: 10.1002/mds.28352.
PubMed Abstract available

YE Z, Zhang G, Zhang Y, Li S, et al
The Role of the Subthalamic Nucleus in Sequential Working Memory in De Novo Parkinson's Disease.
Mov Disord. 2020 Oct 24. doi: 10.1002/mds.28344.
PubMed Abstract available

VAN DER HEIDE A, Meinders MJ, Speckens AEM, Peerbolte TF, et al
Stress and Mindfulness in Parkinson's Disease: Clinical Effects and Potential Underlying Mechanisms.
Mov Disord. 2020 Oct 23. doi: 10.1002/mds.28345.
PubMed Abstract available

FU JF, Matarazzo M, McKenzie J, Neilson N, et al
Serotonergic System Impacts Levodopa Response in Early Parkinson's and Future Risk of Dyskinesia.
Mov Disord. 2020 Oct 22. doi: 10.1002/mds.28340.
PubMed Abstract available

YIN W, Lof M, Pedersen NL, Sandin S, et al
Mediterranean Dietary Pattern at Middle Age and Risk of Parkinson's Disease: A Swedish Cohort Study.
Mov Disord. 2020 Oct 20. doi: 10.1002/mds.28314.
PubMed Abstract available

TAKEDA A, Takahashi R, Tsuboi Y, Nomoto M, et al
Randomized, Controlled Study of Opicapone in Japanese Parkinson's Patients With Motor Fluctuations.
Mov Disord. 2020 Oct 19. doi: 10.1002/mds.28322.
PubMed Abstract available

LOWES H, Robertson F, Pyle A, Hussain R, et al
The human coronavirus receptor ANPEP (CD13) is overexpressed in Parkinson's disease.
Mov Disord. 2020 Oct 18. doi: 10.1002/mds.28354.
PubMed

SCHLOSSMACHER MG, Graybiel AM
Conversations With Dr. Oleh Hornykiewicz, Founding Father of the Dopamine Era in Parkinson's: How Do You Wish to Be Remembered?
Mov Disord. 2020 Oct 14. doi: 10.1002/mds.28316.
PubMed Abstract available

TAKAMIYA A, Seki M, Kudo S, Yoshizaki T, et al
Electroconvulsive Therapy for Parkinson's Disease: A Systematic Review and Meta-Analysis.
Mov Disord. 2020 Oct 14. doi: 10.1002/mds.28335.
PubMed Abstract available

MESTRE TA, Kessler D, Cote D, Liddy C, et al
Pilot Evaluation of a Pragmatic Network for Integrated Care and Self-Management in Parkinson's Disease.
Mov Disord. 2020 Oct 14. doi: 10.1002/mds.28332.
PubMed Abstract available

BELVISI D, Fabbrini A, De Bartolo MI, Costanzo M, et al
The Pathophysiological Correlates of Parkinson's Disease Clinical Subtypes.
Mov Disord. 2020 Oct 10. doi: 10.1002/mds.28321.
PubMed Abstract available

DAHODWALA N, Li P, Jahnke J, Ladage VP, et al
Burden of Parkinson's Disease by Severity: Health Care Costs in the U.S. Medicare Population.
Mov Disord. 2020 Oct 8. doi: 10.1002/mds.28265.
PubMed Abstract available

SANTIN MDN, Voulleminot P, Vrillon A, Hainque E, et al
Impact of Subthalamic Deep Brain Stimulation on Impulse Control Disorders in Parkinson's Disease: A Prospective Study.
Mov Disord. 2020 Oct 6. doi: 10.1002/mds.28320.
PubMed Abstract available

ISRAEL Z, Asch N
Reversing a Model of Parkinson's Disease With In Situ Converted Nigral Neurons.
Mov Disord. 2020 Oct 5. doi: 10.1002/mds.28306.
PubMed

BONVEGNA S, Straccia G, Golfre Andreasi N, Elia AE, et al
Parkinsonism and Nigrostriatal Damage Secondary to CSF1R-Related Primary Microgliopathy.
Mov Disord. 2020 Oct 3. doi: 10.1002/mds.28290.
PubMed

KANE PB, Benjamin DM, Barker RA, Lang AE, et al
Comparison of Patient and Expert Perceptions of the Attainment of Research Milestones in Parkinson's Disease.
Mov Disord. 2020 Oct 1. doi: 10.1002/mds.28319.
PubMed Abstract available

TSUBOI T, Charbel M, Peterside DT, Rana M, et al
Pallidal Connectivity Profiling of Stimulation-Induced Dyskinesia in Parkinson's Disease.
Mov Disord. 2020 Oct 1. doi: 10.1002/mds.28324.
PubMed Abstract available

IWAKI H, Blauwendraat C, Leonard HL, Makarious MB, et al
Differences in the Presentation and Progression of Parkinson's Disease by Sex.
Mov Disord. 2020 Oct 1. doi: 10.1002/mds.28312.
PubMed Abstract available

MUFTI K, Rudakou U, Yu E, Krohn L, et al
Comprehensive Analysis of Familial Parkinsonism Genes in Rapid-Eye-Movement Sleep Behavior Disorder.
Mov Disord. 2020 Oct 1. doi: 10.1002/mds.28318.
PubMed Abstract available

ACHBANI A, Sine H, Naciri A, Baba MA, et al
Reply to: "Can the 2019 Novel Coronavirus Cause Parkinson's Disease?"
Mov Disord. 2020;35:1726.
PubMed

HURWITZ B, Lees AJ, Walusinski O
Light and Shade in Patrick Lewis et al's Paper on the First Photographs of Parkinson's Disease.
Mov Disord. 2020;35:1880-1881.
PubMed

SULLIVAN R, Yau WY, Chelban V, Rossi S, et al
Dopa-Responsive Parkinsonism in a Patient With Homozygous RFC1 Expansions.
Mov Disord. 2020;35:1890-1891.
PubMed

DA SILVA SCHMITT G, Martinez ARM, da Graca FF, de Lima FD, et al
Dopa-Responsive Parkinsonism in a Patient With Homozygous RFC1 Expansions.
Mov Disord. 2020;35:1889-1890.
PubMed

AGUIRRE-PADILLA DH, Lozano AM, Fasano A
Reply to: "Spinal Cord Stimulation for Parkinson's Disease: Dynamic Habituation as a Mechanism of Failure?"
Mov Disord. 2020;35:1883.
PubMed

MONTGOMERY EB JR
Debugging Adaptive Deep Brain Stimulation for Parkinson's Disease.
Mov Disord. 2020;35:1891.
PubMed

CURY RG, Carra RB, Capato TTC, Teixeira MJ, et al
Spinal Cord Stimulation for Parkinson's Disease: Dynamic Habituation as a Mechanism of Failure?
Mov Disord. 2020;35:1882-1883.
PubMed

MONJE MHG, Martinez-Fernandez R
Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Parkinsonism: Is There Evidence for Concern?
Mov Disord. 2020;35:1725.
PubMed

ALVES M, Caldeira D, Reimao S, Ferro JM, et al
N-Terminal Pro-B-Type Natriuretic Peptide Levels in Parkinson's Disease.
Mov Disord. 2020;35:1886-1887.
PubMed

CHOE CU, Petersen E, Potter-Nerger M, Buhmann C, et al
Reply to: "N-Terminal Pro-B-Type Natriuretic Peptide Levels in Parkinson's Disease".
Mov Disord. 2020;35:1888.
PubMed

LEWIS PA, Plun-Favreau H, Rowley M, Spillane J, et al
Reply to: "Light and Shade in Patrick Lewis et al's Paper on the First Photographs of Parkinson's Disease".
Mov Disord. 2020;35:1882.
PubMed

CROTTY GF, Lo RY, Schwarzschild MA
If LRRK2 Set the Fire, Can Nonsteroidal Anti-inflammatory Drugs Wet the Flames?
Mov Disord. 2020;35:1727-1730.
PubMed

September 2020

BLUMENREICH S, Jenkins BJ, Barav OB, Milenkovic I, et al
The Lysosome and Nonmotor Symptoms: Linking Parkinson's Disease and Lysosomal Storage Disorders.
Mov Disord. 2020 Sep 28. doi: 10.1002/mds.28232.
PubMed

RAJPUT AH, Kish SJ
Professor Oleh Hornykiewicz, MD (1926-2020): Remembering the Father of the Modern Treatment of Parkinson's Disease and the Man.
Mov Disord. 2020 Sep 28. doi: 10.1002/mds.28317.
PubMed

AL ALI J, Vaine CA, Shah S, Campion L, et al
TAF1 Transcripts and Neurofilament Light Chain as Biomarkers for X-Linked Dystonia-Parkinsonism.
Mov Disord. 2020 Sep 25. doi: 10.1002/mds.28305.
PubMed Abstract available

ZHANG X
Comment on "Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease".
Mov Disord. 2020;35:1695.
PubMed

LU C, Amundsen Huffmaster SL, Louie KH, Sovell-Brown K, et al
Pallidal Oscillation Dynamics Following Cessation of Deep Brain Stimulation in Parkinson's Disease.
Mov Disord. 2020;35:1697-1698.
PubMed

SPEECKAERT MM, Speeckaert R, Delanghe JR
Standardized 25-Hydroxyvitamin D Measurements in Parkinson's Disease Patients With COVID-19.
Mov Disord. 2020;35:1497.
PubMed

CIRSTEA MS, Yu AC, Golz E, Sundvick K, et al
Reply to: 'Comment on "Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease"'.
Mov Disord. 2020;35:1695-1697.
PubMed

NEUMANN WJ, Feldmann L, Kuhn AA
Reply to: Pallidal Low-Frequency Activity in Dystonia and Subthalamic Beta Activity in Parkinson's Disease.
Mov Disord. 2020;35:1699.
PubMed

CEREDA E, Fasano A, Pezzoli G
Reply to: Standardized 25-Hydroxyvitamin D Measurements in Parkinson's Disease Patients With COVID-19.
Mov Disord. 2020;35:1498.
PubMed

WEIL RS
Visual Dysfunction and Parkinson's Disease.
Mov Disord. 2020;35:1499-1501.
PubMed

August 2020

MARKAKI I, Bergstrom S, Tsitsi P, Remnestal J, et al
Cerebrospinal Fluid Levels of Kininogen-1 Indicate Early Cognitive Impairment in Parkinson's Disease.
Mov Disord. 2020 Aug 15. doi: 10.1002/mds.28192.
PubMed Abstract available

July 2020

LERCHE S, Wurster I, Roben B, Zimmermann M, et al
CSF NFL in a Longitudinally Assessed PD Cohort: Age Effects and Cognitive Trajectories.
Mov Disord. 2020;35:1138-1144.
PubMed Abstract available

February 2020

MAHATO AK, Kopra J, Renko JM, Visnapuu T, et al
Glial cell line-derived neurotrophic factor receptor Rearranged during transfection agonist supports dopamine neurons in Vitro and enhances dopamine release In Vivo.
Mov Disord. 2020;35:245-255.
PubMed Abstract available

RAPPEL P, Grosberg S, Arkadir D, Linetsky E, et al
Theta-alpha oscillations characterize emotional subregion in the human ventral subthalamic nucleus.
Mov Disord. 2020;35:337-343.
PubMed Abstract available

MARTINEZ E, Pasquereau B, Saga Y, Metereau E, et al
The anterior caudate nucleus supports impulsive choices triggered by pramipexole.
Mov Disord. 2020;35:296-305.
PubMed Abstract available

LEE JY, Ahn J, Oh S, Shin JY, et al
Retina thickness as a marker of neurodegeneration in prodromal lewy body disease.
Mov Disord. 2020;35:349-354.
PubMed Abstract available

January 2020

BELLOMO G, Paciotti S, Gatticchi L, Parnetti L, et al
The vicious cycle between alpha-synuclein aggregation and autophagic-lysosomal dysfunction.
Mov Disord. 2020;35:34-44.
PubMed Abstract available

PYATIGORSKAYA N, Yahia-Cherif L, Gaurav R, Ewenczyk C, et al
Multimodal Magnetic Resonance Imaging Quantification of Brain Changes in Progressive Supranuclear Palsy.
Mov Disord. 2020;35:161-170.
PubMed Abstract available

COUGHLIN DG, Hurtig HI, Irwin DJ
Pathological Influences on Clinical Heterogeneity in Lewy Body Diseases.
Mov Disord. 2020;35:5-19.
PubMed Abstract available

CHAUDHURI KR, Schrag A, Weintraub D, Rizos A, et al
The movement disorder society nonmotor rating scale: Initial validation study.
Mov Disord. 2020;35:116-133.
PubMed Abstract available

RESPONDEK G, Grimm MJ, Piot I, Arzberger T, et al
Validation of the movement disorder society criteria for the diagnosis of 4-repeat tauopathies.
Mov Disord. 2020;35:171-176.
PubMed Abstract available

ALCALAY RN, Hsieh F, Tengstrand E, Padmanabhan S, et al
Higher Urine bis(Monoacylglycerol)Phosphate Levels in LRRK2 G2019S Mutation Carriers: Implications for Therapeutic Development.
Mov Disord. 2020;35:134-141.
PubMed Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Parkinson's Disease is free of charge.